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Abstract  
 
Aseptic loosening, as a consequence of an extended inflammatory reaction 
induced by wear particles, remains the most common complication of total 
joint replacement (TJR), representing a major problem for the long-term 
success and survival of prostheses. Despite it is high incidence, in the last 
decade any therapeutic approach has been found to treat or avoid aseptic 
loosening, leaving revision as the only effective treatment for this condition. 
The local delivery of anti-inflammatory drugs to modulate wear-induced 
inflammation has been regarded as a potential therapeutic approach to avoid 
aseptic loosening.  
In this work, an anti-inflammatory drug-eluting implant model system was 
developed and characterised. The model system was obtained by attaching 
DEX to functionalised-TiO2 particles, through different synthetic routes: i) by 
covalently binding DEX to carboxyl-functionalised particles (amino or 
mercapto routes) or ii) by coating amino-functionalised particles using Layer-
by-Layer (LbL) technique. The chemical and physical properties of DEX-
loaded functionalised TiO2 particles have been determined and the release 
profiles investigated. Depending on the synthetic route, the DEX release 
period can vary from hours (amino, mercapto routes) to 3 weeks (LbL route). 
The model system was then tested for its cytotoxic and anti-inflammatory 
properties in a rapid and reproducible in vitro mouse macrophage-like cellular 
model, by utilizing murine RAW 264.7 cells. In this model lipopolysaccharide 
(LPS) was utilized to activate the Raw macrophages, resulting in the 
secretion of pro-inflammatory cytokines, including nitric oxide (NO) and 
tumour necrosis factor alpha (TNF-α), the suppression of which was utilized 
to investigate the anti-inflammatory effect of DEX released from 
functionalised-TiO2 particles. In vitro studies showed that DEX decreased 
LPS-induced NO and TNF-α production at non-cytotoxic concentrations, 
where DEX released from LbL particles showed the most effective 
suppression of inflammation for at least 2 weeks. Collectively, these findings 
show that the model system developed can be a potential therapeutic 
approach to avoid wear-debris induced aseptic loosening of TJR.  
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1. Introduction  
 
1.1 Total joint replacement (TJR)  
Like other parts of the body, bone becomes damaged or weakened by age, accidents or 
disease. Bone and joint degenerative and inflammatory diseases, such as arthritis affect 
millions of people worldwide. In fact, it is estimated that 8 million people in the UK 
(Hughes et al. 2010) and 27 million people in the US (Van Manen et al. 2012) are 
currently suffering from osteoarthritis. As can be seen in Figure 1 total joint replacements 
(TJR) are used as treatment for arthritic or damaged joints, providing pain relief and 
improving quality of life of patients with end-stage arthritis (Goodman et al. 2013, 2014; 
Takakubo et al. 2013). Likewise, data recorded between 2009 and 2017 revealed that 
osteoarthritis was the predominant diagnosis (>40%) for undertaken hip and knee TJR, 
followed by other diagnosis such as infection, aseptic necrosis of head and neck of femur 
and mechanical loosening of joint (National Joint Registry 2017, The NJR Editorial Board 
2016). 
 
 
 
 
 
 
 
Figure 1. Osteoarthritis and total joint replacement undertaken during 2016: (a) Hip 
and (b) Knee prosthesis, according to National Joint Registry (National Joint 
Registry 2017). 
 
Worldwide hip and knee replacement have become popular surgical procedures over the 
past decades (Cobelli et al. 2011, Hunt et al. 2014, Kurtz et al. 2007). In the United States 
(USA) more than 200,000 joint replacements are performed each year, where this 
number is expected to increase dramatically over the next 20 years (Issa & Mont 2013, 
Ulrich et al. 2008, von Knoch et al. 2010). The same trend was observed in United 
108,713 
procedures 
101,651 
procedures 
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Kingdom (UK), according to the last report of the National Joint Registry of England, 
Wales and Northern Ireland (National Joint Registry 2017), 890,681 and 957,739 primary 
hip and knee replacement were carried out, respectively between 2003 and 2017 
(National Joint Registry 2016). Furthermore, from 2015 to 2016 an increase of 3.5% and 
3.8% was recorded respectively for hip and knee procedures in England and Wales 
(National Joint Registry 2016). 
 
1.2. Revision surgery  
Despite regarded as extensively applied and successful orthopaedic medical devices 
(Bauer et al. 2012, Goodman 2014, Goriainov et al. 2014) TJR are not exempt of 
complications. TJR have an expected average life span of 10-15 years post-surgery 
(Labek et al. 2011, Lee & Goodman 2008, Torrecillas et al. 2009). After that period, 
implants start to experience biocompability problems, causing complications to the 
patient i.e. long term-pain and functional problems (Goodman et al. 2014) which normally 
results in revision surgery. The numbers speak from themselves 8% (8417) of the hip 
and 6% (6194) of knee primary procedures undertaken in UK during 2016, resulted in 
revision surgery (National Joint Registry 2017). Of those recorded, aseptic loosening 
(42%, 41%), pain (7%, 10%), adverse soft tissue reaction (13%, 12%) and infection (5%, 
23%), were the most common causes, respectively for total hip and knee revision 
procedures. These statistics are particularly worrisome because due to the aging 
population, obesity, osteoporosis and increasing frequency of osteoarthritis, the number 
of revision surgeries is likely to increase (Mihalko et al. 2014, Ulrich et al. 2008). 
Moreover, the risk of revision surgery after hip or knee replacement has been related to 
patient age and sex.  Last year, an interesting study by Bayliss and co-workers (2017) 
showed the revision rate older than 70 years is 5% (both men and women). Whilst for 
patients in their early 50s, a rate of 35% and 15% was reported respectively for men and 
women groups (Bayliss et al. 2017). In addition, revision results in worse outcome than 
the primary procedure, thus resulting in more discomfort to the patient (Bhandari et al. 
2012, Vallés et al. 2013). All of this involves high healthcare costs, £80 million was the 
estimated expenditure for UK revision surgeries undertaken in 2015 (Kallala et al. 2015). 
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1.3. Aseptic Loosening 
By observing the above revision surgery statistics (1.2. Revision surgery), it is clear that 
among all causes, aseptic loosening was the most common indication for replacement 
surgery, in both hip (MacInnes et al. 2012, Ulrich et al. 2008) and knee replacement 
(Rozkydal et al. 2007, Schroer et al. 2013), accounting for more than 40% of all revision 
procedures (Goriainov et al. 2014). Aseptic loosening of the implant occurs as a 
consequence of an extended inflammatory reaction induced by wear particles, which 
normally results in severe bone loss i.e. osteolysis around the implant (Landgraeber et 
al. 2014). This wear particles, which are extremely small sized particles, normally arise 
from metal-on-metal bearings of TJR after a given period of usage.  
As can be seen in Figure 2, after osteolysis the bone around the TJR is not strong enough 
to fulfil the prosthesis functions leading the implant replacement i.e. revision surgery. 
 
  
Figure 2. X-ray image of progressive acetabular osteolysis over 1.5 years (a), 
including 3D computerized tomography reconstruction demonstrating lesion and 
pelvic discontinuity (b). X-ray taken after surgery, no bone loss observed (c). 
Figure adapted from (Rajpura & Board 2013). 
 
In general, the degree of osteolysis and inflammatory reactions on bone tissue at the 
bone–implant interface will depend on the of wear particles features (e.g. morphology, 
size, material origin) released from the implant surface (Longhofer et al. 2017, Nine et 
al. 2014). Taking the wear material as an example, previous studies have reported that 
different levels of osteolysis were observed when animal models were exposed to 
different wear particles from different materials. Among all metallic particles showed the 
highest loss of bone density when compared to ceramic ones. 
So researchers worldwide have attempted to mitigate release of wear particles and 
consequent periprosthetic osteolysis by improving of surgical techniques such as the use 
of medullary plugs, cement guns, lavage of the canal, pressurization, centralization of 
the stem, and reduction in cement porosity (Holt et al. 2007). Another approach was to 
modify the bearing materials of implants (Gallo et al. 2013, Ryu & Shrotriya 2013). These 
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include the utilization of new implant materials such as highly cross-linked polyethylene, 
titanium and cobalt based alloys, polycarbonate-urethane (Holt et al. 2007, Nine et al. 
2014). Also the modification of implant surface with mechanical and chemical methods 
such as sol-gel, plasma spray, grit-blast, acid-etching, and electrochemical-anodization 
have been applied to mitigate the risk of osteolytic reaction (Dohan Ehrenfest et al. 2010, 
Goodman et al. 2014, Singhatanadgit 2009). Although some of them present 
disadvantages such as non-uniformity in thickness, lack of adherence to implant, and 
high processing temperature (Koju et al. 2017). In fact, some of them have even resulted 
in several adverse complications, for example, acid etching method may lead to micro-
cracks which affect physical integrity of the implant, or granules used on surface plasma 
spraying can detach from implant surface, causing damage on surrounding cells and 
tissues (Ganguly and Shokuhfar, 2013). Despite being considered one of the most 
common causes of revision surgery, currently there are no drug or effective 
prevention/treatment for aseptic implant loosening, leaving revision surgery as the only 
therapeutic option. In this context, a better understanding of the wear-debris induced 
inflammatory reaction that takes place at implantation site could facilitate the 
development of more safe and functional improved implants. 
 
1.3.1 Wear-induced inflammation: acute and chronic phase 
An innate acute host inflammatory reaction will arise immediately after device 
implantation, and consists of the response to inevitable tissue injury during device 
placements and the response to the material itself (Anderson & Cramer 2015, Lucke et 
al. 2015). This inflammatory response is considered a decisive event because it will help 
promote the tissue healing/recovery process and eliminate possible infections around 
implant. Although if prolonged for more time than necessary, inflammation may 
compromise the integration and biological performance of the implant (Bridges & García 
2008). On other hand, there are other factors that can lead to inflammatory response, 
especially in implants like TJR which are intended to remain in situ for the life span of 
the patient. For example, high levels of activity, and usage of TJR result on release of 
wear particles from artificial articulating surfaces, which are also thought to induce an 
inflammatory reaction around the implant (Cobelli et al. 2011, Rao et al. 2012). 
Regardless the cause i.e. wear-debris or tissue injury, biological events that characterize 
inflammation will be the same. In this sense, inflammatory response has been described 
as a complex reaction that comprises different phases (Figure 3), involving recruitment 
and activation of different cells (e.g. macrophages, fibroblast, osteoclasts), protein 
adsorption, and secretion of inflammatory mediator, among others (Bridges & García 
2008).The initial phase, lasting from minutes to days depending on the tissue injury, is 
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defined as acute inflammation. Then a later phase takes place i.e. chronic inflammation, 
where inflammatory reaction continues to develop (1-2weeks) even after tissue 
deposition occurs (Anderson et al. 2008, Bastian et al. 2011, Lin et al. 2014). In more 
detail, the initial acute phase is characterized by blood cells influx, such as short-lived 
neutrophils and monocytes, into the area surrounding the implant (Bridges & García 
2008). This response is initiated in response to tissue injury caused by TJR surgery, and 
aims to recover the tissue homeostasis (Lin et al. 2014). Whereas monocytes will 
differentiate into macrophages that will play a pivotal role during inflammatory reaction 
by engulfing foreign bodies i.e. wear particles, eliminating damaged tissue, cell debris, 
releasing cytokines and other important factors in the transition between inflammation 
and wound repair events (Lucke et al. 2015).  
 
 
Figure 3. The inflammatory response immediately after implantation, acute and 
chronic phase: time-scale, cellular interaction with implant surface and related 
biological events such as osteolysis.  
Inflammatory response comprises different phases, acute and chronic, involving recruitment and 
activation of different cells (e.g. monocytes, macrophages, osteoblasts, osteoclasts). The initial 
phase, lasting from minutes to days depending on the tissue injury and/or wear debris interaction, 
is defined as acute inflammation. Then if prolonged, acute phase becomes chronic, in this case 
inflammatory reaction continues to develop (1-2 weeks) even after tissue deposition occurs. 
Persistent chronic phase involves the continuous activation of macrophages, which consequently 
results in the overexpression of osteoclasts and down regulations of osteoblast. This is the main 
cause for bone erosion and loss around the implant, which is known as osteolysis. 
 
The subsequent chronic phase occurs when the “foreign material” cannot be eliminated 
by a normal homeostatic mechanism, resulting in a higher incidence and prolonged 
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activation of lymphocytes, monocytes and macrophages (Anderson et al. 2008, Buckley 
2011). In the worst scenario, chronic and dysregulated inflammation can lead to a fibrotic 
encapsulation of the implant, leading to increased bone resorption and hampered bone 
formation, thus seriously compromising implant function and even lead to implant aseptic 
loosening (Bastian et al. 2011, Lin et al. 2014, Ren et al. 2013). In this regard, both 
processes of acute and chronic inflammation play an important role in tissue healing 
post-implantation. Among others, the degree and duration of each inflammatory phase, 
acute or chronic, will depend on several factors, including the damage caused during 
implantation procedure, implant type e.g. material biocompability (Anderson & Cramer 
2015, Anderson et al. 2008) and also the type of wear-particles to be released (e.g. size, 
morphology) (Nine, et al., 2014).  According to previous studies, under favourable i.e. 
aseptic conditions and when the implanted material is biocompatible, acute and chronic 
inflammatory phases should  not last more than 2 weeks (Anderson et al. 2008). 
Therefore, the persistence of inflammatory events for more than 3 weeks, acute or 
chronic, normally indicates an unfavourable outcome, such as infection or osteolysis. It 
is important to highlight that the major problem out coming from this extended chronic 
inflammatory reaction, is that the continuous activation of macrophages will 
consequently trigger the formation of bone reabsorbing cells i.e. osteoclasts, exceeding 
the number of bone forming cells i.e. osteoblasts. In addition, it may also evoke 
osteoblasts apoptosis (Rick Sumner 2013). As can be seen in Figure 3., this 
overexpression of osteoclasts and down regulations of osteoblasts, leads to bone 
erosion and loss around the implant i.e. osteolysis (Beck et al. 2012, Ren et al. 2011a). 
 
 
 
 
 
 
 
 
7 
 
1.3.2 Biological mechanism and inflammatory mediators 
Recent studies (Aktan 2004, Lin et al. 2014, Ricciotti & Fitzgerald 2011, Wojdasiewicz et 
al. 2014, Zhang & An 2007) have demonstrated the presence of the different types of 
mediators during a wear-debris induced inflammation as summarized in Table 1.  
 
Table 1. Summary and description of relevant inflammatory mediators/markers. 
All crystal structures represented are from human origin molecules, except COX-
2 and iNOS which are murine-type and were taken from the Research Collaborator 
for Structural Bioinformatic (RCSB) Protein data bank (PDB) (www.rcsb.org). 
INFLAMMATORY MEDIATORS DESCRIPTION 
Tumor Necrosis Factor alpha 
(TNF-α) 
Earliest and key pro-inflammatory cytokine. As 
the initiator of inflammatory reaction, it amplifies 
and prolongs the inflammatory reaction by 
activating a series of inflammatory cells to release 
interleukins and cytokines. Including NF-kβ 
pathway activation, and production of iNOS, COX-
2, and PG2 synthase. 
Interleukin-6 (IL-6) 
 
IL-6 is a pro-inflammatory cytokine that is mainly 
secreted by activated monocytes and synovial 
fibroblasts. It Is a potent inducer of the acute phase 
response, and bone resorption; it is presence is 
highly correlated to osteoclast formation.  
Interleukin-10 (IL-10)  Anti-inflammatory cytokine, that act as potent 
immunoregulatory molecule by controlling the pro-
inflammatory cytokine response. Such as by 
repressing the expression of TNF-α, IL-6 and IL-1 
by activated macrophages. It has been proven to 
be involved in stimulating the synthesis of type II 
collagen and aggrecan. 
Nitric oxide (NO) and iNOS 
 
NO is reactive specie and important signalling 
molecule produced during inflammation, it 
modulates production of prostaglandins and, also 
increases the expression of COX-2 protein. It is 
biosynthesized by inducible nitric oxide synthase 
(iNOS) enzyme from L-arginine. Both NO and 
iNOS are expressed in activated macrophages. 
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Prostaglandin 2 (PG2) and  
COX-2 
PG2, local mediator occurred in the inflamed 
tissues leading to classic signs of inflammation: 
redness, swelling and pain. It is mainly 
biosynthesized by the action of cyclooxygenase-2 
(COX-2). Both are up-regulated at sites of 
inflammation. Their biosynthesis is blocked by 
nonsteroidal anti-inflammatory drugs (NSAISDs). 
 
On the other hand, several studies have been done to have further insight about the 
inflammatory response towards an orthopaedic device (Cherian et al. 2015, Cobelli et al. 
2011, Nine et al. 2014). As it can be seen in Figure 4, Immediately after implantation, 
within seconds, non-specific protein and biomolecules from blood plasma and biological 
fluids surrounding the implant tend to adsorb onto surface of the implant (Anderson & 
Cramer 2015, Anderson et al. 2008).This process is known as Vroman effect (Slack & 
Horbett 1995), and, being one of the first events taking place after implantation, it plays 
a crucial role on the subsequent cascade of inflammatory events (Bixler & Bhushan 
2012). The protein adsorption is a dynamic and competitive process, where the type, 
concentration, and conformation of surface-adsorbed proteins (e.g. fibrinogen, 
fibronectin) will be influenced by the surface chemistry and morphology of the implant 
such as surface charge, energy or hydrophobicity (De Jonge et al. 2008), but is also 
dependent on local surrounding environment i.e. pH, concentration of ions, strength and 
temperature). For example, several studies (Jäger et al. 2007, Lucke et al. 2015) have 
reported the influence of surface charge on the protein adsorption. In these studies, the 
ionic interactions were described as the driving force for protein unfolding and adsorption 
onto an implant charged surface. Since most of proteins present a negative surface 
charge, an implant with a positive surface charge would in theory promote protein 
adsorption.  
The adsorbed protein layer act as an interface that will define which cells i.e. bone, white 
blood cells and their precursors will subsequently approach the implant strongly affecting 
tissue healing around the implant (Anderson & Cramer 2015). For example, 
macrophages functions (e.g. phagocytosis, cytokine expression) and phenotype will 
depend on these layer of proteins adsorbed on implant surface (Bridges & García 2008, 
Zaveri et al. 2014). Subsequently, within minutes of implantation, the cellular response 
becomes predominated by immune cells such as neutrophils and macrophages at the 
host-implant surface. Otherwise, when wear-debris are present, primary immune cells 
are also recruited to inflammatory sites, so they can engulf these foreign particles. 
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Figure 4. Cascade of molecular and cellular processes that occurs following 
biologically release of wear particles resulting from the placement of orthopedic 
implants. 
Immediately after implantation starts the acute phase, where non-specific protein and 
biomolecules (e.g. albumin, fibrinogen) from blood plasma and biological fluids surrounding the 
implant tend to adsorb onto surface of the implant. Within minutes of implantation, the cellular 
response becomes predominated by immune-cells such as neutrophils and macrophages at the 
host-implant surface. Interaction of immune cells and wear particles, particularly macrophages, 
leads to activation of the factor nuclear-kappa β (NF-κβ) pathway. Hence, resulting in secretion 
of key immune-regulatory proteins, cytokines and chemokines (e.g. IL-family, TNF-α, NO), which 
will act as effective messenger molecules by controlling the duration and strength of immune 
response, including recruitment of tissue repair cells. Although when prolonged this acute 
phase/stimulus can trigger a chronic inflammation that normally results in bone loss around the 
implant i.e. osteolytic reaction.  
 
The immune cells response, which takes places within 48-72 hours, is considered to be 
the hallmark of inflammatory acute phase (Anderson & Cramer 2015). During the first 
days following implantation, short-lived neutrophils (24h-48h) are the predominant 
immune cells, then these cells are replaced by long-lived (up to months) 
macrophages/monocytes. Research studies regarding monocytes/macrophages has 
been increasing in recent years regarding orthopaedic medical devices implantation, 
such as TJR (Ingham & Fisher 2005, Linden 2012, Rao et al. 2012). In this context, 
macrophages are described as key elements in both inflammatory and tissue healing 
responses, acting as sentinels of body´s reactions that take place after devices 
implantation (Cobelli et al. 2011, Lucke et al. 2015). 
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More specifically, after wear particles interaction, macrophages secrete key immune-
regulatory proteins resulting from the activation of the factor nuclear-kappa β (NF-κβ) 
pathway (Figure 4). These immune-regulatory proteins, cytokines and chemokines have 
different roles (Goodman & Ma 2010): cytokines act as effective messenger molecules 
by controlling the duration and strength of immune response (e.g. IL-family, TNF-α, 
colony-stimulating factor (CSF). On the other hand, chemokines are a special type of 
cytokines that are responsible for controlling the immune cell migration i.e. chemotaxis 
during the inflammatory response (e.g. monocyte chemoattractant protein, MCP-1). 
Moreover, upon stimulation with different cytokines and environmental stimulus, 
macrophages can either recruit more macrophages or change their phenotype (Getts et 
al. 2014). Macrophages have the ability to differentiate into distinct subpopulations, such 
as M1 and M2-induced macrophages (Lin et al. 2014, Solary 2012). Each type seems to 
play a different role during inflammatory response (Anderson et al. 2008, Porcheray et 
al. 2005), representing two extremes in the spectrum of the macrophages phenotype 
(Lampiasi et al. 2016). Classically activated M1 macrophages are responsible for 
phagocytosis and consequent release of pro-inflammatory cytokines. While M2-like 
macrophages are known for being involved in resolution of inflammation (Italiani & 
Boraschi 2014, Mills & Ley 2014), more specifically in wound healing and tissue repair, 
crucial processes to achieve a successful implant integration. Furthermore, it should be 
noted that although needed to resolve an inflammatory condition, macrophages 
prolonged and uncontrolled activation can trigger a chronic inflammation. Chronic 
inflammation, is a state in which acute inflammation, fibrosis and repair occurs 
simultaneously, and normally results in bone loss around the implant i.e. osteolytic 
reaction (Ingham & Fisher 2005, Lin et al. 2014). This reaction will mainly depend on 
wear debris features (e.g. size, morphology, texture), according to previous studies 
submicron sized (<1µm) particles are considered to be the most reactive (Rao et al. 
2012, Revell 2014). When macrophages cannot digest wear particles, more monocytes 
are recruited to site of inflammation, and according to the level of inflammation they 
release inflammatory mediators such as pro-inflammatory cytokines (e.g. TNF-α and IL-
1β), growth and differentiation factors (e.g. macrophage-colony stimulating factor (M-
CSF), receptor activator of nuclear factor kappa β ligand (RANKL).  Although the 
mechanism of macrophages/monocytes linage differentiation into osteoclasts (Figure 5) 
is still not clear, most of the studies (Bedke & Stenzl 2010, Goodman 2014, Kawai et al. 
2011, Takashiba et al. 1999) showed that when exposed to a combination of 
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-
kappa β ligand (RANKL), macrophages have the ability to differentiate into pre-
osteoclasts (Solary 2012). 
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Figure 5. Differentiation of monocytes into osteoclasts and differentiated 
macrophages (M1 and M2) within exposure to chemokines and cytokines e.g. TNF-
α, Interleukins and M-CSF, that are released upon inflammatory stimuli.  
 
These pre-osteoclasts will eventually evolve to mature multinucleated osteoclasts which 
after cell polarization gain resorptive activity, thus playing central role in osteolysis and, 
in long term, in aseptic loosening (Lampiasi et al. 2016). In addition, macrophages not 
only promote osteoclasts formation but they are also capable of directly resorb bone 
themselves (Tamaki et al. 2008). Konttinen and co-workers (Konttinen et al. 2001) 
showed that macrophages expressing cathepsin-K, an enzyme involved on bone 
resorption, were found among the cells collected around loosened hip joint. These data 
suggest that besides contributing for the pathogenesis of the inflammatory response, 
macrophages also present an osteolytic potential by directly resorbing periprosthetic 
bone after being challenged by wear particles. Regarding bone formation, macrophages 
can also interfere osteoblasts formation; recent study (Ren et al. 2011b) reported that 
during wear-debris phagocytic process macrophages release high levels of reactive 
oxygen species that will affect the osteoblast progenitor cells and consequently the 
process of bone formation. One the reactive oxygen species release is nitric oxide (NO), 
which is a pro-inflammatory mediator released in high concentrations by activated 
macrophages (Sharma et al. 2007). It is known that NO impaired production results in 
undesired effects such vasoconstriction, tissue damage and septic shock (Bogdan 
2001). Previous studies have shown that NO is involved in inflammatory joint diseases 
(Bogdan 2001, Sharma et al. 2007), and its expression reflects the level of inflammation, 
thus providing a measure of the inflammatory response (Oh et al. 2012, Pinho et al. 
2011).  
1.3.3 Inflammation models 
As described in above sections (1.3.1 Wear-induced inflammation: acute and chronic 
phase,1.3.2 Biological mechanism and inflammatory mediators) aseptic loosening is 
caused by an unresolved and extended inflammatory response, which can occur due to 
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different causes such as tissue injury or wear particles release. Regardless the cause, 
biological events that characterize inflammation, will be very similar. In this context 
modulating inflammatory response has been a major focus in the design of novel 
approaches to avoid aseptic loosening. Following the development of novel anti-
inflammatory compounds and systems, it is then important to validate their action in a 
suitable model of inflammation.  
During the last decade different in vitro and in vivo models (Nine et al. 2014) to mimic 
wear-debris induced inflammation conditions have been applied to assess the anti-
inflammatory potential of novel compounds and systems. Relevant cells such as 
macrophages, osteoclasts and osteoblast have been utilized as in vitro models (Ingham 
& Fisher 2005).  As for in vivo models (Langlois & Hamadouche 2011), different species 
e.g. sheep, rabbits, mice have been used to test biological and mechanical parameters 
upon wear-debris stimulation. Particularly, monocyte/macrophage in vitro based-models, 
mainly due to key role that macrophages play in inflammatory response. Namely the 
macrophages ability to i) either recruit more macrophages or change their phenotype 
(Getts et al. 2014) ii) differentiate into distinct subpopulations, such as M1 (phagocytosis 
and release of pro-inflammatory cytokines) and M2-induced macrophages linked to the 
resolution of inflammation (Mills and Ley 2014; Italiani and Boraschi 2014), crucial 
processes to achieve a successful implant integration.  
Among macrophage in vitro based-models, inflammation has been studied in robust, 
rapid and reproducible in vitro macrophage-like model with exposure to the bacterial wall 
component lipopolysaccharide (LPS). Then, at specific time points (post-LPS activation), 
samples are collected for inflammatory markers analysis such cytokines and chemokines 
or interleukins; this has been observed for both in vitro and in vivo models of inflammation 
(Tweedie et al. 2009a). In this context, LPS-activated murine-like macrophages, Raw 
264.7 cell line have been described as a relevant in vitro model to investigate study 
inflammatory process and therefore test the effect of anti-inflammatory compounds and 
systems. Besides, it is efficacy on screening the potential anti-inflammatory activity of 
drugs and delivery systems has been already demonstrated in previous studies (Jeon et 
al. 2000, Yuan et al. 2013). Previous studies have shown the production of inflammatory 
cytokines such IL-6, tumour necrosis factor- α (TNF-α), prostaglandin (PG) E2, and 
reactive oxygen species such as nitric oxide (NO) on LPS-activated Raw 264.7 cells (Kim 
et al. 2012, Saxena et al. 2003, Sharma et al. 2007). The expression of those cytokines 
and chemokines on LPS-activated Raw 264.7 reflects the level of inflammation, and 
therefore provides a measure of the inflammatory response (Oh et al. 2012, Pinho et al. 
2011).  For assay purposes, some studies (Lee et al. 2013, Petruson et al. 2005, Pinho 
et al. 2011) have assessed the anti-inflammatory potential by measuring levels of 
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inflammatory cytokines on LPS-activated cells in presence of materials/compounds to 
be tested.  
From a cellular perspective, the signalling of cytokine metabolic pathway starts 
immediately after LPS exposition: when exposed to macrophages, LPS binds to the LPS-
binding protein (LBP), which delivers LPS to the CD14/TLR4 receptor complex (Sharma 
et al. 2007).  
 
Figure 6. Signalling pathway cascade involved in LPS-induced cytokines 
production in macrophages. Adapted from (Pedersen & Febbraio 2008). 
LPS is recognized by the innate immune system by binding to the TLR4 present on the surface 
of macrophages. Upon LPS binding, signalling proteins e.g. MyD88-associated kinase are 
recruited and common upstream activator e.g. IRAK1/4, TRAF6 of NF-κB and MAP kinase 
(MAPK) are triggered. Specifically, TRAF-6 mediates the activation of inhibitor of κB kinase (IKK) 
and triggers the phosphorylation-induced proteasomal degradation of IκB, and subsequent NF-
κB activation. Activated NF-κB and MAPK translocate to the nucleus and induce the transcription 
of pro-inflammatory genes (iNOS and COX-2), and respectively the secretion of numerous 
inflammatory cytokines, such as NO and TNF alpha. (Abbreviations: AP-1: activator protein-1, 
TLR4: toll-like receptor 4, MyD88: myeloid differentiation primary response gene 88; IRAK: 
interleukin-1 receptor-associated kinase; TRAF6: TNF receptor associated factor 6; MAPK: 
mitogen-activated protein kinase, ERK: extracellular signal-regulated kinase: JNK: c-Jun N-
terminal kinase; AP-1: activator protein-1).  
 
The signalling pathways are activated by TLR4 engage adaptor molecules such as 
myeloid differentiation primary response 88 (MyD88). MyD88 is essential through all the 
signalling process, such as the activation of mitogen-activated protein kinase (MAPK) 
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and the phosphorylation of inhibitor of kappaβ-kinase (IKK) (Li & Yang 2011).  This 
triggers a complex intracellular signalling cascade, including and nuclear translocation 
of nuclear factor (NF) kappaβ (NF-κβ) and of the activator protein-1 (AP-1) (Petruson et 
al. 2005). AP-1 and NF-κB have been classified as the master regulators of inflammation 
(Li & Yang 2011). Thus, coordinated actions of NF- κB and AP-1 propagate inflammation 
via promoting the transcription of numerous pro-inflammatory genes (e.g. inducible nitric 
oxide synthase enzyme (iNOS) and COX-2) and respectively of inflammatory mediators 
e.g. NO, and cytokines e.g. PGE2 and TNF alpha (Figure 6). 
Regarding NO production, the metabolic L-arginine: NO pathway is the central source 
for NO production in macrophages (Zamora et al. 2000). This metabolic pathway is 
triggered by the inducible nitric oxide synthase enzyme (iNOS). The catalytic activity of 
iNOS is mainly regulated by co-factors (e.g. NADPH) and by the availability of substrates 
such as calmodulin (Calm) and L-arginine. Then, iNOS utilizes the oxygen and electrons 
from NADPH to oxidize L-arginine into OH- L-arginine, which will be oxidized into NO 
(Bogdan 2001). As for TNF-α production, it has been reported in several studies 
(Bouwmeester et al. 2004, Sabio & Davis 2014, van der Bruggen et al. 1999) that it 
involves the activation of multiple groups of mitogen-activated protein (MAP) kinases 
family, such as: extracellular-signal-regulated kinases (ERKs); the cJun NH2-terminal 
kinases (JNKs); and the p38 MAP kinases (Figure 6). It is worth to note that the utilization 
of in vitro inflammation models, such as LPS-activated Raw 264-7 cells, are less-
expensive, simpler and provide faster results, when compared to in vivo models; making 
them ideal models to provide an initial pharmacological screening. Although it is 
important to recognize that these models have limitations. And in this sense the studies 
determined by in vitro cellular models should be further translated to in vivo models, 
which are more clinically relevant due to their similarity with human in terms of 
physiology, anatomy and biomechanics (Langlois & Hamadouche 2011). 
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1.4 Approaches to improve longevity/success rates of total joint 
replacement procedures 
Taking into account the dramatic increase of TJR revision surgeries, in both younger and 
more active patients (Kurtz et al. 2009), different approaches are being applied to avoid 
adverse post-operative outcomes such as pain, periprosthetic inflammation and 
consequent osteolysis around the implant.  One of the most common clinical practices 
is the drug-regimen that usually takes place after orthopaedic surgeries (Bhusal et al. 
2016). Normally patients go through, antibiotics and/or anti-inflammatory prophylaxis, in 
order to manage pain, prevent infectious and inflammatory conditions  (Ganguly, et al., 
2013; Popat, Eltgroth and Desai, 2007). As well as to promote integration of the implant 
with the natural tissue (Waldron et al. 2013). Particularly, the administration of anti-
inflammatory drugs in the post-operative period, and their beneficial effect on patients 
recovery are well described in other studies (De Oliveira GS Jr.; Almeida MD; Benzon 
HT;McCarthy RJ 2011, Holte & Kehlet 2002, Salerno & Hermann 2006). The main benefit 
of administrating anti-inflammatory drugs, is not the treatment of the osteolytic condition 
itself, but an attempt to avoid it by modulating periprosthetic acute inflammation (Hickey 
et al. 2002a,b). In theory, the administration of anti-inflammatory drugs, which can be 
classified as steroidal/corticosteroids and non-steroidal, will control the pain and the 
overproduction proteins, enzymes, and cells involved in the chronic inflammatory 
response (Dawes et al. 2011). Since in this study, the model drug (DEX) utilised is a 
corticosteroid this section will be focused on their anti-inflammatory mechanism of action. 
The benefits of corticosteroids administration have been extensively reviewed and their 
clinical efficacy demonstrated over the last decades (Barnes 2006, Baschant et al. 2013, 
Coutinho & Chapman 2011, Vandevyver et al. 2013). As reported by a previous study 
regarding knee replacement (Smith et al. 2006) a small single dose (16mg) of a synthetic 
glucocorticoid, DEX, was sufficient to reduce the C-reactive protein (CRP) levels by 50%, 
three days following the surgery. Recent studies (Huebner et al. 2014, Urbanska et al. 
2014) have reported that DEX has been locally released aiming to modulate the 
inflammatory reaction. These studies have demonstrated that DEX was able to suppress 
the activity of inflammatory genes and respective inflammatory cytokines and 
chemokines, including nitric oxide.  As can be seen in Figure 7, corticosteroids, such as 
DEX, suppress the multiple inflammatory genes that are activated in inflammation, 
mainly by reversing histone acetylation of activated inflammatory genes through binding 
of liganded glucocorticoid receptors (GR) to co-activators, and recruitment of histone 
deacetylase-2 (HDAC2) to the activated transcription complex. Alternatively  
corticosteroids can also interact with DNA recognition sites to active transcription of anti-
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inflammatory genes and then inhibit transcription of several genes linked to corticosteroid 
side effects (Barnes 2006, Vandevyver et al. 2013). 
 
Figure 7. Anti-inflammatory mechanism of action of corticosteroids, by 
suppression of activated inflammatory genes through signal transduction by their 
steroid receptor, the glucocorticoid receptor (GR). Adapted from (Barnes 2006) 
Inflammatory genes are activated by inflammatory stimuli (e.g. LPS), resulting in activation of 
IKK2 (inhibitor of I-kB kinase-2), which activates the transcription factor NF-Кβ. A dimer of p50 
and p65 NF-κB proteins translocate to the nucleus and binds to specific κB recognition sites, as 
well as to co-activators, such as cyclic binding protein (CBP) or p300-CBP associated factor 
(pCAF), which have intrinsic histone acetyltransferase (HAT) activity. This results in acetylation 
of core histone H4, resulting in increased expression of genes encoding multiple inflammatory 
proteins. Glucorticoid receptor (GR) after activation by corticosteroids translocate to the nucleus 
and bind to coactivators to inhibit HAT activity directly and recruiting histone deacetylase-2 
(HDAC2), which reverses histone acetylation leading in suppression of these activated 
inflammatory genes. Besides corticosteroids, GR homodimers can also interact with DNA 
recognition sites to active transcription of anti-inflammatory genes and thus inhibit transcription of 
several genes linked to corticosteroid side effects. (Abbreviations: CBP: cyclic binding protein; 
LPS: Lipopolysaccharide; IKK2: inhibitor of I-kB kinase-2, NF-Кβ: nuclear transcription factor Кβ; 
pCAF:p300-CBP associated factor; HAT: histone acetyltransferase; GR: glucorticoid receptor; 
HDAC2: histone deacetylase-2; DEX: dexamethasone.)  
 
 
Moreover other studies have shown that DEX has also the ability of promoting 
osteoblasts differentiation (Tavakoli-Darestani et al. 2014) and down-regulating the 
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macrophages functions (Bridges & García 2008). Despite all the advantages of anti-
inflammatory drugs administration, normal doses of drugs are not effective delivered via 
conventional administration routes, leading to the administration of high doses which 
may cause several side effects in other tissues (Oray et al. 2016, Saag et al. 2008) 
including gastrointestinal bleeding and perforation, osteoporosis (Baschant et al. 2013) 
and even heart failure or myopathy (Sun et al. 2010, Zhang et al. 2015). 
In other words, anti-inflammatory drugs are efficient candidates from a molecular point 
of view, although when administrated via conventional routes, the cell-type specificity is 
lacking, thus demanding the utilization of high doses to achieve an in vivo therapeutic 
effect.  From the clinical point of view, there are already some drug delivery strategies to 
locally target joint inflammation in development (Evans et al. 2014), although 
intraarticular injection remains the method of choice for local therapeutic delivery (Allen 
et al. 2010, Wernecke et al. 2015). A recent study by Wernecke et al. (2015) showed 
that DEX intra-articular injection after an injury may prevent later cartilage damage and 
joint degeneration (Wernecke et al. 2015). For example, the standard approximate dose 
for intraarticular injection of a corticosteroid, such as dexamethasone sodium phosphate, 
is between 0.8-4 mg, depending on the joint size (MacMahon et al. 2009). Despite the 
clear advantages, there are several known contraindications to the corticosteroids 
injections, including intraarticular sepsis, intraarticular fracture, and joint instability 
(MacMahon et al. 2009). Other approaches, such as bone grafts and bone grafts 
substitutes have been applied to restore bone loss during osteolytic reaction (Dattani 
2007), however these can only be applied when bone defect is moderated. A revision 
study regarding hip replacements (Pierson & Harris 1994), reported that the utilization of 
new cemented femoral components helped to reduce periprosthetic osteolysis, where 
only 7% of the patients showed osteolysis 8.5 years later. Moreover, gender-specific 
sizing of implants and utilization of more effective bearing surface have also been 
employed (Mihalko et al. 2014). Recent studies to treat osteolysis have been dedicated 
administration of bisphosphonates and anti-cytokines, or gene therapy (Landgraeber et 
al. 2014, Ren et al. 2013, Talmo et al. 2006).  Results obtained are promising however 
the in vivo efficacy of most of these approaches has yet to be proven (Goodman et al. 
2013, 2014). 
Altogether, the approaches described in this section have shown some significant 
improvements, although at the same time they produce high incidence of early and late 
complications, leading to the conclusion that no effective solutions for osteolysis has yet 
been found in the last decade. Therefore better approaches to modulate inflammatory 
response developed post-device implantation are needed to maintaining a balance 
between inflammatory response and effective recovering and tissue healing process (Li 
18 
 
et al. 2015). With this aim, improvements in materials and implants designs are being 
developed to improve the current limitations (e.g. periprosthetic infection, wear-debris 
induced inflammation, poor osteointegration) affecting the longevity of TJR. Thus, 
maximizing the in vivo performance of the implant, and of course avoid aseptic loosening. 
These includes the utilization of passive (e.g. non-biofouling coatings) or more active 
approaches such as the local delivery of anti-inflammatory agents, which are going to be 
addressed on the next chapter. 
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1.4.1 Anti-fouling coatings 
Over the past years, the design of orthopaedic devices has primarily focused on the 
improvements of mechanical properties and function of the implant (De Jonge et al. 
2008, Goodman et al. 2013).  The goal relies in achieving device stabilization by 
promoting a more robust tissue healing response and osteointegration i.e. direct bond 
with adjacent bone at the implant site (Koju et al. 2017). Consequently, the patient will 
have an earlier rehabilitation and faster functional recovery.  
For instance, biocompatible coatings, known for evoking a reduced host response, are 
currently an option to improve the bio-integration of medical devices after implantation. 
Ideally an implant coating besides being non-toxic, mechanical and chemical stable 
(Bridges & García 2008). It should also avoid additional tissue injury and ensure effective 
device-tissue communication; and preferably present a surface to minimize non-specific 
protein adsorption i.e. biofouling and inflammatory/immune cell adhesion that would 
exacerbate the foreign body response (Zhang et al. 2014a). Among the foreign body 
response events, protein and leukocyte adsorption process i.e. bio-fouling is one of the 
first events taking place soon after implantation, thus playing a crucial role on the 
subsequent cascade of inflammatory events (Bixler & Bhushan 2012). For this reason, 
the utilization of the so-called anti-fouling coating, which are know for minimizing the 
adsorption of non-specific protein, cell have been the subject of much interest and 
extensive research within the last few years. In terms of TJR, the aim is to diminish the 
extension of an inflammatory response or at least avoid the adverse fibrotic 
encapsulation of the implant, that is known for impairing the implant function (Bixler & 
Bhushan 2012, Bridges & García 2008).  
Among all, polyethylene glycol (PEG) has been one of the most studied anti-fouling 
coatings (Banerjee et al. 2011); when grafted to a surface this hydrophilic polymer has 
demonstrated to be a impair specific proteins and bacteria adhesion, mainly due to its 
ability of retaining interfacial water molecules. More details regarding PEG utilization as 
anti-fouling strategy can be found in the excellent review published by Banerjee et al. 
(Banerjee et al. 2011). Other studies (Zhang et al. 2014a,b) have also demonstrated that 
other polymers such as heparin, chitosan and hyaluronic acid can be utilized as anti-
fouling coating in orthopedic field to improve the performance (e.g. implant surface 
osteointegration, bone regeneration) of orthopedic devices (Singhatanadgit 2009, Tejero 
et al. 2014). The reactive groups (e.g. amino and hydroxyl) present in the polymeric chain 
have been used to bind these biopolymers to orthopedic metal implants surface (Chiang 
et al. 2012). For example, chitosan coatings, due to its cationic nature are reported to 
attract negative charged cytokines and growth factors, promoting cellular attachment and 
support the formation of natural extracellular matrix (EM), which are crucial factors for 
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bone healing (Bosco et al. 2012, von Wilmowsky et al. 2014). Also fibronectin, a non-
collagen and natural occurring protein that contains in its structure the peptide sequence 
arginine-glycine aspartic-acid (RGD), has been widely used to facilitate adhesion and 
spreading of osteogenic cells (Lieder et al. 2012) to a variety of implant surfaces, 
including titanium (Middleton et al. 2007). Additionally, other studies reported the 
utilization combination of different bioactive compounds to form a coating with anti-
inflammatory properties. Li et al (2014)  assessed the co-immobilization of heparin and 
fibronectin in order to improve biocompatibility and anti-inflammatory properties of 
titanium surface (Li et al. 2014). Results obtained from in vitro macrophage culture, 
including TNF-α (pro-inflammatory cytokine) production, suggested that the co-
immobilization of heparin and fibronectin complex improves the anti-inflammatory 
properties of untreated titanium surfaces. 
More recent review (Koju et al. 2017), highlights the utilization of orthopedic implant 
coatings using the “ old biomimetic technique” with some interesting modifications. The 
main advantage of this technique is that coating is applied onto the implant surface under 
biomimetic conditions under favorable physiological conditions by using different 
compositions of simulated body fluid (SBF) (medium pH of 7.4 at 37ºC). As a result, a 
bone-like calcium deficient carbonated hydroxyapatite coating is formed on the implant 
surface, which is especial beneficial to form a direct bond with the adjacent implant bone. 
Regarding the approaches utilised to coat the implants surface it should be noted that 
despite extensive research efforts only a few techniques have made it to clinical trials 
and respective commercialization (Bosco et al. 2012). In fact, most of the techniques are 
still in the early-clinical phase. Determining factors such as coating adhesion, cost-
effectiveness and high costs related to upscaling limited the utilization of various novel 
surface engineering techniques 
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1.4.2 Anti-inflammatory drug-eluting implants  
The systemic drug delivery approaches i.e. drug is administrated via the circulatory 
system to accomplish anti-inflammatory effect have been shown in the above chapter 
(1.4 Approaches to improve longevity/success rates of total joint replacement). 
In this chapter, the local delivery strategies reported in the last decades and their 
numerous recognized advantages are reviewed (Figure 8). Local drug delivery is a more 
direct and site-specific manner to modulate inflammatory response, and in general it 
implicates the utilization of active surface containing anti-inflammatory agents such as 
drugs or biomolecules (Luo et al. 2011, Ma et al. 2016, Urbanska et al. 2014). Mainly 
this approach instigates more efficient therapies with significantly reduced side effects 
for patients. 
 
 
Figure 8. Summary of the advantages of local drug delivery strategies over 
systemic drug delivery, and examples of some approved local-drug delivery 
products. Adapted from (Wu & Grainger 2006). 
 
In the last few decades, drug-eluting implants have emerged as an advantageous 
alternative to traditional systemic drug administration for a broad range of clinical fields 
(Santos et al. 2014). This concept relies on the utilization of drug delivery systems 
incorporated on the implant, i.e. drug-eluting implants, capable of locally delivering the 
different drugs, including anti-inflammatory ones (Bhusal et al. 2016, Chung et al. 2015, 
Wang et al. 2013, Zhang et al. 2014a). The first drug eluting system to be developed was 
hormone pellets, which were implanted under the skin of livestock, aiming to improve 
their growth and make production more efficient (Santos et al. 2014). Regarding 
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periprosthetic inflammation treatment, the developed drug delivery system should 
modulate the inflammatory response in way that, a balance between inflammation and 
repair must be achieved to ensure successful tissue healing around the implant. Mainly, 
an ideal system will initially modulate acute inflammation, avoiding this way chronic 
inflammation and thus successfully starting a reparative wound healing phase (Goodman 
et al. 2013). The utilization of drug delivery systems provides several advantages apart 
for the drug entrapped per se (Dawes et al. 2011, Erdemli et al. 2014, Pioletti 2008), 
such as; (a) the drug is rapidly and effectively available at peri-implant bone overcoming 
limitations of systemic delivery; (b) reduction of the amount of drug needed to achieve 
therapeutic effects, decreasing the potential side-effects of the drug (Lopes et al. 2013, 
Sun et al. 2010), among others (Anselmo & Mitragotri 2014). 
In medical field, the utilization of drug/device combination products has been growing, 
products such as drug eluting-cardiovascular stents (Zhang et al. 2015), ocular implants 
(Feng et al. 2014), scaffolds and insulin pumps (Vallejo-Heligon et al. 2016) More 
detailed reviews regarding drug-eluting devices for orthopedic applications can be find 
in the literature (Goodman et al. 2013, Koju et al. 2017, Lyndon et al. 2014). From all 
these, cardiovascular eluting drug-stents to prevent restenosis, and drug-eluting 
implants to prevent infection in orthopedic and dental application are the ones which 
have been showing more approved products (Dangas et al. 2010, Gutowski et al. 2014). 
Recently, FDA approved a DEX intra-vitreal eye-implant, OZURDEX ® that is able to 
provide an extended 3 months drug release, avoiding the frequent need of DEX 
injections (Haller et al. 2011). Although, corresponding to the orthopedic applications, 
most of the studies on drug delivery systems have been performed for targeting infection 
(Moskowitz et al. 2010, Taha et al. 2013), such as bone cements associated with 
antibiotics or by simply immobilizing antibiotics onto implant metallic surfaces (Hickok & 
Shapiro 2012, Lyndon et al. 2014). Other biomaterials such as phosphate cements, 
hydroxyapatite, chitosan and poly (lactic-co-glycolic acid) have been prepared into 
different forms e.g. granules, matrices, coatings, foams, hydrogels, membranes, 
sponges) to be used to develop drug-eluting implants for bone related applications 
(Lyndon et al. 2014, Santos et al. 2014).  For instance, Mendez and co-workers (Mendez 
et al., 2004) reported the study of an injectable bone cement formulation as a potential 
carrier of anti-inflammatory drug model, fosfosal 2-(Phosphonooxy) benzoic. Results 
demonstrated a local release of fosfosal from PMMA-Bioactive glass cement that could 
eliminate the need of anti-inflammatory drugs systemic administration, although further 
in vitro and in vivo studies are needed to prove this theory. Likewise application of 
nanotubes as anti-inflammatory delivery systems have been extensively reported in 
literature (Doadrio et al. 2015, Minagar et al. 2012). These systems have clearly shown 
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several advantages in orthopaedic applications such as in vivo and in vitro biological 
activity in terms of osteoblasts attachment, proliferation and differentiation (Das et al. 
2009, Sobieszczyk & Klotzke 2011) and anti-inflammatory activity per se (Luo et al. 
2011). Also the utilization of dendrimer-conjugates stand out as particularly promising 
system to modulate inflammation, mainly due to the possibility of achieving a high drug–
loading and a controlled release profile into the site of periprosthetic inflammation 
(Caminade & Turrin 2014, Gillies & Fréchet 2005, Wu et al. 2015). Some examples 
regarding utilization of anti-inflammatory delivery systems with potential application in 
the orthopedic field are summarized in Table 2. 
 
Table 2. Anti-inflammatory delivery systems with potential application to 
orthopedic field. 
Anti-
Inflammatory 
Agent 
Delivery 
System 
In Vitro/In 
Vivo Assay 
Anti-
Inflammatory 
Effect 
Reference 
Curcumin Exosomes Raw 264.7 
macrophage 
cell line 
Inhibition of IL-6 
and TNF-α 
when compared 
to curcumin 
alone 
 
(Sun et al. 
2010) 
Dexamethasone 
(Dex) 
Polylactic-co-
glycolic acid 
(PLGA) 
microspheres 
Simian Virus-
immortalized 
Human Fetal 
Osteoblast 
(SV-HFO) 
cells 
Promoted 
osteoblast 
differentiation  
and matrix 
mineralization, 
when compared 
to free drug. 
 
 
(Dawes et 
al. 2011) 
Erythromycin 
(em) 
Poly(amidoa
mine) 
dendrimer 
(PAMAM) 
LPS-activated 
Raw 264.7 
macrophages 
cell line 
Inhibition of 
inflammatory 
marker i.e. nitric 
oxide 
concentration 
(NO) (~65mM) 
when compared 
with cells 
 
(Bosnjakovi
c et al. 
2011) 
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treated with free 
EM (~85mM). 
Dex 
 
N-(2-
hydroxypropy
l) 
methacrylami
de (HPMA) 
co-polymer 
Murine 
calvaria model  
Single injection 
of Dex-
conjugated-
HPMA had the 
same 
therapeutic 
effect 
i.e.osteolysis 
attenuation as a 
daily Dex 
administration  
 
 
(Wang et al. 
2007)  
Fluvastatin Polylactic-co-
glycolic acid 
(PLGA) 
microspheres 
Rat tibia model Transdermal 
injection 
enhanced 
formation and 
mechanical 
properties of the 
bone around 
titanium implants 
when compared 
to free drug. 
 
 
(Masuzaki et 
al. 2010)  
Dex 
 
Rosette 
nanotubes 
Osteoblast cell 
line  
 
DEX released 
from nanotubes 
increased 
osteoblasts 
density (3400 
cells/cm2) when 
compared to 
free DEX (2800 
cells/cm2). 
 
 
(Chen et al. 
2011)  
 
One of the requirements for these systems is that the drug release should be controlled 
and reproducible in order to avoid a toxic level or an inefficient level of therapeutic 
concentration (Ginebra et al. 2012). Moreover anti-inflammatory drug delivery systems 
must be able to modulate inflammatory reaction, but at the same time allow the bone 
growing/tissue regeneration in order to promote the implant osteointegration (Bridges & 
25 
 
García 2008). A recent study reported that diclofenac sodium-incorporated in PEF 
scaffold successfully inhibited PGE2 production and therefore COX-2 pathway. Although 
efficient in the treatment of acute inflammation, the inhibition of COX-2 also hampered 
the processes involved in bone regeneration and fracture healing (Sidney et al. 2015). 
In this case the anti-inflammatory delivery system does not respect the balance between 
inflammatory response and bone growth around the implant (osteointegration), making 
it unappropriated for orthopaedic application.  
A potential approach to improve the design of these anti-inflammatory drug-delivery 
systems might be based on the physiological environment of inflammatory events. 
Recently it was reported (Chung et al. 2015, Rajamaki et al. 2013) that during 
inflammation, the pH in joints may reach 6.6. This so called “local acidosis” during 
inflammation, is a result of infiltration and activation of inflammatory cells in the tissue, 
leading to increased oxygen and energy demand, enhanced glucose consumption and 
thus increased secretion of lactic acid. In patients with arthritis the synovial fluid pH was 
reported to had average pH range of 6.8-7.1, compared with a pH range of 7.4-7.8 
observed in healthy synovial fluid (Cummings & Nordby 1966, Fan et al. 2012, Jebens & 
Monk-Jones 1959). This information suggests that acidic environment (i.e. decrease of 
pH) may be an important stimulus to trigger the release of anti-inflammatory drugs from 
total joint replacement surface.  
Despite the lack of success of the systems reported above (Table 2), it as to be 
considered that anti-inflammatory drug delivery systems for orthopaedic applications is 
still a very recent research topic. In this sense, some optimization of this systems is 
needed, mainly critical parameters such as the drug releasing kinetics needed to keep 
concentration within the therapeutic dose, and how to personalize the drug dosage for 
different clinical applications/therapies. Specifically, to target inflammation, more 
research is needed to increase the probability of developing a successful system, where 
the appropriate release and concentration of anti-inflammatory drug would be able 
modulate the inflammatory response after device implantation, and consequently to 
reduce the need for revision surgery due to aseptic loosening. 
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1.5 Aim of the project  
Over the past decades, the utilization of TJR has expanded dramatically owing to 
increased life-expectancy, changing lifestyles and improved implant technology (Losina 
et al. 2012, Revell 2014). This has extensively improved quality of life of patients 
worldwide. However, early implant failure and problems during healing have been 
reported for certain patient groups such diabetic and elder people where bone 
regeneration is compromised. Besides, with the increasing age of the population, the 
number of patients with poor bone quality is constantly rising. Also, the increasing 
lifespan after primary surgery increases the probability for the exigency of revision. 
These present and upcoming challenges require a better TJR implant device technology. 
One of the major problems associated with TJR are the exacerbated inflammatory events 
caused either by tissue injury or wear debris (Gallo et al. 2013), that might end-up as 
osteolytic events and when not treated in aseptic loosening. Over last decades, although 
much research has been focused to overcome the TJR aseptic loosening (Ren et al. 
2011a, 2013), still this condition cannot yet be prevented or treated by existing 
nonsurgical methods. It is therefore apparent that localized acute inflammation must be 
modulated to ensure TJR long lifetime and functionality. This can be achieved using anti-
inflammatory agents, such as DEX.  Nevertheless, undesired side effects of DEX 
systemic delivery had been extensively reviewed last decades (Oray et al. 2016, Saag 
et al. 2008, Schäcke et al. 2002). Hence, strategies have been applied in clinical practice 
to minimize the undesired side effects of anti-inflammatory drugs, including the local 
administration/injection of anti-inflammatory drugs into the articular cavity (Petit et al. 
2014). Although in terms of clinical outcome, being a soluble drug, a rapid clearance of 
DEX (e.g. DEX sodium phosphate) is observed, requiring the frequent administration of 
the therapeutic drug such daily administration for 3−6 weeks (Chung et al. 2015, Elron-
Gross et al. 2009). An ideal solution could be the functionalisation of implant surface with 
an anti-inflammatory agent, where a controlled, and continuous local delivery of DEX 
therapeutic concentration at the implantation site would be achieved. In this context, 
hypothetically the model system developed in this study, which consists on the 
functionalisation of implant surface with an anti-inflammatory drug (DEX) was suggested 
as a potential approach to avoid aseptic loosening. The DEX eluting model system was 
prepared through the surface functionalization of TiO2 particles using different 
approaches, amino, mercapto and LbL routes. Respectively DEX was either attached by 
covalent bounding (amino and mercapto routes), or by electrostatic interaction (LbL 
route), where DEX was attached to (amino)-functionalised TiO2 particles, with 
subsequent deposition of CH and ALG layers. The benefits of using functionalised TiO2 
particles as device surface model for drug eluting implants has been extensively 
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reviewed in literature (Bagherifard 2017, Lyndon et al. 2014, Popat et al. 2007, Wu et al. 
2014). The main advantage of this system is that the surface modification performed on 
TiO2 particles can be applied on clinically used TJR, made of titanium and titanium alloys. 
Besides, DEX will be directly release from implant surface rather than systemically, 
reducing unnecessary side effects. The utilization of different synthetic routes to attach 
DEX to functionalised- TiO2 particles, was investigated to assess if the utilization of 
different linkers i.e. functional groups between DEX and TiO2 particles will affect the 
loading efficiency of DEX, drug release profile, and the cellular behaviour e.g. toxicity, 
bioactivity of the model system.  
Regarding model system characterisation, zeta potential measurements, TGA analysis, 
FT-IR, were performed, thus respectively providing evidence of the different organic 
group attached i.e. -NH2, -SH on the surface of TiO2 particles. DEX attachment was also 
investigated by assessing drug loading and encapsulation efficiency. Moreover, average 
size and morphology of model system was evaluated by means of transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM). In addition, in vitro release 
studies were performed to investigate DEX release profile for each route and under 
different joint conditions, healthy joint  (pH=~7) (Goldie & Nachemson, 1970), and 
inflamed joints, which are associated with local acidosis (pH between 6-6.5)  (de Nadai, 
et al., 2013). On the other hand, in vitro studies, using a murine macrophages cell line, 
Raw 264.7, were conducted to investigate parameters such as toxicity or anti-
inflammatory properties of the model system herein developed. For that an in vitro 
inflammation model, LPS-activated cells, was previous optimized and validated to 
investigate the anti-inflammatory activity of DEX released from TiO2 particles under 
biological conditions. 
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The present PhD project aims to develop an anti-inflammatory drug eluting model implant 
to target one of the major causes for joint revision surgery, aseptic loosening secondary 
to periprosthetic osteolysis. We hypothesize that local release of an anti-inflammatory 
drug at bone-implant interface will modulate the inflammatory response induced by wear 
debris, avoiding this way an uncontrolled and prolonged chronic inflammation, and the 
following bone loss i.e. osteolysis around the implant (Figure 9). 
 
Figure 9. Schematics of (a) an anti-inflammatory drug-eluting surface model 
system and (b) potential effect when incorporated at implant surface.  
 
To achieve the mentioned goals, an experimental research plan was defined: 
 
(i) Anti-inflammatory drug delivery model system development by different 
synthetic routes (amino, mercapto and Layer-by-Layer routes): 
In an initial stage, the goal was to develop a model system capable of locally delivering 
an anti-inflammatory drug. With this aim TiO2 particles, widely applied in biomedical 
field for its biocompability, easy scale-up and cost-effective characteristics, were 
selected as drug delivery model system.  It is expected that surface modification 
performed on TiO2 particles can be applied on clinically used total joint replacements, 
made of titanium and titanium alloys. We hypothesize that by preparing TiO2 particles 
loaded with DEX through different synthetic routes, it will result in different level of 
drug loading, different release kinetics and subsequently different anti-inflammatory 
efficacy. With this aim, TiO2 particles containing DEX were prepared by modifying the 
surface of TiO2 particles through different synthetic routes: Amino, mercapto and 
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Layer-by-Layer (LbL), were targeted to introduce surface functionality on TiO2 
surface for subsequent attachment of an anti-inflammatory drug model. For this 
purpose, DEX, a synthetic glucocorticoid has been employed as a drug model, since 
it is already clinically used to modulate the inflammatory reaction after prosthesis 
implantation. 
a) Amino and Mercapto routes, the model system was prepared by 
covalently binding DEX to carboxyl functionalised TiO2 particles. In this case, 
the carboxyl-functionalized surface will interact with hydroxyl group of DEX, thus 
forming an ester bond between the anti-inflammatory drug and surface of TiO2 
particles.  
 
b) Layer-by-Layer (LbL) route the aim was to test an alternative synthetic 
route to covalent bonding, where the anti-inflammatory drug will be adsorbed 
into amino-functionalised TiO2 particles (template) using electrostatic 
interactions, and it will be surrounded by multilayer of positively and negatively 
charged polymers, chitosan and alginate. 
(ii) Surface and chemical/material analysis:  
In a second stage, aiming to gain further insight on functionalization of TiO2 particles 
and attachment of DEX, the whole synthetic process of TiO2 particles surface 
modification in different routes (before and after DEX loading) was investigated by 
means of thermogravimetric analysis (TGA), Fourier Transformed infra-spectroscopy 
(FT-IR) and zeta potential measurements. Also, other parameters such as the average 
size and morphology of DEX loaded-functionalised TiO2 particles were evaluated by 
Transmission electron microscopy (TEM), as well as DEX release profile under different 
pH conditions. 
 
(iii) In vitro cell studies:  
Macrophages are the first immune cells to act towards invading organisms or tissue 
injury, and they play a key role in inflammatory response (Goodman et al. 2014, Hallab 
2016). Thus, making them the in vivo targets in the orthopaedic applications envisaged 
for model system here in studied. For this purpose, in vitro Raw 264.7 macrophage cell 
line, was used to assess the biological behavior i.e. cytotoxicity and anti-inflammatory 
activity of DEX released from functionalised-TiO2 particles. Besides, it is efficacy on 
screening the potential anti-inflammatory activity of drugs and delivery systems has been 
already demonstrated in previous studies (Jeon et al. 2000, Yuan et al. 2013).  
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(a) Cytotoxicity assessment  
Before assessing the bioactivity of drug delivery model system on the cells, preliminary 
studies were done to investigate the individual effect of LPS and DEX on the RAW 264.7 
cells viability. This way is possible to assess if the concentration of DEX that is released 
from the functionalised-TiO2 particles, and the LPS concentration used to induce 
inflammation, will cause any adverse reaction to the cells. To assess cell cytotoxicity 
Methylthiazolyl Tetrazolium (MTT) and Lactase dehydrogenase (LDH) release assay 
were performed. 
 
(b) Characterization and optimization of in vitro inflammation model 
Murine macrophage cell line (Raw 264.7) is known for exhibiting features in common 
with monocyte macrophages, although it does not mimic macrophages behaviour under 
inflammatory conditions.  For this purpose, RAW 264.7 cells were treated with 
lipopolysaccharide (LPS), a component of bacterial wall, known to induce a variety of 
inflammatory cytokines production in macrophages. Different Raw 264.7 cell seeding 
densities upon different LPS concentrations were tested to optimize the in vitro model. 
For this purpose, after exposing the cells to LPS, nitric oxide (NO) and tumor necrosis 
factor-alpha (TNF-α) production was measured to investigate the RAW 264.7 cells LPS-
activation and consequently the reliability of the in vitro inflammation model. Being 
respectively a pro-inflammatory mediator and a pro-inflammatory cytokine, NO and TNF-
α expression was simultaneous assessed to get further insight about the inflammation 
level. Moreover, cellular morphological changes after LPS addition were observed using 
fluorescence microscopy. 
 (c) Anti-inflammatory activity assessment 
Once the preliminary in vitro studies (iii, a and b) were performed, the biological activity 
of DEX-loaded functionalised-TiO2 particles was investigated to assess the anti-
inflammatory activity. For this purpose, the LPS-stimulated RAW 264.7 cells were 
exposed to the broths collected from drug release studies. This way the cytotoxicity and 
anti-inflammatory activity of DEX released from drug delivery model system were 
investigated. As reported in previous studies (Joo et al. 2014, Soromou et al. 2012, van 
der Bruggen et al. 1999) LPS-activated macrophages secrete several inflammatory 
cytokines. Particularly, high production of NO and TNF-α has been associated with 
chronic inflammation (Parameswaran & Patial 2010, Zamora et al. 2000).  On the other 
hand, DEX is known to block transcription if nuclear factor-kappa B (NF-Кβ), and 
consequently suppress the expression of inflammatory cytokines including nitric oxide 
(NO) and tumor necrosis factor-alpha (TNF-α) (Huebner, Shrive, & Frank, 2014).  
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Therefore, inhibition of NO and TNF-α production in LPS-stimulated cells was 
simultaneous assessed to get further insight about inflammatory effect of DEX released 
from functionalised-TiO2 particles. Aiming to analyse the levels pro-inflammatory 
cytokines, Enzyme Linked Immunosorbent Assay (ELISA) (TNF-α,), and Griess reagent 
(Nitric oxide) assay were performed. As shown in Figure 9.b, we speculate that release 
of DEX from functionalised-TiO2 particles will modulate the inflammation in LPS-activated 
macrophages. Moreover, cellular morphological changes after LPS addition were 
observed using inverted microscopy. 
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2. Materials & Methods 
 
2.1 Chemicals 
Dex-Loaded TiO2 Particles synthesis 
Titanium (IV) oxide (Anatase, <25nm, 99.7%), (3-mercaptopropyl) trimethoxysilane 
(MPTMS, 95%), (3-Aminopropyl)triethoxysilane (APTS, 99%), succinic anhydride 
(≥99%), Dexamethasone (Dex, >97%), 4-Pentenoic acid (≥98%, FG), 1-(3-
Dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (EDC, 98+%), N-
hydroxysulfosuccinimide (Sulfo-NHS, 98%), N-morpholino) ethanesulfonic acid (MES) 
hydrate (>99.5%), Chitosan, Sodium Alginate, Phosphate buffer solution (PBS, pH=7.4) 
tablets, Sodium acetate trihydrate (≥99%), sodium chloride (ACS reagent, ≥99%), citric 
acid monohydrate (ACS reagent, ≥99%), disodium phosphate (ACS reagent, ≥99%) 
were purchased from Sigma-Aldrich, UK. HPLC grade acetonitrile, Glacial Acetic Acid, 
Methanol, Dichloromethane (DCM) and Toluene were all purchased from Fisher, UK. All 
other chemicals were reagent grade, stored according to manufacturer's guidelines and 
used as received. 
 
2.2. Buffers preparation  
2.2.1 2-(N-morpholino) ethanesulfonic acid (MES) buffer 
MES buffer (10-2 M, pH 6) was prepared by dissolving 1,95g of MES hydrate in 100 mL 
of deionized water. The pH was achieved by dissolving one pellet of sodium hydroxide 
into MES buffer solution.  
2.2.2 Acetate buffer 
Acetate buffer (10-3 M, pH 4 and 5) was prepared by combining different volumes of 
sodium acetate hydrate (CH3COONa·3H2O) and acetic acid (CH3CO2H) solutions, 
according to the following table (Table 3). 
Table 3. Acetic Acid-Sodium acetate buffer preparation.  
pH Acetic Acid (0.1 M) mL Sodium acetate (0.1 M) mL 
4 82 18 
5 30 70 
6 7 93 
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2.2.3 Sodium Chloride (NaCl) buffer 
NaCl buffer (10-3 M, pH 7) was prepared by dissolving 0.058 g of NaCl in 100 mL of 
deionized water 
2.2.4. Citric acid-disodium phosphate buffer  
Citric acid-disodium phosphate buffer was used to obtain pH values between 4 and 7. 
The buffer was prepared by combining different volumes of citric acid (C6H8O7) and 
disodium phosphate dodecahydrate (H25 Na2O16P) solutions, according to the following 
table (Table 4): 
    Table 4.Citric acid-disodium phosphate buffer preparation.  
pH Citric acid (10-3  M) mL Disodium phosphate (10-3  M) mL 
4 61.45 38.55 
5 48.50 51.50 
6 36.85 63.15 
7 17.65 82.35 
 
2.2.5. Phosphate buffer saline (PBS) 
PBS buffer was obtained by dissolving 1 Tablet of PBS (pH=7.4) in 100 mL of 
deionized water. 
2.3 DEX-loaded functionalised TiO2 particles synthesis 
2.3.1 Amino-route  
1 g of TiO2 particles were dispersed in 15 mL of anhydrous toluene. The TiO2 particles 
surface was functionalized with amine groups by adding 100µl of APTS under stirring 
and incubation for 24 hours. Subsequently, the amine-functionalized particles (NH2-TiO2) 
were isolated by centrifugation at 14000 rpm for 5 minutes (LE-80K Ultracentrifuge, 
Beckman Coulter, UK) at 20°C followed by washing for at least three cycles with toluene 
to remove unreacted APTS. To re-disperse the centrifuged particles in the fresh toluene, 
they were vortex mixed (WhirliMixerTM, Fisherbrand, UK) to make sure a visually well-
dispersed suspension was regained before centrifuging again. The resulting particles 
were dried under the fume hood for 24 hours. Then amine-functionalized particles (NH2-
TiO2) (250 mg) were dispersed in 100mL of DCM and purged with nitrogen. Succinic 
anhydride (25 mg) was dissolved in 2.5 mL of DCM and added to the reaction mixture to 
obtain carboxylic acid functionalized surface. This solution/suspension was kept under 
nitrogen for 18 hours. Subsequently, the succinilated-particles (COOH- NH2-TiO2) 
suspension was isolated by centrifugation at 14000 rpm for 5 minutes at 20°C followed 
by washing for at least three cycles with methanol to remove unreacted materials, 
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including re-dispersion/stirring step. The resulting particles were dried under the fume 
hood for 24 hours.  The DEX was loaded into particles following two different methods: 
DEX adsorption and DEX conjugation.  
DEX conjugation 
To obtain DEX loading (covalent attachment), 50mg of DEX was dissolved in 100 mL 
MES buffer (0.1 M, pH 6.0). This solution was used to disperse 250mg of functionalized 
particles (Amino, Mercapto or Dendron), 10 mg EDC and 10 mg Sulfo-NHS. The 
suspension was kept under vigorous mixing for 24 hours. The Dex loaded particles were 
recovered by centrifuging at 14000 rpm for 5 minutes at 20°C by washing for at least 
three cycles with methanol to remove unattached DEX. To re-disperse the centrifuged 
particles in the fresh solution, they were vortex mixed for 5 minutes to make sure a 
visually well-dispersed suspension was regained before proceeding to a new 
centrifuging/washing cycle again. Then DEX loaded particles were left to dry under the 
fume hood for 24 hours.  
 
DEX adsorption  
For comparison purposes, the physical adsorption of DEX was also assessed. 50mg of 
DEX was dissolved in 100 mL MES buffer (0.1 M, pH 6.0). This solution was used to 
disperse 250mg of functionalized particles (Amino, Mercapto or Dendron). The 
suspension was kept under vigorous mixing for 24 hours. The Dex-loaded particles were 
recovered by centrifuging at 14000 rpm for 5 minutes at 20°C by washing for at least 
three cycles with methanol to remove unattached DEX. To re-disperse the centrifuged 
particles in the fresh solution, they were vortex mixed for 5 minutes to make sure a 
visually well-dispersed suspension was regained before proceeding to a new 
centrifuging/washing cycle again. Then DEX loaded particles were left to dry under the 
fume hood for 24 hours. 
2.3.2 Mercapto-route 
A similar protocol to the one utilized on the amino route (2.3.1 Amino-route) was adopted, 
with some modifications. Instead of using APTS, the TiO2 particles surface was 
functionalized with thiol groups by adding 100µl of MPTMS under stirring and incubation 
for 24 hours. Similarly, the carboxyl functionalization step was different, where 
functionalization was achieved through dispersion of thiol-functionalized (Ti-SH) particles 
(250 mg) in 100 mL of methanol: water (2:1) solution, and then addition of 4-Pentenoic 
acid (25mg). This suspension was kept under ultraviolet using a hand-held UV lamp 
(UVGL-58, Cambridge, UK) set at λ = 254 nm for approximately 3 hours. Furthermore, 
the protocol applied to load DEX was also the same, where DEX conjugation and 
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adsorption were assessed.  
2.3.3 Layer-by-Layer (LbL) Route 
2.3.3.1 Preparation of polyelectrolyte solutions  
The polyelectrolyte solutions were prepared dissolving sodium alginate (ALG) (2mg/mL), 
chitosan (CH) (2mg/mL), and DEX sodium phosphate (10mg/mL) in acetate buffer (0.1M, 
pH 5) with agitation using a magnetic stirrer (at 600 rpm), during 2 h at room temperature 
(20 ºC). 
 
2.3.3.2 Assessment of polyelectrolytes solution charge  
In layer by layer deposition the charge of polyelectrolyte solutions (CH, ALG, and DEX) 
must be measured to guarantee a correct electrostatic interaction, between the layers 
i.e. between NH2-TiO2 nanoparticles, DEX, ALG and CH layers. So, before starting LbL 
assembly the charge of each polyelectrolyte solution was evaluated by means of zeta 
potential measurements. 
 
2.3.3.3 Synthesis of multilayer DEX-loaded-TiO2 particles 
Multilayer capsules were prepared by alternating deposition of alginate, chitosan and 
DEX layers onto a positively charged template i.e. amino functionalised particles (NH2-
TiO2 particles). To prepare the template (NH2-TiO2 particles), the same method 
described in 2.3.1 Amino-route was utilized. After that, the alginate, chitosan, and DEX 
layers were deposited onto NH2-TiO2 particles, by adopting the following protocol: Briefly 
250mg of NH2-TiO2 particles were exposed to 20mL of ALG (2 mg/mL) solution. The 
mixture was incubated at room temperature, for 10-15 min under gentle stirring.  The 
excess of polyelectrolyte was removed by two repeated circles of centrifugation at 4000 
rpm for 5 minutes (LE-80K Ultracentrifuge, Beckman Coulter, UK) at 20°C with 
consequently removal of supernatant and re-dispersion in fresh acetate buffer (0.1 M, 
pH 5), discarding the unabsorbed ALG. The suspension was vortex mixed 
(WhirliMixerTM, Fisherbrand, UK) to make sure a visually well-dispersed suspension was 
regained before centrifuging again. After the second cycle of centrifugation, the 
supernatant was removed, and particles were re-suspended in 20 mL of CH solution (2 
mg/mL). The mixture was incubated at room temperature, for 10-15 min under gentle 
shaking, thus assembling the 2nd layer of the capsule (CH layer). The excess of 
polyelectrolyte was removed by centrifugation/ re-dispersion cycle in fresh acetate buffer 
(0.1 M, pH 5), discarding the unabsorbed CH.  
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Figure 10. Schematics regarding the preparation of DEX-loaded particles, using 
amino-functionalised (NH2-TiO2) particles as template. 
 
The following DEX layer was deposited using a similar procedure to the one described 
before, with the exception that LbL particles were re-suspended in 10 mL of DEX solution 
(10 mg/mL). To optimize this methodology after depositing the first DEX layer, different 
approaches i.e. experiment 1 and 2 were tested (Figure 10) by varying the type and 
combination of layers deposited onto template. Therefore, after the first DEX layer 
deposition, alternating CH, ALG or DEX layers were deposited according to the approach 
(Experiment 1 or 2) utilized, until the desired number of layers was achieved. 
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2.4 Particle characterization 
2.4.1 Size measurements and surface morphology 
Transmission electron microscopy (TEM) 
Images of particles were obtained using a Zeiss 902 transmission electron microscope 
(TEM) operating at a voltage of 80 kV. The aqueous dispersion of the particles was drop-
cast onto a carbon-coated copper grids, and grid was dried at room temperature (20ºC) 
before loading into the microscope (direct deposition). The average particle size, size-
distribution and morphology analysis of the samples was carried out from transmission 
electron micrographs, where average size was estimated using the software Image J for 
Windows (Version 1.50i). 
Scanning electron microscopy (TEM) 
The surfaces of the TiO2 particles and functionalised ones, were gold coated using a 
sputter compact coater (Shimadzu model CC-50), and imaged using a scanning electron 
microscope (SEM, VEGA3, TESCAN) at 15 KeV, with an integrated microanalysis X-ray 
system (EDS -energy dispersive spectrometer). 
2.4.2 Zeta potential measurements 
The electrophoretic mobility was determined by Dynamic Light Scattering (DLS) with a 
Malvern Zetasizer, ZS particle characterization system (Malvern Instruments Limited, 
UK), using a He–Ne laser (wavelength of 633 nm) at an angle of 17° which is combined 
with the reference beam to analyse the samples. Zeta potential values were determined 
by applying the Henry equation to convert electrophoretic mobility(𝑈ா) to zeta potential 
(ζ) values Equation 1): 
Equation 1: Henry Equation              𝑼𝑬 =
𝟐𝜺𝜻𝒇(𝑲𝒂) 
𝟑𝜼
 
Where, ζ describes the zeta potential, ε is the dielectric constant, 𝜂 describes the 
viscosity, and f (κa) is Henry’s function. As electrophoretic determinations of zeta 
potential are most commonly made in aqueous media and using moderate electrolyte 
concentration, the f (Ka) is equal to 1.5, and is referred to as the Smoluchowski´s 
approximation (Nita, Chiriac, Bercea, & Wolf, 2013). The electrophoretic mobility is 
obtained by performing an electrophoresis experiment on the sample and measuring the 
velocity of the particles using Laser Doppler Velocimetry (LDV). For measuring zeta 
potential, 1mg of particles was dispersed in 1mL of buffer solution using the vortex and 
the ultrasonic bath (~30min). Then suspension was immediately transferred into the 
capillary cell. For pH 4 and 5, an acetic acid/sodium acetate buffer (0.01 M or 10-3 M) 
was prepared. As for pH 7, Sodium Chloride (NaCl) buffer (0.01 M) was utilized. Results 
were given as the average ± standard deviation of three measurements. 
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2.4.3 Fourier Transformed infrared spectroscopy (FT-IR) 
FT-IR was used to identify the functional group in the samples before and after 
functionalization steps. Spectra were recorded on a Shimadzu IRAffinity-1S apparatus 
equipped with ATR diamond accessory, at room temperature between 4000 and 300 cm-
1 with 4 cm-1 resolution running 16 scans. 
2.4.4 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) was performed using a Perkin-Elmer TGA 4000 
instrument. The samples were heated from 50 to 800 °C with a constant heating rate of 
10 °C per minute. Weight loss percentage of each sample was calculated relative to 
initial weight of sample, prior to heating. As for organic and inorganic material 
percentage, it was calculated by subtracting the point at initial weight loss (%) up to when 
the line plateaus (approximately around 800°C). 
  
2.4.5 DEX loading and entrapment efficiency estimation  
Drug loading was calculated using the High-Performance Liquid Chromatography 
(HPLC) standard calibration curve of DEX and DEX sodium phosphate, which were 
plotted to define the quantitative relationship between observed absorbance and 
concentration of the drug (Figure 81, 
I. Appendix). The mass of DEX loaded into functionalised-TiO2-particles was estimated 
by analysing the supernatants obtained during the centrifugation/washing cycles, which 
was part of DEX loading step. Briefly, for amino and mercapto routes, the supernatants 
were collected from each centrifugation step (3 cycles). As for LbL route, supernatants 
were collected from each centrifugation step (2 cycles) after loading of each DEX, CH, 
and ALG layers.  
Then, the collected supernatants were analysed using HPLC to quantify the amount of 
DEX which was lost during centrifugation/washing cycles, and therefore was not loaded 
into the particles, as previously described (Pu et al. 2014). The DEX loading (%) and 
entrapment efficiency (%) were estimated based on the following equations (2 and 3)  
(Papadimitriou & Bikiaris 2009): 
 
Equation 2 Drug loading (%): 
𝑫𝒆𝒙𝒂𝒎𝒆𝒕𝒉𝒂𝒔𝒐𝒏𝒆 𝒍𝒐𝒂𝒅𝒊𝒏𝒈 (%) =
 (𝑫𝒆𝒙 𝑴𝒂𝒔𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒍𝒍𝒚 𝒂𝒅𝒅𝒆𝒅 − 𝑫𝒆𝒙 𝑴𝒂𝒔𝒔 𝒍𝒐𝒔𝒕 𝒄𝒆𝒏𝒕𝒓𝒊𝒇𝒖𝒈𝒂𝒕𝒊𝒐𝒏 
 (𝑷𝒂𝒓𝒕𝒊𝒄𝒍𝒆𝒔 𝑴𝒂𝒔𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒍𝒍𝒚 𝒂𝒅𝒅𝒆𝒅 )
 
Equation 3 Entrapment Efficiency (%): 
  𝑬𝒏𝒕𝒓𝒂𝒑𝒎𝒆𝒏𝒕 𝑬𝒇𝒊𝒄𝒆𝒏𝒄𝒚 (%) =  (𝑫𝒆𝒙 𝑴𝒂𝒔𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒍𝒍𝒚 𝒂𝒅𝒅𝒆𝒅 ି𝑫𝒆𝒙 𝑴𝒂𝒔𝒔 𝒍𝒐𝒔𝒕 𝒄𝒆𝒏𝒕𝒓𝒊𝒇𝒖𝒈𝒂𝒕𝒊𝒐𝒏 
 (𝑫𝒆𝒙 𝑴𝒂𝒔𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒍𝒍𝒚 𝒂𝒅𝒅𝒆𝒅 )
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All experiments were performed in triplicate. results are presented as the average and 
standard deviation of three samples. 
 
2.5 DEX release profile   
DEX loaded-functionalised TiO2 particles prepared as described above (2.3 DEX-loaded 
functionalised TiO2 particles synthesis), were dispersed in citric acid-disodium 
phosphate buffer (10 mg ml-1) within a pH range from 4-5, and in sodium acetate buffer 
(10 mg ml-1) within a pH range from 6-7 at 37°C. The solution was replaced daily with 
fresh buffer and analysed to quantify the amount of DEX release using reverse-phase 
High Performance Liquid Chromatography (HPLC). An Agilent series 1100 HPLC system 
was equipped with analytical column (Waters Spherisorb®, Sigma-Aldrich, St Louis, MO, 
USA), with Pore size- 80Å, 5 µm, and width x length- 4.6 mm X 150 mm), thermostated 
at 25°C. The method was adapted from Martín-Sabroso et al. (Martín-Sabroso, et al. 
2013); briefly, the injection volume was 10 μL, the mobile phase was PBS: acetonitrile: 
acetic acid (70:26:4), with a flow rate of 1 mL/min, and the detector was a UV 
spectrophotometer at 244 nm. An example of a chromatogram for a 1 mg/mL solution of 
DEX in DMSO is shown in Figure 81.B ( 
I. Appendix); the calibration curve of the HPLC detection of DEX is presented in Figure 
81.A ( 
I. Appendix). The renovation of the release medium volume (1 mL) was guaranteed after 
each sample withdraw. All experiments were performed in triplicate. Results obtained 
from HPLC analysis are presented as the average and standard deviation of three 
samples. 
2.6. Cell culture and treatments 
Cell studies were performed using a commercially available murine macrophage-like cell 
line, Raw 264.7 cells. We decide to utilize macrophage cell line because, as seen in the 
introductory chapter (1.3.2 Biological mechanism and inflammatory mediators), 
macrophages are the one the most important immune cells to act towards invading 
organisms or tissue injury. Consequently macrophages play a key role in inflammatory 
response (Goodman et al. 2014, Hallab 2016) by producing different inflammatory 
mediators (e.g. cytokines, NO) in response to pathogens such as bacterial LPS (Oh et 
al. 2012). For that reason, Raw 264.7 macrophages have been widely used in other 
studies to investigate the toxicity and bioactivity of different anti-inflammatory 
compounds(Kim & Ha 2009, Pinho et al. 2011, Vairappan et al. 2013), and potential anti-
inflammatory delivery systems (Bosnjakovic et al. 2011, Joo et al. 2014, Yuan et al. 
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2013).Regarding the treatments, the choice of treating the cells with different 
concentrations of DEX (3.9- 100 µg/mL) was based on the results obtained on drug 
release assay studies previously performed (4.2. DEX release profile). In addition, the 
DEX concentration of 100 µg/mL was tested to assess if a higher concentration will 
induce cell toxicity. As for LPS (LPS; E. coli serotype 026: B6; Sigma Cat. No. L2762) 
concentrations (0.1-1 µg/mL), it was chosen according to previous studies (Lee et al. 
2013, Oh et al. 2012, Pinho et al. 2011). Moreover, aiming to test the effect of DEX 
released from functionalised-TiO2 particles, Raw 264.7 cells were treated with broths 
collected from drug release studies previously performed as described above (2.5 DEX 
release profile). 
 
2.6.1 Raw 264.7 macrophages cell line 
RAW 264.7 cells (Figure 11) were obtained from European Collection of Cell Cultures 
(ECACC). Cells were grown in Dulbecco’s modified Eagle’s Medium (DMEM) containing 
10% fetal bovine serum and 100 U/mL of penicillin/streptomycin, under 5% CO2 at 37°C, 
in humidified air, and 70% of ethanol was used for disinfection of all stages throughout 
the experiments. The culture media was changed every 3 days, except when cells were 
thawed, in this case culture media was changed after 1 day to remove debris and 
unattached cells.  
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Figure 11. Pictures of Raw 264.7 cell line (medium confluence) (a) and High 
confluence (b). Pictures were taken under inverted microscope with X10 and x20 
magnification. (Scale bar=100 µm).  
The adherent cells were split once a week before reaching confluence. For splitting the 
culture medium was removed, 10 mL of fresh medium was added, and cells were 
scraped off the flask bottom and transferred to universal tube to be centrifuged (5000 
RPM, 5 minutes).  The obtained pellet of cells was re-suspended in 1mL of fresh media, 
and 10 µL aliquot of cell suspension was taken to perform cell counting. The cell number 
and viability in the cell suspension was determined as cells/mL, by using a cell counting 
chamber. Dead cells were stained with a trypan blue solution and were excluded from 
counting. Then, after cell counting, the cell suspension obtained after centrifugation was 
diluted and transferred to a new flask. For all experiments, the cells were subjected to 
no more than 10 cell passages. 
 
 
 
Figure 12. Schematic of the experimental plan adopted to assess the cellular 
viability and anti-inflammatory activity of DEX-loaded functionalised-TiO2 particles 
obtained by different synthetic routes. Cells were exposed to broths (i.e. DEX 
release from functionalised-TiO2 particles) according to release profile obtained 
for each synthetic route. 24h broths for amino/mercapto route (A) and at 24h, 48h, 
72h and 2 weeks broths for LbL route (B) studies. 
 
For all assays, cells were seeded at a density of 2x105 cells/mL and permitted to adhere 
over 4-5-hour period, before treatments were added, as previously described (Pinho et 
al. 2011). Preliminary studies to optimize cell density (cells/well) were performed, as can 
be seen in the appendix section ( 
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I. Appendix. Preliminary in vitro studies). All treatments were freshly prepared by diluting 
the stock solution in culture DMEM medium. In all experiments, a control was performed 
where cells were incubated only with culture medium. Raw 264.7 cells were cultured for 
7 days, (culture media changed every 3 days), and the cellular behaviour (e.g. viability, 
NO/TNF-α production) was assessed at different time points. Although all experiments 
were performed for 7 days, only results up to 3 days were showed in this thesis, mainly 
because after 3 days, MTT assay and cells observation under inverted microscope, 
revealed that macrophages were over confluent ( 
I. Appendix. Figure 87)  Moreover, as can be seen from drug release studies (3.4 DEX 
release profile), the route utilized to synthesize DEX-functionalised-TiO2 particles 
significantly affected the drug release profile. Not only the DEX concentration, but also 
the release duration were different for particles obtained by amino/mercapto (24 hours), 
(Figure 40 and Figure 41), and LbL route (2-3 weeks) (Figure 42 and Figure 43). For this 
reason, cellular behavior of RAW 264.7 macrophages was investigated according to 
release profile obtained for each synthetic route. Briefly, cells were exposed to broths 
(i.e. DEX release from functionalised-TiO2 particles) collected at different time points: 
24h for amino/mercapto route (Figure 12.A), and 24h,48h, 72h and 2 weeks for LbL route 
studies (Figure 12.B). The aim of this experimental set up was to assess the potential 
anti-inflammatory effect during the total period that is DEX released: 24h for 
amino/mercapto and 2 weeks for LbL routes.    
 
2.6.2 LPS-activated Raw 264.7 cell line: inflammation model 
Murine macrophage cell line, Raw 264.7 is known for exhibiting features in common with 
monocyte macrophages, although it does not mimic macrophages behaviour under 
inflammatory conditions.  For this purpose, in several studies RAW 264.7 cells were 
treated with lipopolysaccharide (LPS), an endotoxin, known to induce a variety of 
inflammatory modulators production in macrophages (Pinho et al. 2011, Sharma et al. 
2007). This is entirely applicable, since LPS-activated Raw 264.7 cells have been utilized 
in previous studies to evaluate the anti-inflammatory effect of potential anti-inflammatory 
drugs and delivery systems (Bosnjakovic et al. 2011, Joo et al. 2014, Lee et al. 2013, 
Terra et al. 2007, Yuan et al. 2013). LPS concentrations to be tested were chosen 
according to previous studies (Lee et al. 2013, Pinho et al. 2011), which also aimed to 
investigate anti-inflammatory activity. 
In an initial stage, preliminary studies were performed to assess the more effective LPS 
concentration to activate the cells, and the optimal seeding density which will produce 
measurable amounts of NO. Briefly, during preliminary studies, 2.5 x10^4 cells/well were 
stimulated with LPS concentrations ranging from 0.01-1 µg/ml and NO was measured at 
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18, 24, 48 and 72 hours to optimize LPS concentration. Then different cell densities were 
stimulated with 1 µg/ml of LPS, and NO and TNF-α were measured at 18, 24, 48 and 72 
hours to optimize cell seeding density, and evaluate the temporal pattern of inflammatory 
markers production.  
Raw 264.7 cells were seeded at a density of 2x105 cells/mL in a 96 well-plate and 
permitted to adhere over a period of 4-5 hours. Cell were then treated with DEX or broths 
collected from drug release studies for one hour, followed by incubation with LPS 
(1µg/mL), to stimulate/activate the macrophages.  After the addition of LPS the cells were 
cultured for 3 days. Then cellular behavior (e.g. viability, NO production) was then 
assessed at different time points. The effect of treatments (DEX and broths collected 
from drug release studies performed at pH 4, 6 and 7) in the absence of LPS were also 
assessed, to observe if they induced changes in basal levels of the assays performed.  
 
2.7 Cellular viability  
 
2.7.1 Methylthiazolyl Tetrazolium (MTT) assay 
Cellular viability/proliferation of cells after being exposed to tested compounds was 
assessed using the mitochondria dependent reduction of Methylthiazolyl Tetrazolium 
(MTT) to formazan (Figure 13), according to Oh and collaborators (Oh et al., 2012) with 
some modifications.  
 
 
Figure 13. The reduction reaction of the tetrazolium salt MTT to a formazan dye, is 
catalyzed by mitochondrial reductases only in living cells and is therefore used to 
assess cell viability. 
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After described above incubation (2.6. Cell culture and treatments), the culture medium 
was removed and 20μL of the MTT solution (5mg/mL) was added to each well and 
incubated at 37°C in a humidified 5% CO2 atmosphere, for another 4 hours. Then 
supernatant was carefully discarded and 100µL of Dimethyl sulfoxide (DMSO) was 
added to each well to solubilize formazan. The absorbance at 540 nm was measured 
using ELISA reader. The absorbance (MTT values) by untreated cells (control) was 
chosen as the 100% value.  Although, for LPS-activated Raw 264.7 cells the absorbance 
of treatment groups was normalized to the LPS-treated control and expressed as a 
percentage 
2.7.2 Lactase dehydrogenase (LDH) release assay 
Quantification of lactate dehydrogenase (LDH) is a method to investigate the cytotoxicity 
of a substance. This assay is based on the release of LDH, cytosolic enzyme, upon cell 
lysis. Therefore, LDH released into culture media assay was used to evaluate cell 
damage after treatment with test compounds.  Briefly an aliquot of cell culture medium 
was carefully taken from each well, and the LDH activity in the medium was determined 
using an LDH cytotoxicity detection kit (Sigma). A 150 μl of reaction mixture was added 
to 75 μl aliquot of each well, and the reaction was incubated for 30 min at 37°C in a 
humidified 5% CO2 atmosphere. The absorbance of each well was measured at 490 nm 
using a microplate reader. Results are expressed as a percentage of the respective 
control (with or without LPS). 
2.8 Inflammatory markers measurement 
2.8.1 Measurement of Nitric oxide (NO) levels (Griess reagent) 
Previous studies have shown the production of inflammatory reactive oxygen species 
such as nitric oxide (NO) on LPS-activated Raw 264.7 cells (I.-T. Kim et al. 2012; 
Saxena, Vallyathan, and Lewis 2003; Sharma, Al-Omran, and Parvathy 2007). The 
expression of those cytokines and chemokines on LPS-activated Raw 264.7 reflects the 
level of inflammation, and therefore provides a measure of the inflammatory response 
(Pinho et al. 2011; Oh et al. 2012).  NO is a very short-lived and reactive molecule, and 
easily degrades into more stable end products, such as nitrate and nitrite (Lundberg et 
al. 2008). Therefore, NO formation has to be quantified by measuring its stable 
decomposition products, nitrite (NO2-) and nitrate (NO3-) in the cell culture media (Bryan 
& Grisham 2007).  This method requires that NO3- first be reduced to NO2-, and then 
NO2- is determined by the Griess reagent, a spectrophotometric technique based in an 
enzymatic reaction(Sun et al. 2003), as shown in Figure 14.  
The Griess reagent system (Thermo Fisher Scientific ®) was utilized to measure nitrite 
(NO2-), which is the stable metabolite of nitric oxide (NO), in the supernatants of Raw 
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264.7 macrophages, as previously described by (Pinho et al. 2011). After incubation (as 
described in 2.6. Cell culture and treatments), 100 μL of cell culture supernatant was 
mixed with the same volume of Griess reagent for 30 min at room temperature. Samples 
of fresh culture media were used as blanks for all experiments. Then nitrite produced 
was determined by measuring optical density of the mixture at 540 nm in a microplate 
reader. Nitrite was quantified by an external standard, using sodium nitrite (NaNO2) to 
generate a standard calibration curve (Figure 82,supplementary information). 
 
Figure 14. A. Nitric oxide production in LPS activated macrophages (A.).  In the 
Griess Reaction (B.), the nitrosating agent dintrogen trioxide (N2O3) generated 
from acidified nitrite (or from the autoxidation of NO) reacts with sulfanilamide to 
yield a diazonium derivative. This reactive intermediate will interact with N-1-
naphthylethelene diamine to yield a coloured diazo product that absorbs strongly 
at 540 nm. Image adapted from (Bryan & Grisham 2007). 
 
Results are expressed as the nitrite production percentage compared with the respective 
control (with or without LPS). The NO concentration was calculated by comparison with 
a NaNO2 (0–100 µM) standard curve. The results were expressed as inhibition of NO 
production compared to the control (LPS) using:   
Equation 4 NO production (%to LPS): 
                NO production (%to LPS) = ([nitrite]t*100)/[nitrite]c                                      
where [nitrite]c and [nitrite]t is the nitrite concentration in the LPS control group and test 
sample, respectively. Under the same experimental conditions, cell viability was 
evaluated by conducting MTT assay. MTT assays were performed to simultaneous 
evaluate the cytotoxic effect of tested compounds toward RAW 264.7 cells with and 
without LPS. Briefly, after transferring 100 µL of media to 96-well plate to measure NO 
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production, MTT solution was added to each well, and cells were further incubated at 
37°C for 3-4 h as described above (2.6. Cell culture and treatments). 
2.8.2 Assessment of TNF-α expression  
Tumor necrosis factor alpha (TNF-α) expression was assessed using the murine TNF-α 
enzyme-linked immunoabsorbent assay (ELISA) development kit (Peprotech, US). For 
this study, 3.5 × 104 macrophages/well were cultured in 48-well plates, then treatments 
were added with or without LPS (1µg/mL).  
 
Figure 15. Schematic diagram of Sandwich ELISA assay utilized to detect TNF-α. 
(i) Capture antibody specific affinity for murine TNF- α was attached to 96-well plate. (ii) Sample 
is added to the well and the target protein (TNF-α) is captured by the ligand. (iii) A detection ligand 
that also binds to the target protein (TNF-α) is added to the well and creates a “sandwich” with 
two ligands surrounding the target protein. (iv) Streptavidin protein with a horse radish peroxidase 
(HRP) is added to the well. The streptavidin binds to the biotin end of the detection ligand. (v) 
then, the TMB (HRP substrate) is added to the well and a blue coloured product is produced that 
can be detected with a spectrophotometer. 
Briefly, TNF-α concentration was quantified according to the folowing protocol (Figure 
15) : 
(i) Plate preparation: 100μL of the capture antibody (Polyclonal Rabbit Anti-
Murine TNF-α, 0.50μg/ml in PBS) were added to each ELISA plate well, the 
plate was sealed and incubated overnight at room temperature. Then, the 
wells were washed (0.05% Tween-20 in PBS) three times and incubated with 
300 μL of blocking buffer (1%BSA in PBS) for at least 1 hour at room 
temperature. 
(ii) Sample incubation : 100μL of sample were added to each well in triplicate, 
and incubated at room temperature for at least 2 hours. 
(iii) Detection : the wells were aspirated and washed at least four times. Then 
100μL of detection antibody (Biotinylated Rabbit Anti-Murine TNF-α, 
0.25μg/ml in diluent) were incubated at room temperature for 2 hours. 
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(iv) Streptavidin-HRP Conjugate: the wells were aspirated and washed at least 
four times.  Then 100μl of Streptavidin-Horseradish Peroxidase (HRP) 
(0.025ug/ml in diluent) were added to each well and incubated for 30 minutes 
at room temperature. 
(v) TMB (3,3’,5,5’-tetramethylbenzidine) Liquid Substrate: the wells were 
aspirated and washed at least four times. Then 100μl of substrate solution 
(room temperature) was added to each well and Incubated at room 
temperature for color development for 20 minutes. Colour development was 
measured with an ELISA plate reader at 410nm, and with wavelength 
correction set at 650nm. 
 
2.9 Fluorescent staining of actin  
Previous studies have described an important role that cytoskeleton f-actin 
reorganization/remodelling plays in mediating inflammatory markers production in 
response to LPS stimulation (Ion et al. 2015, Isowa et al. 1999).  
Briefly, RAW 264.7 macrophages grown on glass coverslips were stimulated with LPS 
for 24h to induce inflammation. The cells were fixed in buffered 4% formaldehyde for 10 
min, permeabilized with Tris buffered saline (TBS) containing 0.5% Triton X-100 for 30 
minutes, and then blocked in TBS containing 10% of horse serum (NHS) for 1 h. The 
cells were incubated for 40min with phalloidin-FITC (fluorescein isothiocyanate) (10 
μg/ml; Sigma-Aldrich Co.) diluted 1:50 in TBS. After incubation, the coverslips were 
washed three times in TBS and transferred to glass slides. Cells were mounted using 
Vectashield mounting medium containing 4',6-diamidino-2-phenylindole (DAPI). The 
cells were then imaged using an Olympus IX70 fluorescence microscope. Samples were 
excited at 496 nm and 350 nm wavelength respectively for FITC and DAPI channels.  
 
2.10 Statistical analysis 
The statistical significance of differences between means was determined by first testing 
for global differences by one- or two-way analysis of variance (ANOVA). Experimental 
results were considered statistical significant at 95 % confidence level (*p<0.05).  When 
a P value of <0.05 was found, multiple comparisons post-test was performed to compare 
treatment groups with control group. All analyses were run using the Graph Pad Prism® 
software (Version 6.0; GraphPad Software, Inc., San Diego, CA). According the 
software, statistical difference was very significant (**p<0.05), and extremely significant 
(***p=0.001 to 0.01) or (****p<0.001). Data are the mean± standard deviation (SD) of 
three replicate cultures, and at least two independent experiment (n≥2). 
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3. Results 
In this study, an anti-inflammatory eluting implant model system was developed and 
characterised: TiO2 particles were chosen as model system to mimic the implant titanium 
surface. DEX, a synthetic glucocorticoid approved by FDA and clinically used to 
modulate the inflammatory reaction (Holte & Kehlet 2002), was chosen as a model drug 
because of its potential use to modulate inflammatory events in TJR. The main 
advantage of this model system is that can be easy translated to clinical application; 
since all the surface modification performed on TiO2 particles can be applied on clinically 
used TJR, made of titanium and titanium alloys. Besides, DEX will be directly release 
from implant surface rather than systemically, reducing unnecessary side effects. For 
this purpose, the surface of TiO2 particles was functionalised to attach DEX by using 
different synthetic routes, amino, mercapto and Layer-by-Layer (LbL) routes. In this 
chapter, the results regarding the synthesis and characterization of the model system, 
DEX-loaded functionalised TiO2 particles, were described (Figure 16).  Including 
chemical reactions scheme for each synthetic route, surface charge, fourier transform 
infrared-spectroscopy (FT-IR), thermogravimetric analysis (TGA), drug loading and 
entrapment efficiency, DEX release profile, and charge/size/morphology of the 
functionalized and DEX-loaded particles.  
 
Figure 16. Summarised scheme of (a) synthetic routes, (b) characterization 
methods and (c) biological studies performed to study the anti-inflammatory-drug 
eluting model system, DEX-loaded functionalised TiO2 particles. 
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Moreover, further biological studies were performed to test the cytotoxic and anti-
inflammatory efficacy of the model system. A robust, rapid and reproducible in vitro 
mouse macrophage-like cellular model, utilizing RAW 264.7 cells was hence employed. 
In this model a component of bacteria wall, LPS, was used to activate the Raw 264.7 
macrophages, resulting in the secretion of inflammatory mediators including nitric oxide 
(NO) and tumour necrosis factor alpha (TNF-α). The suppression of which was utilized 
to investigate anti-inflammatory effect of DEX released from functionalised-TiO2 
particles. Being respectively a pro-inflammatory mediator and a pro-inflammatory 
cytokine, NO and TNF-α, which high production has been associated with chronic 
inflammation (Parameswaran & Patial 2010, Zamora et al. 2000), their expression 
provide noteworthy information about the level of inflammation  Therefore, by 
simultaneously assessing NO and TNF-α expression in LPS-activated macrophages, it 
was possible to get further insight about DEX anti-inflammatory mechanism of action. 
This was combined with assessment of cell viability to exclude the decrease of 
inflammatory mediators due to drug-induced toxicity. 
 
3.1 DEX amino-functionalized particles 
3.1.1 Chemical reactions 
When amino route was utilized, TiO2 particles were first functionalized with amine groups 
(-NH2) and then with carboxylic groups (-COOH). Initially the TiO2 inorganic surface was 
modified with silane agent, APTS, to give terminal amines (-NH2) (Schematic Reaction 
1. Figure 17). After that, succinic anhydride was added to the reaction (Schematic 
Reaction 2. Figure 17), to obtain particles with carboxylic-functionalized surface (-
COOH-TiO2). As previously described, (Wu et al. 2011), the carboxylic acid group arises 
from the ring opening of succinic anhydride through a reaction with the amine group (-
NH2) on the surface of the TiO2 particles, creating an amide bond, as previously 
described (Hermanson 2013, Zhao et al. 2014). The attachment of this –COOH is 
of outmost importance to obtain successful drug loading, since it will act as a binding site 
to DEX. 
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Figure 17. Schematic of reaction regarding carboxyl-TiO2 particles 
functionalization, using amino route. Functional groups on TiO2 particles are 
highlighted with blue colour. 
 
Finally, DEX was then added to the succinilated-TiO2 particles, to obtain Dex-loaded TiO2 
particles, with (conjugated) or without adding EDC/Sulfo-NHS (adsorbed) (Figure 18). 
 
 
Figure 18. Schematic of reaction regarding DEX loading into carboxyl- 
functionalized TiO2 particles using amino route. Functional groups on TiO2 
particles are highlighted with blue color. 
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NHS/ EDC cross-linking agent was added as an attempt to improve the reaction 
efficiency, and stability of the bond formed between DEX and –COOH-TiO2 surface 
(Hermanson, 2013b). Several reports describe the successful attachment of 
biomolecules, such as peptides (Bartczak & Kanaras 2011), collagen (Cao & Xu 2008) 
and heparin (Wissink et al. 2001) to delivery systems. Mainly due to EDC/Sulfo-NHS 
superior properties i.e. biocompability and non-cytotoxicity in vivo and in vitro when 
compared to other to cross-linking agents such as glutaraldehyde. As can be seen in 
Figure 19, EDC and sulfo-NHS have different roles during DEX attachment. EDC is 
responsible for the activation of carboxyl groups, from EDC and carboxyl acid interaction 
arises the reactive o-acylisourea intermediate that when attacked by a hydroxyl 
nucleophile it will form an ester bond. Although o-acylisourea is very labile/unstable, so 
it can be attacked by other nucleophiles such as the oxygen atoms from H2O, thus 
cleaving-off this intermediate and inactivating EDC.  
 
Figure 19. EDC and Sulfo-NHS role during DEX attachment. EDC activates the 
carboxyl groups, from EDC and carboxyl acid interaction arises the reactive o-
acylisourea ester intermediate. Then, when added to the reaction Sulfo-NHS 
increases water solubility due to the presence of the charged sulfonate group, and 
thus a more stable intermediate ester is created. 
 
Due this reason sulfo-NHS is added to the reaction, to improve EDC efficiency and 
reaction stability (Conde et al. 2014) by forming a very hydrophilic and stable 
intermediate ester with –COOH on surface of TiO2 particles. Then in presence of hydroxyl 
nucleophiles from DEX, this intermediate ester is easily hydrolyzed allowing the 
formation of ester bond (Bartczak & Kanaras 2011, Hermanson & Hermanson 2013) 
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between DEX and activated carboxyl groups on TiO2 particles surface. Moreover due to 
the ease removal of the reaction by-products, coupling of DEX is obtained under 
physiologic conditions and without adding extra chemical entities or organic solvents to 
the TiO2 particles (Everaerts et al. 2008).  
3.1.2 Determination of morphology and average size  
A detailed examination of the morphology of the DEX-loaded TiO2 particles and the 
distribution of their size were investigated by transmission electron microscopy (TEM). 
TEM images of the bare functionalised-TiO2 particles and functionalized ones with and 
without DEX (Figure 20) were taken to determine the shape/structure and size of the 
particles after each step of functionalization. 
 
Figure 20. Transmission electron microscopy (TEM) different surface-modified 
TiO2 particles: (a) TiO2 particles, (b) amino-functionalized, (c) carboxyl-
functionalized and (d) DEX conjugated-loaded TiO2 particles for amino route. 
 
The TEM image of uncoated TiO2 particles show that these particles have a very small 
size of around 20-25nm diameter with a narrow size distribution. Moreover, they show a 
cubical and spherical-like shape with dense core (Figure 20.a) which is characteristic of 
TiO2 particles.  We then observed the morphology and size of the particles after each 
step of functionalization (amino, carboxyl and DEX loading). As shown in  Figure 20 (b. 
c. and d.) the particles did not present obvious morphological changes, after different 
steps of surface modification, including DEX loading. 
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Table 5. Average size values of particles after each functionalization step, for 
amino route. Data are the mean ± standard deviation (SD) of two independent 
experiments (n=2). 
Sample Average size (nm) ± SD 
Tio2-particles 32.7±5.6 
Amino-functionalised particles 31.0±5.2 
Carboxyl-functionalised particles 36.4±6.4 
DEX-loaded particles 41.5±3.5 
 
The average size of TiO2 particles after each step of functionalisation (e.g. amino-
functionalised vs TiO2 particles, or DEX-loaded vs carboxyl-functionalised particles) was 
also investigated (Table 5). Results showed that minor differences were observed when 
comparing the size of bare TiO2-particles with that of functionalised-ones. The most 
significant (p<0.05) difference in size was observed when comparing TiO2-particles 
(32.7±5.6nm) with DEX-loaded ones (41.5±3.5nm), where increase of ~9nm was 
observed. Moreover, aiming to complement the study of particles morphology and 
dispersion/aggregation (Pereira-da-silva & Ferri 2017, Singh 2016) after each step of 
functionalisation, scanning electron microscopy was also utilised (Figure 21). 
 
Figure 21. Scanning electron microscopy (TEM) different surface-modified TiO2 
particles: (a) TiO2 particles, (b) amino-functionalized, (c) carboxyl-functionalized 
and (d) DEX conjugated-loaded TiO2 particles for amino route. 
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SEM images showed that after each step of functionalisation, the TiO2 particles 
maintained the spherical morphology, where no visible aggregation was observed, when 
compared to the bare-TiO2 particles. 
3.1.3 Zeta Potential measurements 
Zeta potential measurements were utilized to assess the attachment of organic groups 
i.e.–NH2, -SH, -COOH, after each step of TiO2 particles functionalization, including DEX 
loading.  
 
 
Figure 22. Zeta potentials of different surface-modified TiO2 particle suspensions 
at different pH values. Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). Standard deviation is less than 5% of mean value. 
 
 
Figure 22 shows that surface potential of TiO2 particles differ after each step of 
functionalization. Additionally, it can be observed that for all functionalized particles, zeta 
potential versus pH conditions is consistent, following the same trend: as pH becomes 
more basic, decrease on surface potential is observed, on the other hand the highest 
surface potentials are observed under more acidic pH conditions. Moreover, after amino-
functionalization, the surface charge of the modified-TiO2 particles was more positive 
when compared with bare TiO2 particles, for all pH values tested (4-6 pH range). As for 
succinic anhydride-TiO2 particles and DEX loaded particles, lowest surface potentials 
were observed especially for more alkaline pH values (Figure 22). Particularly, Dex-
functionalised-TiO2 particles conjugated present a more negative zeta potential (-
25.8±0.8 mV) when compared to Dex-TiO2 particles adsorbed (-17.8±0.9 mV) 
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3.1.4 Fourier Transformed infrared spectroscopy (FT-IR) 
FT-IR was used to assess the chemical groups present on the surface of TiO2 particles 
after each functionalization step. The spectra of bare-TiO2 particles and functionalized 
ones (i.e. with APTS, succinic anhydride and DEX) are shown in Figure 23. Firstly, it can 
be observed that all the peaks between 400 and 700 cm−1 (Figure 101,  
I. Appendix) are to bending and stretching mode of Ti–O–Ti in TiO2 particles. Particularly,  
the  intense peak which appears in the vicinity of 500 cm−1 is attributed to the stretching 
vibration of Ti–O–Ti in anatase morphology (Bagheri et al. 2013, Zhao et al. 2012). In 
addition, the spectrum of bare-TiO2 particles showed a broad band appearing at 3100–
3600 cm–1 which is assigned to vibrations of hydroxyl groups (O-H) on TiO2 surface  
(Bach et al. 2013, Gao et al. 2004, Vuk et al. 2005).  
As for spectrum of functionalised-TiO2 particles, new bands which could not be observed 
in the spectrum of bare-TiO2 particles were detected. For example, the presence of 
bands at ~3000 and 2857 cm−1 which can be respectively assigned to the methyl (C–H 
vibration) of methoxy (OCH3) and methylene (CH2) groups. 
 
 
Figure 23. FT-IR spectra for different steps of TiO2 nanoparticles functionalisation: 
bare-TiO2 particles (---), amino-functionalised TiO2 particles (---), carboxyl-
functionalised TiO2 particles (---), and DEX-loaded TiO2 particles (---).   
 
Moreover, for amino and carboxyl functionalised TiO2-particles (Figure 24) a new peak 
was observed at ~950cm−1 which is characteristic of Si-O chemical bonds. Also, the 
broad band appearing at 3100–3600 cm-1 which is assigned to vibrations of hydroxyl 
groups (OH) on TiO2 surface is less visible for particles functionalised with APTS.  
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Figure 24. FT-IR spectra for different steps of TiO2-particles functionalisation 
using amino route: bare-TiO2 particles (---), amino-functionalised TiO2 particles (--
-), carboxyl-functionalised TiO2 particles (---).  *Amino-functionalization was obtained 
using APTS ** Carboxyl functionalization was obtained using succinic-anhydride. 
 
Particularly after APTS-functionalisation, when compared to bare-TiO2 particles new 
peaks can be observed at ~3000 cm-1, ~1800 cm-1 and ~1350 cm-1, which can be 
assigned to N-H and C-N bending and stretching bonds. Similarly, in the spectra of 
functionalised-TiO2 particles with succinic anhydride, new visible peaks which can be 
assigned to the carboxyl group were observed. For example, the presence of a broad 
band around ~3100–3600 cm-1 for (hydroxyl groups) (OH) on TiO2 surface. And the two 
new strong peaks between 1600-1800 cm-1, which are characteristic of C=O stretching 
vibration.  Moreover, it is worth to note that the peak at ~1350 cm-1 was not observed for 
carboxyl-functionalised TiO2 particles. Although the FT-IR equipment was not sensitive 
enough to detect the characteristic peaks/bands observed for DEX (as observed in pure 
DEX, Figure 103), it was clear that a different FT-IR spectra was observed for DEX-
loaded particles; such as the presence of strong band around 3100–3600 cm1 and at 
~1600-1800 cm-1, respectively suggests the presence of C=O stretching vibration band 
and of hydroxyl groups (OH) on TiO2 surface. Furthermore, the two sharp peaks 
observed in the region of 1050-1160 cm-1 and 1185 cm-1, 1277cm-1 for both carboxyl and 
DEX-loaded functionalised particles can be attributed to the symmetrical and 
asymmetrical stretching frequencies of the C-O ester groups. 
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3.1.5 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) was performed assess the organic functionalization 
(e.g. amine, carboxyl and DEX attachment) of TiO2 particles surface. The TGA analysis 
of the different functionalization steps of TiO2 particles are shown in Figure 25. TGA 
studies were only performed for the conjugated DEX-loaded TiO2 particles surface, 
mainly because these particles showed better results in terms of drug attachment (3.1.3 
Zeta Potential measurements). 
 
Figure 25. Thermogravimetric curves for the different surface-modified TiO2 
particles: TiO2 particles, amino (NH2)-TiO2, carboxyl-(COOH) TiO2 particles, and 
Dex-TiO2 particles conjugated. Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
 
The TGA profile of TiO2 particles after each functionalization step revealed an initial 
weight loss (~1%) at about 100°C, which is normally attributed to the evaporation of 
adsorbed water from the samples (Ganesh & Lee 2013). Due to this reason, the organic 
content of each sample (Table 6) was calculated based on the weight loss beyond 
100°C, that truly corresponds to the combustion of organic species (Yodyingyong et al. 
2011).  
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Table 6. Percentage of organic material in functionalized-TiO2 particles at each 
step of the amino-route synthesis. Data are the mean ± standard deviation (SD) of 
two independent experiments (n=2). *Amino-functionalization was obtained using 
APTS ** Carboxyl functionalization was obtained using succinic-anhydride. 
Samples Organic content (%) 
TiO2 particles 1.5±0.1 
Amino-TiO2 particles 6.1±0.3 
**Carboxyl-TiO2 particles 9.2±2.6 
Dex-TiO2 particles conjugated  14.8±0.1 
 
Results obtained from TGA analysis (Table 6) show an increase of organic content after 
amino and carboxyl functionalization when compared with organic content of TiO2 
particles (1.54%):  6.05% for amino-TiO2 particles and 9.16% for carboxyl-functionalized 
TiO2 particles. Moreover, the same behaviour was observed for DEX loaded particles, 
where an increase of organic content of approximately 6% was detected when compared 
to carboxyl-functionalized TiO2 particles.  
 
3.2 DEX mercapto-functionalized particles  
3.2.1 Chemical reactions 
Mercapto route, was another strategy to obtain DEX loaded-functionalised-TiO2 
particles. When this route was used, instead of an amine group, a thiol group (-SH) was 
initially immobilized onto the surface of TiO2 particles (Figure 26). In more detail, the 
synthesis of DEX functionalised-TiO2 particles was achieved using a two-step surface 
functionalization process. Firstly, TiO2 particles were mixed with MPTMS to immobilize 
the thiol groups (-SH) on the surface of TiO2 (Schematic Reaction 1. Figure 26). As 
previous reported (Bach et al. 2013) this reaction results from the interaction between 
the hydroxyl (-OH) group present on the TiO2 surface and triethoxysilane group of 
MPTMS. Consequently, to obtain carboxylic-functionalized TiO2 particles (-COOH-TiO2), 
pentanoic-acid was added to the reaction (Schematic Reaction 2. Figure 26). This 
reaction is the same described for amino route (3.1.1. Chemical reactions), but in this 
case the carboxylic acid group arises from the addition of pentanoic-acid to the reaction. 
Once more, carboxyl (–COOH group) will act as a binding site to attach DEX. 
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Figure 26. Schematic of reaction regarding carboxyl-TiO2 particles 
functionalization, using mercapto route. Functional groups on TiO2 Particles are 
highlighted with blue colour. 
 
Finally, DEX was then added to the carboxyl-functionalized TiO2 particles, to obtain DEX-
loaded Functionalised-TiO2 particles, with (conjugated) or without adding EDC/Sulfo-
NHS (adsorbed) (Figure 27). 
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Figure 27. Schematic of reaction regarding DEX loading into carboxyl-
functionalized TiO2 particles using mercapto route. Functional groups on TiO2 
particles are highlighted with blue colour. 
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3.2.2 Determination of morphology and average size  
A detailed examination of the morphology of the DEX-loaded functionalised-TiO2 
particles obtained via mercapto route, and the average size of the particles was 
investigated by TEM. With this aim, TEM images of the uncoated TiO2 particles and 
functionalized ones (Figure 28), were taken after each step of functionalization.   
 
Figure 28. Transmission electron microscopy (TEM) different surface-modified 
TiO2 particles: (a) TiO2 particles, (b) mercapto-functionalized, (c) carboxyl-
functionalized and (d) DEX conjugated-loaded TiO2 particles for mercapto route.  
 
TEM picture of uncoated TiO2 particles show that these particles have a spherical like-
shape, and very small size of around 30-35nm diameter with a narrow size distribution. 
Then the morphology and size of the particles after each step of functionalization (amino, 
carboxyl and DEX loading) was observed. As shown in Figure 28 (b. c. and d.) the 
particles did not present obvious morphological changes after different steps of surface 
modification, including DEX loading 
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Table 7. Average size values of particles after each functionalization step, for 
mercapto route. Data are the mean ± standard deviation (SD) of two independent 
measurement (n=2). 
Sample Average size (nm) ± SD 
Tio2 particles 32.7±5.6 
Mercapto-functionalised particles 38.9±9.7 
Carboxyl-functionalised particles 44.2±7.5 
DEX-loaded particles 44.9±10.4 
 
Moreover, the average size of particles after each functionalization step was estimated 
(Table 7).  
 
Figure 29. Scanning electron microscopy (TEM) different surface-modified TiO2 
particles: (a) TiO2 particles, (b) amino-functionalized, (c) carboxyl-functionalized 
and (d) DEX conjugated-loaded TiO2 particles for mercapto route. 
 
It can be observed that when comparing the average size after each step of 
functionalisation (e.g. mercapto-functionalised vs TiO2 particles, or DEX-loaded vs 
carboxyl-functionalised particles), the average size does not show significant differences 
(p<0.05), except after carboxyl-functionalisation and DEX loading steps where the 
average size shows a significant increase (p<0.05) of ~12nm was observed when 
compared with bare-TiO2 particles. Moreover, aiming to complement the study of 
particles morphology and dispersion/aggregation (Pereira-da-silva & Ferri 2017, Singh 
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2016) after each step of functionalisation, scanning electron microscopy was also utilised 
(Figure 21). SEM pictures showed that after each step of functionalisation, the TiO2 
particles maintained the spherical morphology, where no visible aggregation was 
observed when compared to the bare-TiO2 particles. 
 
3.2.3 Zeta potential measurements 
Zeta potential after each step of TiO2 particles functionalization, including DEX loading, 
was measured to assess the changes in surface charge after the attachment of new 
organic groups i.e.–NH2, -SH, -COOH. As depicted in Figure 30 a consistent behavior 
was observed for all functionalized-TiO2 particles, where zeta potential measurements 
are pH-dependent: the highest surface potentials are verified at low pH conditions, 
whereas when pH increases the zeta potentials are lower.  
 
Figure 30. Zeta potentials of different surface-modified TiO2 particle suspensions 
at different pH values. Data are the mean ± standard deviation (SD) of three 
independent measurement (n=3). Standard deviation is less than 5% of mean 
value. 
After thiol-functionalization, the surface charge of the modified-TiO2 particles was more 
positive when compared with bare TiO2 particles. Furthermore, after pentanoic-acid 
conjugation, an unexpected result was observed, where COOH-TiO2 particles show a 
negative zeta potential, higher than the one observed at DEX-loaded particles (Figure 
30). Although this behavior was not observed at pH=7, where the DEX-conjugated 
loaded particles presented a more negative surface charge (-27.8±0.6) than the 
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functionalised COOH-TiO2 particles (-21.6±1).  Regarding Dex-Functionalised-TiO2 
particles, conjugated (-27.8±0.6) exhibit a more negative zeta potential when compared 
to Dex-adsorbed ones (-17.8±0.9) mV for all pH values. 
3.2.4 Fourier Transformed infrared spectroscopy (FT-IR) 
Figure 31 shows the FT-IR spectrum of bare TiO2 particles and functionalised-particles 
ones (i.e. with MPTES, pentanoic-acid and DEX) using mercapto route. Firstly, it can be 
observed that all the peaks bellow 700 cm−1 (Figure 102, appendix section) are 
characteristic from TiO2 particles. Particularly, the intense peak which appears around 
500 cm−1 is attributed to the stretching vibration of Ti–O–Ti in anatase morphology. In 
addition, spectrum of bare-TiO2 particles shows a broad band appearing between 3100 
and 3600 cm–1 which is assigned to vibrations of hydroxyl groups (-OH) which are 
present on the surface of TiO2 particles. 
 
 
Figure 31. FT-IR spectra for different steps of TiO2-particles functionalisation 
using mercapto route: bare-TiO2 particles (---), mercapto-functionalised TiO2 
particles (---), carboxyl-functionalised TiO2 particles (---). and DEX-loaded TiO2 
particles (---). * Mercapto-functionalization was obtained using MPTES ** Carboxyl 
functionalization was obtained using 4-pentanoic-acid. 
 
When comparing bare-TiO2 particles with the ones functionalised with mercapto-silane 
(MPTES), the band corresponding to thiol (SH) group could not be clearly observed 
(Figure 32) due to relative low content of thiol and poor sensitivity of IR to this functional 
group. However, other new bands were observed at ~3000 cm-1 and 2800 cm-1, which 
are attributed to the C–H stretch of methylene of the alkyl chain. 
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Figure 32. FT-IR spectra for different steps of TiO2-particles functionalisation 
using mercapto route: bare-TiO2 particles (---), mercapto-functionalised TiO2 
particles (---), carboxyl-functionalised TiO2 particles (---). * Mercapto-
functionalization was obtained using MPTES ** Carboxyl functionalization was obtained 
using 4-pentanoic-acid. 
 
The other visible peaks between 900 and 1100cm−1 are due to Si–O–Si and Si–O 
stretching vibrations, Additionally, the O–H broad peak (3100–3600 cm-1) which 
appeared in the spectrum of bare-TiO2 particles, is less visible, which coincides with a 
decrease in the hydroxyl groups due to the attachment of the MPTES. As for carboxyl 
and DEX functionalisation, the FT-IR equipment was not sensitive enough to detect the 
characteristic peaks/bands. Although different FT-IR spectra was observed, particularly 
a broad peak between 3100–3600 cm-1 is visible, which coincides with the increased 
presence the hydroxyl groups (O–H) due to the attachment of COOH functional and OH 
groups on surface of functionalised-TiO2 particles. 
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3.2.5 Thermogravimetric analysis (TGA) 
The TGA analysis of the different functionalization steps of TiO2 particles are shown in 
Figure 33. 
 
Figure 33. Thermogravimetric curves for the different surface-modified TiO2 
particles: Bare TiO2 particles, mercapto-TiO2 and succinilated-TiO2 particles, and 
Dex-loaded-TiO2 conjugated particles. Data are the mean ± standard deviation (SD) 
of two independent experiments (n=2). 
 
Based on TGA results (Figure 33) the % of organic content present on the surface of 
TiO2 particles after each step of functionalization was calculated (Table 8). It can be 
observed that after each functionalization step there is an increased amount of organic 
content on the surface of TiO2 particles. Results show an increase of organic content 
after mercapto and carboxyl functionalization when compared with organic content of 
TiO2 particles (1.53%), 4.84% for mercapto-TiO2 particles and 5.37% for carboxyl-
functionalized TiO2 particles. 
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Table 8. Percentage of inorganic and organic material in functionalized-TiO2 
particles at each step of the mercapto-route synthesis. Data are the mean ± 
standard deviation (SD) of two independent experiments (n=2). *Mercapto-
functionalization was obtained using MPTMS ** Carboxyl functionalization was obtained 
using succinic-anydride.** Carboxyl functionalization was obtained using 4-pentanoic 
acid. 
Samples Organic content (%) 
TiO2 Particles 1.6±0.1 
Mercapto-TiO2 Particles 4.8±0.2 
**Carboxyl-TiO2 Particles 5.4±0.3 
Dex-TiO2 Particles conjugated 9.2±0.4 
 
Moreover, the same behavior was observed for DEX loaded particles, where an 
increase of organic content to approximately 9.23% was detected when compared to 
carboxyl-functionalized TiO2 particles (5.37% of organic content). 
3.3 LbL DEX-loaded particles 
3.3.1 Zeta Potential measurements 
Firstly, it is important to assess the charge density of the CH, ALG and DEX 
polyelectrolyte solutions that are going to be used during the different set of experiments 
(Table 9). This initial procedure is crucial to guarantee a successful LbL assembly. 
 
Table 9. Zeta potential values of polyelectrolyte solutions. Data are the mean ± 
standard deviation (SD) of three independent measurements (n=3). 
Polyelectrolyte solution Zeta Potential (mV) ± SD 
Alginate (ALG) solution (2mg/mL) -24.8±1.1   
Chitosan (CH) solution (2mg/mL) 19.3±1.5 
DEX solution (10mg/mL)  -9.2±1.2 
 
As can be seen in Table 9, CH and ALG/DEX solutions present opposite surface charge 
as required to begin the LbL assembly, which means that they can interact by 
electrostatic forces. Amino-functionalised-TiO2 particles (NH2-TiO2 particles), used as 
LbL template, presented a positive surface charge of +25.30 mV, as confirmed by zeta 
potential measurements (Figure 34). The positive value was due to ionized amino-groups 
that are on the surface of TiO2 particles. After ensuring all the necessary conditions, the 
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preparation of multilayer DEX-loaded-functionalised-TiO2 particles was assessed by the 
measurement of zeta potential values after the addition of each new polyelectrolyte layer. 
Zeta potential was measured for the different LbL approaches tested, experiment 1 
(Figure 34), and experiment 2.  
 
Figure 34. Zeta potential values during LBL assembly of ALG/CH layers and DEX 
onto amino-functionalised-TiO2 particles (NH2-TiO2 particles), using approach 
described in experiment 1. Data are the mean ± standard deviation (SD) of three 
independent measurements (n=3). 
The layer 0 represents the template used (NH2-TiO2 particles). Standard deviation 
is less than 5% of mean value. 
 
 
Figure 35. Zeta potential values during LBL assembly of ALG/CH layers and DEX 
onto amino-functionalised-TiO2 particles (NH2-TiO2 particles), using approach 
described in experiment 2. Data are the mean ± standard deviation (SD) of three 
independent measurements (n=3). 
The layer 0 represents the template used (NH2-TiO2 particles). Standard deviation 
is less than 5% of mean value. 
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It was observed that in experiment 1 (Figure 34) and experiment 2 (Figure 35) , the zeta 
potential measured followed the same trend. In general, the values alternate depending 
on the last adsorbed outer layer (n) on amino-functionalised TiO2 particles: starting from 
a positive potential of the template, the charge turned to positive after deposition of the 
positively charged CH and more negative value after deposition of the negatively 
charged ALG. Overall, for all approaches testes, upon adsorption of the 1st layer (ALG) 
the surface charge changed to a negative value (-20 to -30 mV). Subsequently, when 
the cationic polyelectrolyte (CH) was added the zeta potential turned to a positive value 
(+30 to +40 mV). Then, when the DEX layer (anionic polyelectrolyte) was added, the 
surface charge of particles remained positively charged (+5 to +10 mV). This lack of 
symmetric inversion in zeta potential, observed after DEX deposition, could be attributed 
to an incomplete coverage by DEX of the surface of functionalised NH2-TiO2 particles. 
On the other hand, it should be noted that when the ALG layer was added after the DEX 
layer (experiment 2, Figure 35) a more negative charge surface value was observed (-
23 mV), when compared to the ones observed for DEX deposition. 
 
3.3.2 Thermogravimetric analysis (TGA) 
The amount of organic content (%) on the surface of multilayer DEX-loaded-TiO2 
particles, after the deposition of each new layer of alginate (ALG), chitosan (CH) and 
DEX was evaluated by thermogravimetric analysis (TGA) for experiment 1 (Figure 36, 
Table 10) and experiment 2 (Figure 37,Table 11). 
Overall, an increase of organic content (%) was observed after the addition of new layers. 
For example, for experiment 1 (Table 10), the organic content present on the particles 
surface after deposition of 10th layer was higher than the one observed for 9th,8th,7th,6th 
and 5th layer. Although this increase on organic content was not constant or gradual, 
since the organic content (%) observed after 3rd and 4th layers deposition was higher 
than the one observed after the deposition of 10th layer (Table 10). Regarding the 
deposition of DEX layers, it can be observed that an increase on organic content of 
2.33%, 2.09% and 1.60% was, respectively, observed after the deposition of 3rd, 7th, and 
9th layers of DEX. 
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Figure 36. Thermogravimetric curves in multilayer DEX-loaded TiO2 particles after 
addition of a new layer of alginate (ALG), chitosan (CH) and dexamethasone (DEX) 
(experiment 1). Data are the mean ± standard deviation (SD) of two independent 
experiments (n=2). 
 
Table 10. Percentage of organic material in multilayer DEX-loaded TiO2 particles 
after addition of a new layer of alginate (ALG), chitosan (CH) and dexamethasone 
(DEX) (experiment 1). Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
Sample Organic content (%) 
TiO2 particles 2.5±0.1 
NH2-TiO2 particles 4.6±0.1 
1st Layer (ALG) 8.5±0.1 
2nd Layer (CH) 9.7±0.1 
3rd Layer (DEX) 12.1±0.2 
4th Layer (CH) 12.1±0.2 
5th Layer (DEX) 6.7±0.1 
6th Layer (CH) 7.3±0.2 
7th Layer (DEX) 9.4±0.3 
8th Layer (CH) 8.0±0.4 
9th Layer (DEX) 9.6±0.1 
10th Layer (CH) 11.7±0.1 
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Figure 37.Thermogravimetric curves in multilayer DEX-loaded TiO2 particles after 
addition of a new layer of alginate (ALG), chitosan (CH) and dexamethasone (DEX) 
(experiment 2). Data are the mean ± standard deviation (SD) of two independent 
experiments (n=2). 
 
Similar results were observed for experiment 2 (Table 11), where an increase of organic 
content was observed after deposition of 3rd (1.36%), 5th (1.52%) and 8th layer (0.67%) 
of DEX.  
Table 11. Percentage of organic material in multilayer DEX-loaded TiO2 particles 
after addition of a new layer of alginate (ALG), chitosan (CH) and dexamethasone 
(DEX) (experiment 2). Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
Samples Organic content (%) 
TiO2 particles 1.9±0.0 
NH2-TiO2 particles 6.0±0.0 
1st Layer (ALG) 12.5±0.1 
2nd Layer (CH) 12.7±0.3 
3rd Layer (DEX) 14.0±0.3 
4th Layer (CH) 14.8±0.4 
5th Layer (DEX) 16.3±0.1 
6th Layer (ALG) 17.1±0.3 
7th Layer (CH) 19.7±0.3 
8th Layer (DEX) 20.4±0.0 
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When comparing experiment 1 and 2,  it can be seen that only for experiment 2 (Table 
10, Table 11) a gradual increase of organic content (%) after the addition of each new 
layer was observed, where after the addition of 10 layers it was observed a weigh loss 
of approximately 20%, when compared to the TiO2 bare nanoparticles.   
Overall results showed that for approach utilized in experiment 2, particularly the 
increase of organic content (%) observed after each DEX layer deposition, together with 
zeta potential measurements (i.e. high surface charge values after each layer 
deposition), strongly suggests that this approach could be the most suitable to obtain 
reproducible and stable LbL-DEX loaded particles. Therefore, the subsequent studies 
(e.g. Size and morphology, FTIR, drug release profile and biological studies) was 
assessed with LbL particles prepared by approach described in experiment 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
3.3.3 Fourier Transformed infrared spectroscopy (FT-IR) 
 
FTIR was used to investigate the deposition of CH, ALG and DEX layers in DEX-
loaded functionalised TiO2 particles.  
 
 
Figure 38. FTIR spectra for CH/ALG multilayer DEX-loaded functionalised TiO2 
particles after each addition of (A) ALG/CH layers and (B) DEX layer. Amino-
functionalised TiO2 particles (---), ALG (1st Layer) (---), CH (2nd Layer) (---) and DEX 
(3rd layer) (---). The black arrow indicates the peak corresponding to the C-N bond 
on amino-functionalised TiO2 particles (---).  
Overall, FT-IR results showed that similar spectra were observed for CH/ALG multilayer 
DEX-loaded functionalised TiO2 particles after the addition of CH, ALG and DEX layers 
(Figure 38). As shown in Figure 38 the same peaks were detected for all LbL particles, 
including the broad band between ~3400-3200 cm-1, which is assigned to hydroxyl 
groups (O-H). As well as the double peak at ~2800 cm-1 which corresponds to the C=H 
stretching. It is worth to note that though a similar spectrum was observed after 
deposition of CH, ALG and DEX layer, the band at ~1350 which can be assigned to the 
C-N bond and was observed for amino functionalised particle was absent on the spectra 
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of DEX-loaded CH/ALG functionalised-TiO2 particles (Figure 38.B). Also, some new 
peaks were also observed when comparing the spectra of amino functionalised TiO2 
particles with the one of CH/ALG multilayer DEX-loaded functionalised TiO2 particles; 
such as the strong peak observed at ~1650 cm-1 which belongs to the carbonyl group 
(C-O) stretching groups which are attributed to ALG and CH saccharide structure or 
characteristic group of DEX. Similar peaks were observed in the spectrum of pure 
(powder form) of CH, ALG (Figure 105, Figure 104), and DEX (Figure 103) 
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3.3.4 Determination of morphology and average size 
A detailed examination of the morphology of the DEX-loaded functionalised-TiO2 
particles obtained via LBL route (experiment 2), and their average size were investigated 
by TEM. With this aim, TEM images of amino-functionalized TiO2 particles with alginate 
(ALG), chitosan (CH) and DEX layers (Figure 39) were taken after deposition of each 
new layer. 
 
Figure 39.Transmission electron microscopy (TEM) of amino-functionalised-TiO2 
particles with 2 multilayers of CH/DEX/ALG. Images are shown after addition of 
alginate (b,g), chitosan (c,e), and DEX (d,f) layers, for LbL route.   All images scale 
bar is 0.1 µm and 40nm for insets scale bar. 
 
It should be noted that, TEM image of amino-functionalised TiO2 particles was not 
included on Figure 39, because it was already showed in TEM results for amino route 
(Figure 20). 
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Table 12. Average size values of particles obtained via amino route after each new 
layer deposition on the template, amino-functionalized particles (NH2-TiO2 
particles). Data are the mean ± standard deviation (SD) of two independent 
measurements (n=2). 
Sample Average size (nm) ± 
SD 
Tio2 bare particles 32.7±5.6 
Amino-functionalized-Tio2 particles (NH2-TiO2 particles) 31.7±4.4 
(NH2-TiO2 particles) -ALG- 40.4±9.3 
(NH2-TiO2 particles) -ALG-CH 48.8±6.2 
(NH2-TiO2 particles) -ALG-CH-DEX 41.6±3.7 
(NH2-TiO2 particles) -ALG-CH-DEX-CH 38.6±5.3 
(NH2-TiO2 particles) -ALG-CH-DEX-CH-DEX 44.7±5.8 
(NH2-TiO2 particles) -ALG-CH-DEX-CH-DEX-ALG 38.3±4.4 
 
Additionally, the average size of particles obtained via LBL route was estimated (Table 
12). It can be observed that when comparing the average size of particles after the 
deposition of new layer (e.g. NH2-TiO2 particles vs (NH2-TiO2 particles)-ALG), the 
average showed significant differences (p<0.05). Although this increase on particles size 
was not constant or gradual, since the particles with more layers (~39nm for NH2-TiO2 
particles-ALG-DEX-CH-DEX-CH-ALG) showed a smaller average size than that of 
particles with less layers (~48nm NH2-TiO2 particles-CH-ALG).  
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3.4 DEX release profile 
The drug release profile of the DEX from functionalised-TiO2 particles obtained via 
different routes (amino, mercapto and LbL) was carried out at different pH values (5-7), 
and the presence of DEX on samples was quantified using HPLC. 
3.4.1 Amino-route 
Results revealed that, for most part of the conditions tested, pH=5, 6 and 7, the DEX was 
released within the first 24 hours (Figure 40). Moreover, the DEX released from amino-
functionalised TiO2 particles was pH-dependent: the highest concentrations of DEX were 
released at higher pH values, pH=7 (13.1 ±0.2 µg/mL) and pH=6 (13.8±0.3 µg/mL). While 
at more acidic conditions (pH=5) minor concentrations of DEX (2.8±0.1 µg/mL) were 
released.  
 
 
Figure 40. Cumulative release of conjugated DEX from functionalised-TiO2 
particles obtained via amino route at different pH values (pH=5,6 and 7). Data are 
the mean ± standard deviation (SD) of two independent experiments (n=2). 
Standard deviation is less than 5% of mean value. 
 
 
 
 
 
 
 
80 
 
3.4.2 Mercapto-route 
In Figure 41 is shown the drug release profiles for functionalised-TiO2 particles obtained 
by mercapto route. For all the conditions tested (pH=5, 6 and 7) DEX was released from 
functionalised-TiO2 particles, within the first 24 hours. 
 
Figure 41. Cumulative release of conjugated DEX from functionalised-TiO2 
particles obtained via mercapto route at different pH values (pH=5,6 and 7). Data 
are the mean ± standard deviation (SD) of two independent experiments (n=2). 
Standard deviation is less than 5% of mean value. 
 
Moreover, the release of DEX is pH-dependent, where the highest amount of DEX, 
7.5±0.1 µg/mL and 4.3±0.0 µg/mL, was respectively released at higher pH values, pH=7 
and pH=6. On the other hand, at more acidic conditions (pH=5) minor concentrations of 
DEX (1.8±0.0 µg/mL) were released.  
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3.4.3 Layer-by-Layer route 
The DEX release from functionalised-TiO2 particles obtained via LbL route was also 
investigated, and release profile at pH=6 and pH=7 (Figure 42, Figure 43) was plotted. 
Experimentally the release profile of DEX from the LbL-functionalised TiO2 particles 
portrays an initial release phase during the first 24 hours, followed by a constant release 
of DEX for at least 20 days; where a gradual decrease in the rate release was observed 
for both pH=6 (Figure 42), and pH=7 (Figure 43). Although constant, the pH conditions 
and number of layers deposited on the surface of TiO2 particles, particularly around DEX 
layer, significantly (p<0.05) affected DEX release profile. For instance, at pH=6 the total 
amount of drug released when DEX is the outer layer (DEX sample) was higher (1.1-1.3 
mg/mL), than the one released at pH=7 (0.6-0.8 mg/mL).  
 
 
Figure 42. Cumulative release of DEX from LbL-functionalised TiO2 particles at 
pH=6. The DEX release profile for functionalised TiO2 particles with different 
number and type of outer layers was investigated: for LbL particles where DEX 
was the outer layer (DEX (LbL 0) and DEX+CH+DEX (LbL 2) samples). And for 
particles where CH or ALG were the outer layers:  DEX+CH (LbL 1), 
DEX+CH+DEX+ALG (LbL 3) and DEX+CH+DEX+ALG+CH (LbL 4). Data are the 
mean ± standard deviation (SD) of two independent experiments (n=2). Standard 
deviation is less than 5% of mean value. 
 
Furthermore, for both pH=6 and pH=7, DEX released from functionalised-TiO2 particles 
where DEX was the outer layer, LbL 0 and LbL 2, was higher than the one released from 
particles where DEX layer was surrounded by CH/ALG layers, LbL 1, LbL 3 and LbL 4. 
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For example, at pH=7 (Figure 43), results showed the highest concentrations of DEX 
were released from LbL 0 (~1 mg/mL) and LbL 2 (~0.9 mg/mL). On the other hand, the 
smallest concentrations were released from LbL 1 (~0.85 mg/mL), LbL 3 (~0.56mg/mL) 
and LbL 4 (~0.53mg/mL). Similar trend was observed for DEX release at pH=6 (Figure 
42), where the higher concentrations of DEX were released for functionalised-TiO2 
particles where DEX was the outer layer (LbL 0 and LbL 2 samples). 
 
Figure 43. Cumulative release of DEX from LbL-functionalised TiO2 particles at 
pH=7. The DEX release profile for functionalised TiO2 particles with different 
number and type of outer layers was investigated: for LbL particles where DEX 
was the outer layer (DEX (LbL 0) and DEX+CH+DEX (LbL 2) samples). And for 
particles where CH or ALG were the outer layers:  DEX+CH (LbL 1), 
DEX+CH+DEX+ALG (LbL 3) and DEX+CH+DEX+ALG+CH (LbL 4). Data are the 
mean ± standard deviation (SD) of two independent experiments (n=2). 
 
Moreover, independently of the pH conditions and for all LbL particles (LbL 0, LbL 1, LbL 
2 and LbL 4) it was observed that the concentration of DEX release from LbL particles 
decreased over time. Likewise, the highest concentrations of DEX were released during 
the initial 24h, whilst smaller concentrations were released in the following days (~20 
days).  Taking as example LbL 0 and LbL 4, the following concentrations of DEX were 
released at pH=6 (Figure 42) for LbL 0 (1.05, 0.8, 0.05 and 0.04 mg/mL), and for LbL 4 
(0.24,0.07, 0.06 and 0.04 mg/mL) respectively at 24h, 48h, 72h and 2 weeks. Similarly, 
at pH=7 (Figure 43) the following concentrations of DEX were released from LbL 0 (0.55, 
0.14, 0.12 and 0.05 mg/mL), and for LbL 4 (0.25, 0.06, 0.07 and 0.05 mg/mL), 
respectively at 24h, 48h, 72h and 2 weeks.  
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3.5 DEX Loading (%) and Entrapment Efficiency (%) 
The amount of DEX loaded onto functionalised-TiO2 particles, and respective 
encapsulation efficiency (EE%) were calculated for the different synthetic routes (Table 
13). Functionalised-TiO2 particles obtained by amino and mercapto presented very 
similar values for both drug content (~0.13mg of DEX/mg of functionalised-TiO2 particles) 
and encapsulation efficiency (~68%).  
Table 13. Drug loading and entrapment efficiency of DEX-loaded functionalised 
TiO2 particles prepared by amino, mercapto and LbL routes. Data are the mean ± 
standard deviation (SD) of two independent experiments (n=2). 
DEX-loaded TiO2 particles 
(Synthetic route) 
Loading (%) Entrapment efficiency (%) 
Amino route 13.6±0.2 68.1±0.1 
Mercapto route  13.6±0.0 67.9±0.2 
LbL route: Sample LbL 0 27.2±0.1 42.9±0.2 
LbL route: Sample LbL 4 40.5±0.1 50.6±0.2 
 
For LbL route, drug loading and entrapment efficiency were calculated for samples 0 
(DEX was the outer layer) and sample 4 (DEX was surrounded by 4 CH/DEX/ALG 
layers). This was performed because drug release studies (3.4.3 Layer-by-Layer route) 
have shown that the number of layers surrounding DEX-loaded functionalised TiO2 
particles significantly affected the DEX release profile. Accordingly, results (Table 13) 
showed that when compared to sample 0, both encapsulation efficiency and drug loading 
were higher for sample 4. This difference was more evident for drug loading calculations 
(%), where an 0.35-fold increase of drug loading was observed for sample 4. 
3.6 Cellular viability studies 
The assessment of cytotoxicity of drug delivery systems is a central factor in the 
evaluation of novel systems for future in vivo applications. Although, before assessing 
the cytotoxicity of the model system, a preliminary study was performed to determine if 
the broths collected from drug release experiments and concentrations of DEX released 
from functionalised-TiO2 particles were potentially toxic to the Raw 264.7 macrophages. 
For this purpose, a range of DEX concentrations (3.9-100µg/mL), and the broths 
collected from drug release assay performed at pH=6 and pH=7 were exposed to Raw 
264.7 macrophages with and without LPS. The broths collected from drug release 
studies performed at pH=4 and pH=5 were not tested, due to the low cellular viability 
they caused when exposed to the cells ( 
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I. Appendix Figure 77). 
3.6.1. Preliminary studies on Raw 264.7 cells 
DEX 
The effect of DEX concentrations (3.9–100 µg/mL) effect on cellular viability was also 
assessed, with and without LPS (Figure 44). After 18h, 24h and 48h, DEX alone caused 
a significant (p<0.001) 264.7 Raw macrophages death of approximately 20-30%, as 
evaluated by MTT assay (Figure 44.A). This decrease on cellular viability was more 
evident when cells were exposed to a higher DEX concentration such as 40 and 100 
µg/mL. However, for the same concentrations of DEX (3.9–100 µg/mL), and in the 
presence of LPS after 18h, 24h and 48h, cell viability of RAW 264.7 macrophages were 
significantly (p<0.05) equal or higher than 100% relative to control (Figure 44.B). After 
72 hours, the DEX affected cellular viability in a dose-dependent manner for both cells 
treated with or without LPS (Figure 44). Accordingly, the cells treated with minor 
concentrations of DEX (3.9 and 10 µg/mL) showed the lowest (10-15% relative to control) 
or any decrease on cellular viability, respectively for Raw 264.7 macrophages without 
(Figure 44.A) or with LPS (Figure 44.B).On the other hand, Raw 264.7 cells treated with 
higher DEX concentrations (≥20 µg/mL), caused a higher cell death, 25-40% and 5-15%, 
respectively for cells without or with LPS. 
 
Drug release buffers 
Before exposing the cells to the DEX released from functionalised TiO2 particles (i.e. 
broths collected from drug release studies), preliminary studies were done to assess if 
the buffers utilized to perform the drug release studies, acetate buffer (pH=6) and PBS 
(pH=7), were potentially toxic to the macrophages. Therefore, Raw 264.7 cells were 
exposed to different concentrations (0-100%) of PBS (Figure 45). In this study, the 100% 
PBS means that cells were only treated with buffer, and 50% means the buffer was 
diluted (1:2) in DMEM media. 
For cells without LPS (Figure 45.A), results show that all concentrations of PBS tested, 
except 10%, caused a significant (p<0.05) decrease on the cellular viability, in a 
concentration-dependant manner, where the higher concentration of buffer tested (100% 
of PBS) caused a cell death of about 90%, relative to control.  However, for the same 
concentrations of PBS (10–100%), and in the presence of LPS (Figure 45.B), the cell 
viability of RAW 264.7 macrophages was overall higher than for cells without LPS. 
Particularly, when cells were exposed to higher PBS concentrations such as 100% and 
75%. Despite this fact, the same behaviour was observed for cell treated with or without 
LPS, where among all concentrations tested only 10% of PBS did not cause a significant 
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decrease (p<0.05) on cellular viability, showing almost the same behaviour as the LPS 
control group. The same trend was observed when LPS-activated Raw 264.7 cells were 
exposed to different concentrations (0-100%) of acetate buffer (pH=6), except after 72h 
exposure, where 10% acetate buffer caused a significant (p<0.05) but minor decrease 
of cellular viability when compared to control group ( 
I. Appendix, Figure 89,). 
 
 
Figure 44. Effect of DEX without (A) and with LPS (B) in cell viability. RAW 264.7 
macrophages were exposed to range of concentrations between 3.9 and 100 
μg/mL during 18h, 1day, 2 days and 3 days. Cell viability was assessed by MTT 
study done with 2 x10^4 cells /well. Data are the mean ± standard deviation (SD) 
of two independent experiments (n=2). 
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Figure 45. Effect of different concentrations of PBS, buffer utilized for drug release 
studies (pH=7), (A) with and (B) without LPS in cell viability. RAW 264.7 
macrophages were exposed to range of PBS concentrations (10-100%) diluted in 
DMEM media, for 18, 24, 48 and 72 hours. In the control group cells were only 
treated with DMEM. Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
 
 
Filtered versus non-filtered broths  
Results from preliminary studies with drug release buffers have shown that broths should 
be diluted on DMEM media up to a concentration of 10% before being added to the cells. 
This way, it can be guaranteed that anti-inflammatory effect of DEX released from 
functionalised-TiO2 particles will not be due to a decrease of cellular viability. Although, 
when the cells were exposed to the broths, it was observed that after 18h exposure some 
black spots were surrounding the cells (Figure 46.A). 
 
18 24 48 72
C
el
l v
ia
bi
lit
y 
(%
to
 L
PS
)
24 48 72
C
el
l v
ia
bi
lit
y 
(%
to
 c
on
tr
ol
)
A
B
87 
 
 
Figure 46. The effect of A. non-filtered and B. filtered broths on the Raw 264.7 
macrophages after 18h-exposure was assessed by inverted microscopy. Dark 
spots are indicated by the white arrows. 
 
To assess the effect of these black spots (Figure 46.A), the cellular viability of cells 
exposed to non-filtered and filtered broths was investigated (Figure 47, Figure 48). 
Results obtained from MTT assay, showed that for most of the broths tested the cellular 
viability was significantly (p<0.05) higher when cells were exposed to filtered samples for 
both pH=6 and pH=7 (amino and mercapto routes). Overall ~ a 2-fold increase on cell 
viability was observed when comparing cells exposed to filtered broths over the unfiltered 
ones   (Figure 47, Figure 48). Even after 72 hours-exposure, the cells treated with the 
filtered broths presented a higher % of cellular viability. Particularly, the broths collected 
from drug release studies performed pH=7, where cellular viability was very similar 
(~85% cellular viability) to the one observed for the control group.  
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Figure 47. Effect of filtered and non-filtered broths, collected from drug release 
studies (Amino Route) performed at pH 6, in cell viability. RAW 264.7 macrophages 
were exposed to broths during (A) 18h, (B) 24h, (C) 48h and (D) 72 hours. Cell 
viability was assessed by MTT assay. In the control group cells were only treated 
with DMEM. Data are the mean ± standard deviation (SD) of two independent 
experiments (n=2). 
 
The same experiment was performed for LPS-activated cells (Figure 49). Similar results 
were found, overall the LPS-activated Raw 264.7 cells exposed to filtered samples 
showed significant (p<0.05) and higher cellular viability when compared to non-filtered 
ones. This behaviour was mostly observed after 72 hours, where the cells treated with 
filtered broths less than 25% of cell death relative to control. Particularly for cells exposed 
to filtered broth collected from pH=7 (Figure 50), in this case less than 10% of cell death 
was observed, when compared to the control. 
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Figure 48. Effect of filtered and non-filtered broths, collected from drug release 
studies (Amino Route) performed at pH 7, in cell viability. RAW 264.7 macrophages 
were exposed to broths during (A) 18h, (B) 24h, (C) 48h and (D) 72 hours. Cell 
viability was assessed by MTT assay. In the control group cells were only treated 
with DMEM. Data are the mean ± standard deviation (SD) of two independent 
experiments (n=2). 
 
Furthermore, as shown in Figure 46.B, filtered broths did not induce the black spots 
previously observed for cells treated with unfiltered samples. Hence, due to the 
significant higher cellular viability, all subsequent Raw 264.7 cells studies were 
performed using filtered samples and 1:10 media dilution (concentration of 10% in 
release buffer).  
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Figure 49. Effect of filtered and non-filtered broths, collected from drug release 
studies (Amino and mercapto route) performed at pH 6, in cell viability. LPS-
activated-RAW 264.7 macrophages were exposed to (A) 18h, (B) 24h, (C) 48h and 
(D) 72 hours. Cell viability was assessed by MTT assay. In the control group cells 
were only treated with DMEM. Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
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Figure 50. Effect of filtered and non-filtered broths, collected from drug release 
studies (Amino and Mercapto route) performed at pH 7, in cell viability. LPS-
activated-RAW 264.7 macrophages were exposed to (A) 18h, (B) 24h, (C) 48h and 
(D) 72 hours. Cell viability was assessed by MTT assay. In the control group cells 
were only treated with DMEM. Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
 
 
The same preliminary toxicity studies, for filtered and non-filtered samples, were 
performed for the broths collected from DEX-loaded functionalised-TiO2 particles 
obtained by LbL route ( 
I. Appendix, Figure 84, Figure 85). 
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3.6.2 Dexamethasone loaded functionalised-TiO2 particles  
The viability of cells exposed to DEX released from functionalised-TiO2 particles was 
investigated to exclude the decrease of inflammatory mediators i.e. TNF-α and NO, due 
to drug-induced toxicity.  The broths collected from drug release studies at pH=6 and 
pH=7 performed for functionalised-particles obtained via amino/mercapto (Figure 51) 
and LbL routes were exposed to LPS-activated Raw 264.7 macrophages, and cellular 
viability was assessed. 
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Figure 51. Effect of DEX, released from functionalised-TiO2 particles, in LPS-
activated RAW 264.7 cell viability. Cells were exposed to filtered broths collected 
at 24h time point (i.e. DEX released after 24h) during 18, 24, 48 and 72 hours. 
Broths were collected from drug release studies performed at (A) pH=6 and (B) 
pH= 7 for amino (24h amino) and mercapto (24h mercapto) routes. Cellular viability 
was assessed by MTT assay. 10%acetate buffer and 10%PBS buffer were 
respectively used as positive control for broths collected from release studies 
performed at (A) pH=6 and (B) pH= 7. Data are the mean ± standard deviation (SD) 
of two independent experiments (n=2). 
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Amino and mercapto routes 
Results obtained from MTT assay showed that the viability of cells exposed to DEX 
released from functionalised-particles was very similar (>90% cellular viability) to the one 
observed for the LPS control group (Figure 51) for both amino and mercapto routes. 
Except at 72h, where a higher decrease on viability, 7-11% relative to control group, was 
observed, for cell treated with DEX released at pH=6 (Figure 51.A). Although significant 
(p<0.05), when compared to control group, this decrease on cellular viability for 24h 
amino (~7%) and for 24h mercapto (~11%) was not as significant (p<0.05) as the one 
induced on Raw macrophages (~20%) treated with release buffer alone. 
 
LbL route 
The same preliminary cellular viability studies were performed for DEX released from 
functionalised TiO2 particles obtained by LbL route (experiment 2).  For this study 
samples were collected from release studies at pH=6 (Figure 52.A) and pH=7 (Figure 
52.B).  As drug release studies have shown that the concentrations of DEX released 
varied according to the number of layers surrounding functionalised TiO2 particles. 
Accordingly, the cells were exposed to DEX released from LbL-functionalised particles 
where DEX was the outer layer (LbL 0) or where DEX was surrounded by 4 CH/DEX/ALG 
layers (LbL 4). For clarity, different names were attributed to DEX-loaded functionalised 
TiO2 particles obtained by LbL route (experiment 2), where the names varied according 
to different CH ALG or DEX layers deposited around functionalised-TiO2 particles (Table 
14). 
 
Table 14. Sample names for DEX-loaded functionalised TiO2 particles obtained by 
LbL route.  CH, ALG and DEX in bold correspond to layers surrounding DEX-
loaded functionalised TiO2 particles. 
DEX-loaded functionalised TiO2 particles Sample name 
(NH2-TiO2 particles) -ALG-CH-DEX LbL 0 
(NH2-TiO2 particles) -ALG-CH-DEX-CH LbL 1 
(NH2-TiO2 particles) -ALG-CH-DEX-CH-DEX LbL 2 
(NH2-TiO2 particles) -ALG-CH-DEX-CH-DEX-ALG LbL 3 
NH2-TiO2 particles) -ALG-CH-DEX-CH-DEX-ALG-CH LbL 4 
 
For this set of experiments (Figure 52), cellular viability was assessed for broths collected 
from LbL-functionalised particles with 0 layers (DEX sample, LbL 0) and 4 layers 
(DEX+CH+DEX+CH+ALG samples, LbL 4), and collected at different time points (DEX 
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released at 24h and 48h). Mainly because drug release studies performed for LbL 
particles (pH=6 Figure 42, and pH=7 Figure 43) have shown that number of layers (CH, 
ALG and DEX) surrounding functionalised-TiO2 particles, significantly affected the DEX 
release profile (i.e. different release of DEX concentration for same time points).  
 
 
Figure 52. Effect of DEX released from functionalised-TiO2 particles, obtained via 
LbL route in LPS-activated RAW 264.7 cell viability. Cells were exposed to filtered 
broths collected at 24h and 48h time point (i.e. DEX released after 24 and 48h) 
during 18, 24, 48 and 72 hours. Broths were collected from drug release studies 
performed at (A) pH=6 and (B) pH= 7 for DEX-loaded particles surrounded by 0 
layers or 4 layers. Cellular viability was assessed by MTT assay. 10% acetate 
buffer and 10% PBS buffer were respectively used as positive control for broths 
collected from release studies performed at (A) pH=6 and (B) pH= 7. Data are the 
mean ± standard deviation (SD) of two independent experiments (n=2). 
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Therefore, we decided to investigate if the DEX released from functionalised-TiO2 
particles surrounded by 0 (LbL 0) or 4 layers (LbL 4) at different time points, will have a 
different effect in viability of Raw 264.7 cells.  
It can be seen in Figure 52, that after 18h and 24h exposure, DEX released from 
functionalised-TiO2 particles surrounded by 0 and 4 layers from both studies at pH=6 and 
pH=7 had minor effect on LPS-activated cells, with insignificant changes on cellular 
viability (>90%, relative to control). On the other hand, it was observed that after 48h and 
72h-exposure, the 48h-collected broths caused a small, but significant decrease on cells 
viability. Specifically, DEX released from functionalised-TiO2 particles surrounded by 0 
(48h 0 layer) and 4 layers (48h 4 layers) (pH=7 studies, Figure 52.B), respectively caused 
a minor decrease on cellular viability of 10 and 15% relative to LPS control group. 
Although significant (p<0.05), when compared to control group, this decrease on cellular 
viability was not as significant (p<0.05) as the one induced on Raw macrophages (~20%) 
treated with release buffer alone. 
 
3.7. LPS-activated 264.7 Raw macrophages: inflammation model  
Another important factor when assessing the anti-inflammatory activity of DEX-loaded 
functionalised-TiO2 particles, it is to obtain a reliable in vitro inflammatory model. In which 
LPS exposure will be able to induce inflammation i.e. allow measurable production of 
inflammatory markers such as nitric oxide (NO) and tumour necrosis factor alpha (TNF-
α). To obtain a reliable in vitro inflammation model, an appropriate cell density and an 
optimal LPS concentration should be utilized to assay NO and TNF-α production in 
culture. Mainly because if the cell density is not appropriated, the NO and TNF-α 
production might not be detectable in the cell media. As for LPS concentration, high dose 
could cause cell toxicity, and low concentration might not be enough to activate the 
macrophages. For this reason, cell density and LPS concentration were optimised to 
measure the production of inflammatory mediators in LPS-activated macrophages.  Due 
to rapidity and simplicity, the measurement of NO production by Griess reagent was 
utilized as screening tool for this optimisation study. Likewise, NO production was 
assessed when different cell densities and LPS concentrations were utilized to find out 
which experimental conditions would generate the more reliable results. The cellular 
viability of LPS-activated cells under different parameters (e.g. cell density and LPS 
concentration) was also investigated to complement the optimization of in vitro 
inflammation model. 
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3.7.1 Optimal LPS concentration  
Aiming to optimize the LPS concentration to activate the macrophages, the cells were 
treated with different concentrations of LPS (ranging from 0.01 to 1µg/mL) to identify the 
optimal concentration of the stimulant. Particularly for this experiment, cells were seeded 
at a density of 1.5 x 104 cells/well on a 96-well plate, stimulated with LPS and then level 
of NO and TNF-α were analysed at different time points (18, 24, 48 and 72 hours). 
Overall, results showed (Figure 53) that LPS exposure caused a marked and significant 
increase in NO and TNF-α protein levels when compared to the unstimulated 
macrophages, which produced only very low amounts of TNF- α (<35 pg/mL) and NO 
(<20 μM/mL). As can be seen in Figure 53 both NO and TNF-α production follow a dose-
dependent and temporal pattern; where LPS concentration of 1µg/mL was the most 
powerful for Raw 264.7 macrophages activation.  
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Figure 53. A) Nitric oxide (NO) and TNF- α production upon exposure to different 
LPS concentrations (0.01-1µg/mL range) during 18, 24, 48 and 72 hours. In the 
control group cells were only treated with DMEM. For control group, standard 
deviation is less than 5% of mean value. Data are the mean ± standard deviation 
(SD) of two independent experiments (n=2). 
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These results were confirmed after visualising the cells morphology under the inverted 
microscope, where cells exposed to a higher LPS concentration (1µg/mL) showed a 
more dendritic-like morphology, typical of activated macrophages (Saxena et al. 2003) 
(Figure 54).For example (Figure 53), after 18h exposure only macrophages which were 
stimulated with the highest concentration of LPS (1 µg/ml) have shown to secrete a 
significant level of inflammatory NO and TNF-α proteins, respectively with an 
approximate~0.18 and ~68-fold increase when compared to control group. On the 
other hand, after long LPS-time exposure (72h), inflammatory protein levels were 
maximally elevated; LPS stimulated-cells secreted approximately 3000 pg/ml of TNF-α, 
and ~34 µM/mL of NO, respectively a ~100 and 1.1-fold increase when compared 
protein levels of the unstimulated control group.  
 
 
Figure 54. The effect of LPS (0.1 and 1 μg/mL) on the morphology of Raw 264.7 
macrophages after 24h exposure was assessed by inverted microscopy. 
Photographs were taken at magnification of x4 and x10 magnification. 
Moreover, results showed that LPS prepared from fresh stock solution instead of frozen 
one (Figure 86), was more effective i.e. higher NO production for Raw 264.7 
macrophages activation.  
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3.7.2 Optimal cell density 
Macrophage density is also an important parameter to regulate the magnitude of 
inflammatory markers production (Hosseini et al. 2014, Jacobs & Ignarro 2003). 
Therefore, aiming to optimize the seeding density of Raw 264.7 cells to be used for 
measuring inflammatory markers production, cells were seeded at different cell 
densities: 0.5 x 104cells/well, 1.5 x 104 cells/well, 2 x 104, and 2.5 x 104 cells/well in a 96-
well plate. The cells were treated with LPS concentration of 1 µg/ml, which according to 
our previous results (Figure 53, Figure 54), was the most effective concentration for 
optimal NO and TNF-α production, and then cell culture supernatant was analysed for 
NO levels using Griess assay. The data obtained (Figure 55) depicts the relationship 
between cell density and NO production on Raw 264.7 macrophages with and without 
LPS. As expected, the unstimulated Raw 264.7 cells produced minimal amount of NO, 
with the levels remaining lower than 20 μM/mL at all time points tested.  On the other 
hand, LPS-stimulated cells showed a higher NO production at 24, 48 and 72 hours when 
compared to unstimulated ones. 
 
Figure 55. Optimisation of Raw 264.7 cell in culture. Comparison of nitric oxide 
(NO) production (μM/mL) in cells without (left side of the graph) and with LPS (1 
μg/mL) (right side of the graph) during 18, 24, 48 and 72 hours, when different cell 
densities were utilized (0.5 to 2.5 x 104cells/well). Data are the mean ± standard 
deviation (SD) of two independent experiments (n=2). 
 
This trend was particularly observed for high cell densities (2.5 and 2 x 104 cells/well), 
where the LPS-induced NO production was significantly (p<0.05) enhanced, when 
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compared to the one observed for lower cell densities. In addition, the results showed 
that although the Griess reagent assay was not sensitive enough to detect the amounts 
of NO produced, a minor alteration on cell morphology (Figure 56) was observed for 
LPS-activated cells when lower cell densities were utilized (0.5 and 1.5 x 104cells/well), 
especially in the first 24 hours. 
 
Figure 56. The effect of LPS (1 μg/mL) on the morphology of Raw 264.7 
macrophages during 24, 48 and 72 hours-exposure was assessed by inverted 
microscopy, when different cell densities were utilized. White arrows indicate the 
dendritic-like cells, a distinctive feature of LPS-activated macrophages. 
 
The viability of cells treated with and without LPS for different cell densities, was also 
investigated, to evaluate if NO was being released due to LPS cytotoxicity (Figure 57). 
The viability of cells seeded at low density (0.5 x 104cells/well) was not assessed due to 
lower amount of NO detected (Figure 55), when compared to the others cell densities 
investigated (1.5 x 104, 2.0 x 104 and 2.5 x 104cells/well). Individual and more detailed 
graphs showing the viability of different cell density with and without LPS are shown in 
the appendix section ( 
I. Appendix. Figure 87). Results (Figure 57) showed that at 48h, the LPS-stimulated cells 
showed a higher cellular viability i.e. more metabolic active, when compared to the 
control. Except for the high cellular density utilized, 2.5 x 104cells/well, where microscope 
images showed that at 48h the cells start to be overconfluent. Only at 72 hours, a 
decrease on cellular viability was detected for all cell densities, although cellular viability 
was still high, where ~80% of cellular viability was observed for LPS-activated cells when 
compared to control group.  
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Figure 57. The effect of LPS (1 μg/mL) on the cell viability of Raw 264.7 
macrophages during 18, 24, 48 and 72 hours-exposure was assessed by MTT 
assay, when different cell densities were utilized. Results were plotted against 
cells seeded at same cell density but without LPS stimulation (control). In the 
control group cells were only treated with DMEM. Data are the mean ± standard 
deviation (SD) of two independent experiments (n=2). 
 
Overall results showed that NO production and cellular viability of LPS-stimulated 
macrophages followed a pattern, which was affected by cell seeding density. Likewise, 
overtime NO levels showed an increase proportional to cell-density, whereas the higher 
cell density (>0.5 x 104cells/well) was associated with higher production of NO 
(~100µM/mL). Although, cell viability studies showed that over time the highest cell 
density 2.5 x 104cells/well was associated with the smaller cell viability, which may be 
caused by the high toxic levels of NO. Accordingly, 2.0 x 104cells/well was the seeding 
density chosen for the following studies. Mainly to assess the anti-inflammatory activity 
i.e. level of inflammatory markers of DEX released from functionalised TiO2 particles in 
LPS-activated Raw 264.7 macrophages. 
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3.7.3. Optimised model: Cellular morphology, TNF-α and NO production  
After establishing the appropriate cell density (2x104 cells/well) and LPS concentration 
(1µg/mL), we further evaluated the morphology of LPS-activated cells (Figure 58) by 
staining actin rings using fluorescent microscopy.  
 
Figure 58. The effect of LPS (1 μg/mL) on the cellular morphology of Raw 264.7 
macrophages after 24h-exposure was assessed by fluorescence microscopy (A). 
F-Actin rings and nuclei of cells were respectively stained with phalloidin-FITC 
and DAPI. Photographs were taken at fluorescence microscope at magnification 
of ×20.  
 
Results revealed that after 24h exposure, the untreated Raw 264.7 cells showed a 
regular rounded morphology and did not spread over the surface. On the other hand, 
LPS exposure (1µg/mL), induced a reorganization in actin distribution of the 
macrophages resulting in evident difference in cell morphology: cells showed an oval-
shaped configuration and visible size increase. Along with this experiment (Figure 58), 
the cellular viability (Figure 59), TNF-α and NO production (Figure 60) were also 
measured to get further insight on the behaviour of LPS activated-macrophages.  
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Figure 59. Cellular viability of Raw 264.7 macrophages under optimized LPS 
concentration (1 μg/mL) and cell density (2x104 cells/well) was measured. Cells 
were exposed to LPS during 18, 24, 48 and 72 hours. Cellular viability was 
assessed by MTT assay and NO production by Griess reagent assay. In the control 
group cells were only treated with DMEM. Data are the mean ± standard deviation 
(SD) of two independent experiments (n=2). 
 
The LPS cytotoxicity was assessed by preliminary experiment (Figure 57). Results 
showed that the exposure to LPS (1 µg/mL) for 48 hours did not induce a decrease on 
cellular viability, when compared to control (Figure 59). On the contrary, after 18 and 24 
hours of LPS-exposure, an increase on cellular viability (31.5% and 14.0%, relative to 
control) was observed with statistical significance (p<0.001). Only after 72 hours-
exposure, a decrease on cellular viability was detected, although cellular viability was 
still high, where ~80% of cellular viability was observed when compared to control. 
Moreover, cellular viability over time was confirmed by microscope evaluation ( 
I. Appendix, Figure 88). Regarding inflammatory cytokines production (Figure 60), 
results showed that a minimal baseline of NO (DMEM, <16 µM/mL) and TNF-α (DMEM, 
<35 pg/mL) production was observed at non-LPS stimulated macrophages. On the other 
hand, stimulation of Raw 264.7 cells with LPS resulted in a significant increase (p<0.05) 
of NO and TNF-α production, which followed a time and concentration-dependent 
pattern. At 18h, 24h, 48h, 72h activated cells respectively produce 18.7, 19.7, 39.8, 97.3 
µM/mL of NO and 1101.2, 2618.6 2923.8, 3164.4 pg/mL of TNF-α. Particularly after 72 
hours’ exposure, where the LPS-activated Raw-macrophages respectively released 5 
and 103 times more NO and TNF-α, when compared to untreated control cells. 
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Figure 60. Nitric Oxide (A) and TNF-alpha production (B) of Raw 264.7 
macrophages under optimized LPS concentration (1 μg/mL) and cell density 
(2x104 cells/well) were measured. Cells were exposed to LPS during 18, 24, 48 and 
72 hours. In the control group cells were only treated with DMEM. Data are the 
mean ± standard deviation (SD) of two independent experiments (n=2). 
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3.8 Anti-inflammatory activity studies 
As observed in the previous section (3.7. LPS-activated 264.7 Raw macrophages: 
inflammation model), the LPS stimulation (1µg/mL) has shown to activate Raw 264.7 
macrophages, resulting in significant changes on the shape/size of cells (Figure 58), and 
increased  NO and TNF-α production (Figure 60) when compared to the untreated cells 
(control group). Accordingly, these results reflect the aptitude of LPS-activated Raw 
264.7 cells to be utilized as an in vitro inflammation model. 
In this section, the experiments described were performed to investigate the anti-
inflammatory effect of DEX released from the functionalised-TiO2 particles, obtained via 
different synthetic routes, amino, (Figure 40), mercapto, (Figure 41) and LbL route 
(Figure 42 and Figure 43). The anti-inflammatory effect was assessed by measuring both 
NO and TNF-α production on LPS-stimulated RAW 264.7 macrophages. In principle, the 
inhibition of NO and TNF-α production on LPS-activated cell will reveal the anti-
inflammatory effect of the model system herein developed.  
Preliminary studies were performed to investigate the effect of different concentrations 
(3.9-100µg/mL) of pure DEX on NO production of Raw 264.7 cells, with and without LPS 
(Figure 61). Although in this section, only the effect of DEX concentrations up to 20 
µg/mL were shown, mainly because the cellular viability studies (Figure 44.B) showed 
that DEX concentrations higher than 20 µg/mL induced a significant (p<0.05) cell death 
at 72 hours.  
 
3.8.1 Preliminary studies: basal levels 
Preliminary study was undertaken to investigate the effect of different pure DEX 
concentrations (3.9-20µg/mL) on the time course of NO production by Raw 264.7 cells, 
with and without LPS stimulation (Figure 61). Results showed that when cells were 
incubated without LPS (Figure 61.B) none of the tested concentrations of DEX (3.9-
20µg/mL) induced changes in NO basal levels. In fact, the NO production (µM/mL) 
observed for cells without LPS activation was very similar the one observed for DMEM 
media alone (<20 µM/mL). On the other hand, for LPS-activated cells (Figure 61.A), 
results showed that all DEX concentrations tested have significantly (p<0.05) reduced 
NO production on LPS-activated cell, when compared to (LPS) control group.  
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Figure 61. Effect of DEX in nitric oxide (NO) production (µM/mL, or NO% to LPS 
control) in RAW 264.7 macrophages with (A) and without LPS (B). Cells were 
exposed to range of DEX (3.9-20 µg/mL) diluted in DMEM media, during 18, 24, 48 
and 72 hours. In the control group cells were only treated with DMEM. Data are the 
mean ± standard deviation (SD) of two independent experiments (n=2). 
 
In general, the inhibition of NO production followed a time and concentration-dependent 
pattern (Figure 61.A): the highest anti-inflammatory effect (~70-75% reduction of NO 
production relatively to LPS control) was observed at 72h and when cells were treated 
with the highest DEX concentrations (10 and 20 µg/mL).  
Moreover, the effect of pure DEX (3.9 and 10µg/mL) on TNF-α production of Raw 264.7 
cells with and without LPS was also assessed (Figure 62). Results showed that when 
cells were incubated without LPS (Figure 62.B) none of the tested concentrations of DEX 
induced changes on TNF-α basal levels, which were very close to the ones observed for 
cell treated with DMEM media alone.  
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Figure 62. Effect of DEX in TNF-α production (TNF-α % to LPS control) in RAW 
264.7 macrophages with (A) and without LPS (B). Cells were exposed to range of 
DEX (3.9 and 10 µg/mL) diluted in DMEM media, during 18, 24, 48 and 72 hours. In 
the control group cells were only treated with DMEM. Data are the mean ± standard 
deviation (SD) of two independent experiments (n=2). 
 
For LPS-activated cells (Figure 62.A), DEX significantly (p<0.05) decreased TNF-α 
production, in a concentration-dependent pattern: for most of the time points (except 
18h), the cells treated with the DEX concentration of 10 µg/mL showed a higher decrease 
(% relative to LPS) on TNF-α production (~50-45%) when compared to DEX 3.9 µg/mL 
(~35-25%). In addition, the effect of PBS and acetate buffers, drug release buffers 
(mainly component of the broths) on NO productions was also investigated in Raw 264.7 
cells with and without LPS (Figure 63,Figure 64). When Raw 264.7 cells were exposed 
to different PBS and acetate buffer concentrations (Figure 63.B,Figure 64.B), the NO 
production was nearly the same for all treatments, where NO production was very similar 
to the one observed for control group (NO production >20 µM/mL). 
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Figure 63. Effect of different concentrations of PBS, in nitric oxide (NO) production 
(µM/mL, or NO% to LPS control) in Raw 264.7 macrophages (A) with and (B) 
without LPS. Cells were exposed to range of PBS concentrations (10-100%) diluted 
in DMEM media, during 18, 24, 48 and 72 hours. In the control group cells were 
only treated with DMEM. Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
 
On the other hand, in the LPS-activated cells (Figure 63.A, Figure 64.A) the NO 
production was significantly (p<0.05) affected by the PBS and acetate buffers 
concentration in a dose-dependent manner. When compared to LPS control group the 
cells treated with highest buffer concentrations (>25%) have shown the highest decrease 
of NO production, whereas the only cells treated with lowest buffer concentration (10%) 
showed a NO production equivalent to the LPS control group. Particularly, after 72h the 
higher concentration tested (100%) caused a decrease on NO production of about 50% 
(PBS) and 70% (acetate buffer), relative to LPS control group. Although more 
pronounced, in general, this decrease follows the effect caused on cellular viability (PBS, 
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Figure 45, and acetate buffer (I. Appendix, Figure 89), where among all concentrations 
tested only 10% did not cause a significant decrease (p<0.05) on cellular viability.  
 
 
Figure 64. Effect of different concentrations of acetate buffer, in nitric oxide (NO) 
production (µM/mL, or NO% to LPS control) in Raw 264.7 macrophages (A) with 
and (B) without LPS. Cells were exposed to range of acetate buffer concentrations 
(10-100%) diluted in DMEM media, during 18, 24, 48 and 72 hours. In the control 
group cells were only treated with DMEM. Data are the mean ± standard deviation 
(SD) of two independent experiments (n=2). 
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3.8.2 Dexamethasone loaded-functionalised TiO2 particles  
The anti-inflammatory activity of DEX released from model system (DEX-loaded 
functionalised TiO2 particles) obtain by different synthetic routes was assessed by 
comparing the anti-inflammatory activity of the eluted drug to the respective control (cells 
only treated with LPS). Drug release studies (3.4 DEX release profile) have shown that 
the synthetic route utilized to prepare DEX-loaded functionalised TiO2 particles 
significantly affected the DEX release profile. Not only the DEX concentration released, 
but also the release duration have shown to differ for functionalied-TiO2 particles 
obtained by amino/mercapto (24 hours) (Figure 40, Figure 41), and LbL route (2-3 
weeks) (Figure 42 and Figure 43). For this reason, the anti-inflammatory effect of DEX 
released from functionalised-TiO2 particles was investigated according to release profile 
obtained for each synthetic route, as described in materials and methods section (2.6.1 
Raw 264.7 macrophages cell line, Figure 12). For instance, for amino and mercapto 
route, DEX was released within 24 hours, hence Raw 264.7 macrophages (with and 
without LPS) were only exposed to DEX released at 24h. On the other hand, for LbL 
route, DEX release was more prolonged (24h to ~3 weeks), and the concentrations 
released varied according to the number of layers surrounding DEX-loaded particles. 
Accordingly, the cells were exposed to DEX released at 24h, 48h, 72h and 2 weeks from 
LbL-functionalised particles where DEX was the outer layer (LbL 0) or where DEX was 
surrounded by 4 CH/DEX/ALG layers (LbL 4). The anti-inflammatory activity of DEX 
released from functionalised-TiO2 particles, was investigated by measuring NO and TNF-
α production of LPS-activated macrophages. Furthermore, considering that during 
inflammation, a local acidosis (pH<7) will be observed, it was decided that TNF-α 
production would only be assessed for DEX released at pH=6. Priority was given to this 
pH because it mimics the extracellular environment under inflammatory conditions. Anti-
inflammatory activity of DEX released from functionalised-TiO2 particles at more acidic 
pH values (pH<6); was also measured, although preliminary studies revealed that these 
treatments caused high % of cell death (>80% relative to control ( 
I. Appendix, Figure 77). Therefore, only results from pH=6 and pH=7 where presented in 
this thesis. 
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AMINO MERCAPTO ROUTES 
The anti-inflammatory activity of DEX released from functionalised-TiO2 particles 
obtained by amino and mercapto routes was assessed.  
 
Figure 65. Effect of DEX released from functionalised-TiO2 particles, obtained by 
amino route (24h amino) and mercapto (24h mercapto) route, in nitric oxide (NO) 
production (NO% to LPS control) for LPS-activated RAW 264.7 macrophages. Cells 
were exposed 24h amino and 24h mercapto collected from release studies 
performed at pH=6 (A) and pH=7 (B). Culture supernatants were collected at 18, 
24, 48 and 72h then analysed by Griess reagent for NO. RAW 264.7 cells treated 
with 10% buffer and DEX (3.9 µg/mL) were utilized respectively as negative and 
positive controls. In the control group cells were only treated with DMEM. Data are 
the mean ± standard deviation (SD) of two independent experiments (n=2). 
 
For this purpose, Raw 264.7 macrophages (with and without LPS) were exposed to DEX 
released from functionalised-particles obtained by amino (24h amino) and mercapto (24h 
mercapto) routes, and NO and TNF-α production was measured. For unstimulated Raw 
111 
 
264.7 macrophages (I. Appendix, Figure 91), results showed that NO production was not 
significant when exposed to DEX released at pH=6 and pH=7. In fact, NO production for 
24h amino and 24h mercapto treatments was very similar to the one observed for control 
group (NO production >20 µM/mL). Simultaneously, the effect of DEX released from 
amino and mercapto-functionalised particles in TNF-α production of Raw 264.7 
macrophages was investigated. Results showed that DEX released at pH=6 had a 
different effect on TNF-α production of non-stimulated Raw 264.7 macrophages. At 18h, 
when compared to control, an alteration on TNF-α baseline was observed for cells 
treated with 24h amino (I. Appendix, Figure 92). Although significant (p<0.05), this 
alteration in TNF-α baseline was minor when compared to TNF-α production observed 
for LPS-stimulated cells (~10 fold more). Simultaneous, the effect of DEX released at 
pH=6 and pH=7 on NO production of LPS-activated Raw 264.7 macrophages was 
investigated (Figure 65). With few exceptions, results showed that DEX released from 
both amino and mercapto-functionalised particles significantly reduced (p<0.05) the NO 
production (% to LPS) for most of the time points (Figure 65).  
 
Figure 66. Effect of DEX released at 24h from functionalised-TiO2 particles, 
obtained by amino route (24h amino) and mercapto route (24h mercapto), on TNF-
α production (TNF-α expression %to LPS control) of LPS-activated RAW 264.7 
macrophages. Cells were exposed 24h amino and 24h mercapto collected from 
release studies performed at pH=6. Culture supernatants were collected at 18, 24, 
48 and 72h then analysed by ELISA for TNF-α. Data are the mean ± standard 
deviation (SD) of two independent experiments (n=2). 
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Overall, the decrease of NO production was affected by the extracellular environment 
which DEX was released (pH= 6 vs pH=7) and by the type of route utilised to synthesise 
DEX-loaded functionalised-TiO2 particles (amino or mercapto).For instance, 24h amino 
have showed to exert a higher anti-inflammatory effect i.e. higher decrease of NO 
production (% to LPS) than 24h mercapto (Figure 65.A). In fact, results showed that 
when compared to 24h mercapto, 24h amino caused an increase of 0.5, 0.9 and 0.8-fold 
on NO inhibition, respectively at 24h, 48h and 72h. moreover, when comparing the effect 
of DEX released at pH=6 and pH=7, NO data showed that for both 24h amino and 24h 
mercapto, a higher anti-inflammatory effect was observed for pH=7 (Figure 65.B): for 
24h amino the following decrease on NO production was observed at 24h (12%, 40%), 
48h (39%, 46%) and 72h (35% and 48%), respectively for pH=6 and pH=7 studies. The 
same trend was observed for 24h mercapto although the differences observed between 
pH=6 and pH=7 studies were more evident for this treatment. In fact, at pH=6, 24h 
mercapto showed a minor decrease of NO production (<10% relative to LPS group) for 
all time points. Considering that during inflammation, a local acidosis (pH<7) will be 
observed, it was decided that TNF-α production would only be assessed for DEX 
released at pH=6 (Figure 66). Priority was given to this pH because it mimics the 
extracellular environment under inflammatory conditions. When comparing the anti-
inflammatory effect exerted by 24h amino and 24h mercapto at pH=6, TNF-α data 
showed a similar inhibitory trend to that observed for NO production (Figure 65): where 
24h amino treatment induced a more significant inhibition of TNF-α production than 24h 
mercapto. For instance, 24h mercapto only showed to significant decrease TNF-α 
expression at 24 hours (16% relative to LPS group).  In contrast, 24h amino significantly 
decreased (p<0.05) TNF-α production at most of the time points: a decrease of 20%, 
22%, and 11 (% to LPS control) was respectively observed at 18h, 24h and at 72 hours 
(Figure 66). Furthermore, for both NO and TNF-α production, when significant, the 
decrease induced by 24h amino and 24h mercapto was very closely matched the level 
of suppression observed for DEX (3.9 µg/mL) treatments. 
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LbL ROUTE 
The effect of DEX released from functionalised-TiO2 particles obtained by LbL route on 
NO and TNF-α production was investigated. For this purpose, Raw 264.7 macrophages 
(with and without LPS) were exposed to DEX released from LbL functionalised-particles.  
 
 
Figure 67. Effect of DEX released from functionalised-TiO2 particles (LbL route) in 
nitric oxide (NO) production (NO% to LPS control) of LPS-activated RAW 264.7 
macrophages. Cells were exposed to broths collected from drug release studies 
performed at pH=6, from particles surrounded by 0 layers (LbL 0) (A) and 4 layers 
(LbL 4) (B) during 18, 24, 48 and 72 hours. Broths used to treat the cells were 
collected at different time points to assess the effect of DEX released after 24h 
(24h 0 and 4 layers), 48h (48h 0 and 4 layers), 72h (72h LbL 0 and LbL 4) and 2 
weeks (2W 0 and 4 layers). RAW 264.7 cells treated with 10%acetate buffer and 
DEX (10 µg/mL) were utilized respectively as negative and positive controls. Data 
are the mean ± standard deviation (SD) of two independent experiments (n=2). 
 
When exposed to Raw 264.7 cells, results showed that DEX released at 24h, 48h, 72h 
and 2W collected from LbL functionalised-particles surrounded by 0 (LbL 0) or 4 (LbL 4) 
layers induced a NO and TNF-α production (>20 µM/mL) similar to the control group ( 
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I. Appendix, Figure 93 and Figure 94). As for LPS-activated cells, with few exceptions, 
results showed that DEX released from LbL particles at all time points (24h,48h,72h and 
2W), with both 0 and 4 layers, exerted an anti-inflammatory effect i.e. decreased NO and 
TNF-α production for most of the time points (Figure 67,Figure 68, and Figure 69). 
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Figure 68. Effect of DEX released from functionalised-TiO2 particles (LbL route) in 
nitric oxide (NO) production (NO% to LPS control) of LPS-activated RAW 264.7 
macrophages. Cells were exposed to broths collected from drug release studies 
performed at pH=7, from particles surrounded by 0 layers (LbL 0) (A) and 4 layers 
(LbL 4) (B) during 18, 24, 48 and 72 hours. Broths used to treat the cells were 
collected at different time points to assess the effect of DEX released after 24h 
(24h 0 and 4 layers), 48h (48h LbL 0 and LbL 4), 72h (72h LbL 0 and LbL 4) and 2 
weeks (2W 0 and 4 layers). RAW 264.7 cells treated with 10%PBS buffer and DEX 
(10 µg/mL) were utilized respectively as negative and positive controls. Data are 
the mean ± standard deviation (SD) of two independent experiments (n=2). 
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Although significant (p<0.05) for most of the treatments, the production of NO and TNF-
α production showed different inhibitory trends depending on i) the extracellular 
environment which DEX was released (pH= 6 vs pH=7) (Table 15), ii) the number of 
layers surrounding DEX (0 vs 4 layers), as well as the iii) time-point at which DEX was 
released (24h, 48h, 72h or 2 weeks). 
i) Effect extracellular environment which DEX was released (pH=6 vs pH=7) 
When the effect of the extracellular environment (i) was investigated (Table 15), results 
showed that for most of the time points, DEX released at pH=6 caused a higher decrease 
of NO production (% to LPS) when compared to DEX released at pH=7, being this effect 
more evident at 48h and 72h.  
Table 15. Comparison of the effect of DEX released from functionalised-TiO2 
particles (LbL route), at pH=6 and pH=7, on NO decrease (%LPS control). Results 
were only presented for 24, 48h and 72h, because at 18h NO decrease (%LPS) was 
not significant (ns). Data are the mean ± standard deviation (SD) of two 
independent experiments (n=2). 
Time point DEX release Ph 6 Ph 7 Comparison 
 
 
 
24 hours 
24h LbL 0 9±4.2% 10±2.3% Similar 
48h LbL 0 10±0.9% 11±1.9% Similar 
72h LbL 0 21±2.2% 16±3.6% Higher at pH 6 
2 W LbL 0 17±4.1% 7±2.9% Higher at pH 6 
24h LbL 4 9±3.1% 15±0.8% Higher at ph 7 
48h LbL 4 4±3.5% 13±2.1% Higher at pH 7 
72h LbL 4 23±1.2% 9±1.5% Higher at pH 6 
2 W LbL 4 16±1.5% 7±1.7% Higher at pH 6 
Time point DEX release Ph 6 Ph 7 Comparison 
 
 
 
48 hours 
24h LbL 0 27±%7.0 19±1.7 Higher at pH 6 
48h LbL 0 24±%2.5 12±2.0 Higher at pH 6 
72h LbL 0 39±%2.7 17±2.8 Higher at pH 6 
2 W LbL 0 30±2.9% ns Higher at pH 6 
24h LbL 4 24±3.1% 14±2.4 Higher at pH 6 
48h LbL 4 23±1.4% 7±5.0 Higher at pH 6 
72h LbL 4 21±5.1% 5±3.7 Higher at pH 6 
2 W LbL 4 8±2.6% ns Higher at pH 6 
Time point DEX release Ph 6 Ph 7 Comparison 
 24h LbL 0 42±2.0% 25±2.8 Higher at pH 6 
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72 hours 
48h LbL 0 40±2.3% 20±3.0 Higher at pH 6 
72h LbL 0 27±15.1% 18±2.0 Higher at pH 6 
2 W LbL 0 ns ns ns 
24h LbL 4 41±3.8% 15±3.7 Higher at pH 6 
48h LbL 4 50±4.9% 21±6.2 Higher at pH 6 
72h LbL 4 18±7.3% ns Higher at pH 6 
2 W LbL 4 ns ns ns 
 
Simultaneously, TNF-α production was investigated for LPS-activated macrophages 
treated with DEX release at pH=6 ((Table 17 and Figure 69). 
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ii) Effect of number of layers surrounding DEX layer (0 vs 4 layers)  
When the effect of the type of LbL-functionalised particles (0 or 4 layers surrounding DEX 
layer) (ii) was investigated results (Table 16) showed that DEX released from LbL 0 
particles caused a higher anti-inflammatory effect when compared to DEX released from 
LbL 4 particles. For NO production (Table 16) this behaviour was observed for most of 
the treatments at 48h and 72h. As for TNF-α production (Table 17 and Figure 69) results 
showed the same trend i.e. higher anti-inflammatory effect for DEX released from LbL 0 
particles, but mostly for 24h and 48h LbL broths (Figure 69,Table 17). 
 
Table 16. Comparison of the effect of DEX released from LbL functionalised-
particles with 0 layer (LbL 0) or 4 layers (LbL 4) on NO decrease (%LPS control) at 
pH=6. Results were only presented for 24, 48h and 72h because at 18h NO 
decrease (%LPS) was not significant (ns). Data are the mean ± standard deviation 
(SD) of two independent experiments (n=2). 
Time point DEX release LbL 0 LbL 4 Comparison 
 
24 hours 
24h LbL 9±4.2% 9±3.1% comparable 
48h LbL 10±0.9% 4±3.5% Higher for LBL 0 
72h LbL 21±2.2% 23±1.2% comparable 
2 W LbL 17±4.1% 16±1.5% comparable 
Time point DEX release LbL 0 LbL 4 Comparison 
 
48 hours 
24h LbL 27±%7.0 24±3.1% Higher for LBL 0 
48h LbL 24±%2.5 23±1.4% comparable 
72h LbL 39±%2.7 21±5.1% Higher for LBL 0 
2 W LbL 30±2.9% 8±2.6% Higher for LBL 0 
Time point DEX release LbL 0 LbL 4 Comparison 
 
72 hours 
24h LbL 42±2.0% 41±3.8% Higher for LBL 0 
48h LbL 40±2.3% 50±4.9% Higher for LBL 4* 
72h LbL 27±15.1% 18±7.3% Higher for LBL 0 
2 W LbL ns ns comparable 
 
For example, at 48h, NO data showed that a 0.11-fold increase, 0.46-fold increase and 
0.73-fold increase was respectively observed when comparing the ability to inhibit NO 
production of 24h, 72h and 2W broths from LbL 0 over the one observed for LbL 4 
particles (Table 16).  
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Figure 69. The effect of DEX released from functionalised-TiO2 particles (LbL 
route) on TNF-α production (TNF-α expression %to LPS control). LPS-activated 
RAW 264.7 macrophages were exposed to DEX released at pH=6 from LbL-
particles surrounded by (A) 0 layers (LbL 0) and (B) 4 layers (LbL 4) during 18, 24, 
48 and 72 hours. Broths used to treat the cells were collected at different time 
points to assess the effect of DEX released after 24h (24h LbL 0 and LbL 4), 48h 
(48h LbL 0 and LbL 4), 72h (72h LbL 0 and LbL 4) and 2 weeks (2W LbL 0 and LbL 
4). Culture supernatants were collected at 18, 24, 48 and 72h then analysed by 
ELISA for TNF-α. RAW 264.7 cells treated DEX (10 µg/mL) were utilized as positive 
control for anti-inflammatory effect/TNF-α inhibition. Data are the mean ± standard 
deviation (SD) of two independent experiments (n=2). 
 
 
119 
 
Similarly, at 72h a 0.14-fold increase, 0.46-fold increase, 0.73-fold increase on the anti-
inflammatory effect was respectively observed when comparing 24h, 72h and 2W broths 
collected from LbL 0 over the ones collected from LbL 4 particles. Likewise, TNF-α data 
showed the same trend but mostly for 24h and 48h LbL broths (Figure 69,Table 17), at 
18h, 24h and 72h.As can be seen in Table 17, at 18h a decrease of 34% and 35% was 
observed for 24h and 48h LBL 0, whereas a decrease of 26% and 29% was respectively 
observed for 24h and 48h LBL 4 treatments. At 24h a decrease of 33% and 35% was 
observed for 24h and 48h LBL 0, whereas a decrease of 28% and 21% was respectively 
observed for 24h and 48h LBL 4 treatments.   
Table 17. Comparison of the effect of DEX released from LbL functionalised-
particles with 0 layer (LbL 0) or 4 layers (LbL 4) on TNF-α decrease (%LPS control) 
at pH=6 for 18h, 24h, 48h and 72h. Data are the mean ± standard deviation (SD) of 
two independent experiments (n=2). 
Time point DEX release LbL 0 LbL 4 Comparison 
 
18 hours 
24h LbL 34±6.1% 26±5.3% Higher for LBL 0 
48h LbL 35±5.0% 29±5.7% Higher for LBL 0 
72h LbL 17±4.7% 26±5.3% Higher for LBL 4 
2 W LbL ns 39±5.7% Higher for LBL 4 
Time point DEX release LbL 0 LbL 4 Comparison 
 
24 hours 
24h LbL 33±9.4% 28±6.3% Higher for LBL 0 
48h LbL 35±5.8% 21±2.3% Higher for LBL 0 
72h LbL 21±3.4% ns Higher for LBL 0 
2 W LbL ns ns ns 
Time point DEX release LbL 0 LbL 4 Comparison 
 
48 hours 
24h LbL 20±5.2% 30±10.9% Higher for LBL 4 
48h LbL 29±6.4% 17±11%? Higher for LBL 0 
72h LbL 23±4.9% 24±12.0% comparable 
2 W LbL 10±3.5% 13±6.9% comparable 
Time point DEX release LbL 0 LbL 4 Comparison 
 
72 hours 
24h LbL 36±6.4% 25±7.5% Higher for LBL 0 
48h LbL 37±6.0% 29±2.6% Higher for LBL 0 
72h LbL 19±2.5% 20±11.5% Comparable 
2 W LbL 16±4.3% 25±5.5% Higher for LBL 4* 
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Likewise, at 72h a decrease of 36% and 37% was observed for 24h and 48h LBL 0, 
whereas a decrease of 25% and 29% was respectively observed for 24h and 48h LBL 4 
treatments. When comparing the anti-inflammatory effect of LbL 0 and LbL 4, for DEX 
released at 72h and 2W, a different inhibitory trend was observed for TNF- α production. 
Accordingly, for most of the time points results showed that the differences between DEX 
released from LbL 0 and LbL 4 particles were not so evident for 72h and 2W as the ones 
observed for DEX released at 24h and 48h. In fact, for DEX released at 72h and 2W a 
similar or non-significant decrease of TNF-α production was observed at 24h, 48h and 
72h when comparing DEX released from LbL 0 and LbL 4. This is line with the drug 
release profile, where DEX released from LbL 0 or LbL 4 was almost identical for at 72h 
and 2W. Besides, for both NO and TNF-α production, when significant, the decrease 
induced by DEX released from LbL functionalised-particles was very closely matched 
the level of suppression observed for DEX (10 µg/mL) treatments 
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4. Discussion 
4.1 DEX-loaded TiO2 particles characterization 
4.1.1 Average size and morphology  
Overall, images obtained via transmission electron microscopy (TEM), revealed that for 
all synthetic routes tested (amino, mercapto and LbL), DEX-loaded functionalised TiO2 
particles maintained a spherical like-shape, which is characteristic from TiO2 particles 
(Gao et al. 2004, Gouda 2012, Zhao et al. 2014). These results were also confirmed by 
SEM images, where no visible aggregation was detected. 
Wang colleagues (2015) showed similar results during surface modification of porous 
TiO2 particles where no significant morphological changes were observed after loading 
with folic acid and polyethylenimine (Wang et al. 2015a).  
Furthermore, for amino and mercapto routes, TEM images showed an average size of 
32nm for bare TiO2 particles, and 32-45nm for functionalised ones. This increase in size 
could be attributed to DEX loading and surface functionalisation of TiO2 particles. An 
increase of size after drug loading and surface functionalised of TiO2-particles was 
previously reported by (Almalki et al. 2017) after functionalisation of TiO2 particles with 
Polyethylene Glycol and Pentetic acid.  
For LbL route, average size of 32nm was observed for amino-functionalised-TiO2 
particles, and 32-49 nm for LbL coated ones. Though this increase observed for LbL-
coated particles size was not constant/gradual, since the particles with more layers 
(~39nm for ALG-DEX-CH-DEX-CH-ALG) showed a smaller average size than that of 
particles with less layers (~48nm CH-ALG). In other words, although new layers are 
added the average size did not show the expected significant increase, or if there is an 
increase it might be so small that TEM was not sensitive enough to detect it.  
Altogether these results, lack of significant (p<0.05) morphological changes after TiO2 
particles functionalisation and increase of size after DEX loading, suggest the efficacy of 
synthetic routes applied to load DEX into TiO2- particles, without damaging the particles 
structure 
 
4.1.2 Zeta potential measurements 
Amino and Mercapto route 
The functionalization of particles surface is known for modifying the surface charge and 
the thickness of the double layer, therefore resulting in an alteration of the zeta potential 
(Z. Chen, Hsu, Battigelli, & Chang, 2006). In this context, zeta potential measurements 
are a key tool to characterize the functionalized TiO2 particles, as it was observed for 
previous studies, that have utilized zeta potential measurements to assess the surface 
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functionalization of different particles (Y. Wang, Li, & Kong, 2013). Moreover surface 
properties are considered to affect the biological reactions around the titanium implants 
(Cai, et al., 2006), hence the zeta potential measurement of DEX-loaded particles 
obtained could be used to determine the potential biological behaviour (e.g. stability, cell 
affinity) of the model drug delivery system developed in future in vitro cell studies. Our 
results showed that an inverse correlation was observed between zeta potential of 
functionalized TiO2- particles and pH for both mercapto (Figure 30) and amino route 
(Figure 22). These results can be explained based on the effect of the pH on the surface 
charge exhibited by the particles; particularly the influence of pH on the balance between 
protonated and unprotonated groups (Perni et al. 2018) present on the surface of TiO2 
particles. The pH dependence of the functionalised-TiO2 particles (Figure 5) are 
consistent with that previous studies regarding TiO2 functionalization (Cai et al., 2006), 
providing further confirmation of the presence of either the desired groups or DEX on the 
surface of the particles. For example, the positive surface charge observed after amino-
functionalization of TiO2 particles can be related to the amino groups (-NH2) capability of 
accepting protons, becoming more positively charged i.e. NH3+ species (Z. Chen, et al., 
2006). The decrease of surface charge (+20mV) observed under more alkaline 
conditions (pH>6), can be attributed to the deprotonation of the nitrogen groups, while at 
low pH these groups are highly protonated and thus a higher surface charge was 
observed (+40mV). In contrast, when compared to amino-functionalised TiO2 particles 
lowest surface potentials were observed for TiO2 particles-functionalised with succinic 
anhydride and pentanoic-acid, particularly for more alkaline pH values. A possible 
explanation for this character could be attributed to presence of carboxylic acid (–COOH) 
groups on surface of the particles, which exhibit a more negative character than NH2- 
and SH-TiO2 particles. Similar result was reported by Bergman et al., upon succinylation 
of amino-functionalized particles (Bergman et al., 2008). The same behavior i.e. more 
negative surface potential was observed after DEX loading, for both mercapto (Figure 
30) and amino route (Figure 22). The higher negative zeta potential observed can be 
attributed to the presence of functional groups (-OH and -C=O) of DEX, suggesting the 
presence of the drug on the surface of the TiO2 particles. Particularly, the fluorine group 
(9-Fluoro) has been described to affect the electron density of its “neighbors” i.e. 
functional groups (Yamazaki, Taguchi, & Ojima, 2009; Zahr, de Villiers, & Pishko, 2005). 
Therefore, in this specific case, the fluorine seems to be responsible for decreasing the 
pKa value of hydroxyl moiety (11, 17, 21-trihydroxy) on DEX, thus resulting in a more 
negative zeta potential after DEX loading. Fratoddi and co-workers reported a similar 
result., where a negative zeta potential was observed after loading particles with DEX 
under alkaline conditions i.e. aqueous particles suspension (Fratoddi et al., 2012).  
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Moreover, a higher negative charge on the surface of conjugated Dex-loaded 
functionalised-TiO2 particles was observed when compared to that of adsorbed ones, 
suggesting a higher loading of DEX. This result could indicate that EDC/Sulfo-NHS 
crosslinking agent utilized to conjugate DEX into functionalized TiO2 particles have 
improved the reaction efficiency and consequently increased the DEX loading. This 
behavior can be explained based on the type of bond present between DEX and TiO2 
particles: regarding adsorbed particles the DEX is attached via Van der walls forces, 
which is a weaker and less stable bond than the covalent bond observed in conjugated 
particles. Therefore, the more stable bond present in conjugated-particles can easily 
result in higher amount of DEX on particles surface and consequently a more negative 
surface charge. Regarding LbL route the zeta potential measurements of the approaches 
tested (experiment 1,2, and 3) oscillate between 30 and 40 mV after CH adsorption, and 
around −20 to −30 mV after ALG adsorption (Figure 34,Figure 35). Typically, the surface 
charge density of polyelectrolytes, positive or negative, is respectively induced by the 
ionization of functional groups such as amine groups (CH) and carboxyl (ALG) (Lawrie 
et al. 2007). As for the constant alternated switching this is an indicative of the successful 
self-assembly of the polyelectrolytes CH and ALG (Caruso, et al., 1998; Wang, et al., 
2008; Zhao, Mao, et al., 2006) on surface of amino-functionalised particles. These results 
are in line with Ye et al (2005) study that reported similar zeta potential values for the 
same CHI/ALG pair and template. Once more, the alternation of zeta potential after each 
new adsorption was not surprising, considering that this phenomenon is characteristic of 
the LbL assembly (Caruso, 2000; Suflet, et al., 2011). Additionally, it can be observed 
that after DEX layer deposition (anionic polyelectrolyte), the surface charge of particles 
is still positive. This lack of symmetric inversion in in zeta potential could be attributed to 
an incomplete coverage by DEX of the surface of particles. Indeed, previous studies 
reported the deposition of bioactive compounds without obtaining oppositely charged 
zeta potential values (Borkovec & Papastavrou, 2008, Hierrezuelo, et al., 2010). 
Moreover, for all graphs (Figure 34, Figure 35), it can be observed a typical zig−zag 
dependence, which is another evidence for the formation of consecutive layers and 
stability of the obtained multi-layered particles (Bazylińska, Skrzela, et al., 2012). Despite 
the lack of reversal in zeta potential signal, the value obtained after DEX addition was 
more negative when compared to the chitosan layers (+ 30-40 mV). Typically, this fact 
indicates that an electrostatic complex had been formed (Anal, et al., 2008), although 
with incomplete coverage of the particle surface. Therefore, it is possible to hint that the 
DEX layer was adsorbed, however it was not capable of forming layers dense enough to 
cover the charges from the preceding CH layer. This result is in line with that of Zhou et 
al. (2010) that reported a limited electrostatic interaction between bovine serum albumin 
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(BSA) and CH/ALG polyelectrolyte multilayers when CH was the outmost layer (Zhou, et 
al., 2010). 
4.1.3. Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) was used to assess the presence or absence of 
organic components in the surface of TiO2 particles, based on the observation of mass 
loss. Accordingly, a useful tool to confirm the attachment of organic functional groups 
(e.g. thiol, amine and carboxyl) or layers to TiO2 particles surface, including the DEX 
loading. The thermogram of bare TiO2 particles shows slight weight loss (<1.5%) 
suggesting a decreased presence of organic material on their surface, (Figure 25 and 
Figure 33). Moreover, it can be noted that TGA profile obtained was similar and in 
agreement to the one obtained by Batch el al group (Bach, et al., 2012). Bearing in mind 
that weigh loss in the second region (>200ºC) is primarily due to combustion of the 
organic matter, i.e., amine-silane or mercapto-silane, overall the TGA profiles obtained 
for DEX-loaded TiO2 particles prepared by amino and mercapto routes, suggest the 
successful functionalisation of TiO2 particles. As can be seen in the TGA profile of 
particles obtained via amino (Figure 25) and mercapto route (Figure 33) an increase of 
organic material (%) of approximately 3.1% and of 2.6% was respectively observed after 
APTES and MPTS-functionalization, thus confirming the successful attachment of amino 
and mercapto functional groups on the surface of TiO2 particles. Moreover, being the 
molar mass of amine-silane, 209 g/mol, and mercapto-silane, 185 g/mol, it can be said 
that higher increase of organic material in NH2-TiO2 particles when compared to SH-TiO2 
particles is primarily the result of better functionalization by amine-silane than by 
mercapto-silane. Similar result was observed by Marjanovic and co-workers (2013), 
where FT–IR and TGA results showed a more effective functionalization of thermo-acid 
activated sepiolite by amine-silane than by mercapto-silane (Marjanovic et al. 2013). 
Regarding DEX loading, conjugated particles presented a higher % of organic content 
on their surface when compared to adsorbed ones (Table 6, Table 8), particularly for the 
amino route where conjugated particles have 2% more of organic content on their 
surface when compared adsorbed ones. These results agree with zeta potential 
measurement. 
When the LbL route was utilized, an increase of organic content (%) was observed after 
the addition of new layers (Figure 36, Figure 37). Although, since LbL route was being 
optimized i.e. number and type of layers, only for experiment 2 (Figure 37,Table 11), a 
gradual increase of organic content (%) after addition of each new layer was observed. 
Moreover, results showed that for approach utilized in experiment 2, particularly the 
increase of organic content (%) observed after each DEX layer deposition, together with 
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zeta potential measurements (i.e. high surface charge values after each layer 
deposition), strongly suggests that this approach could be the most suitable to obtain 
reproducible and stable LbL-DEX loaded particles. Therefore, the subsequent studies 
(e.g. drug release profile and biological studies) was assessed with LbL particles 
prepared by approach described in experiment 2.  
 
4.1.4. Fourier Transformed infrared spectroscopy (FT-IR) 
FT-IR spectroscopy has been used in previous studies to investigate the chemical 
groups present in a sample after surface modification. Therefore, in this study FT-IR was 
used to assess the chemical groups present on the surface of TiO2 particles after each 
functionalization step. For amino and mercapto routes, results showed all particles 
showed similar peaks between 400 and 700 cm−1 ( 
I. Appendix, Figure 101,) which are characteristic of the model surface used in this study: 
the TiO2 particles (Bagheri et al. 2013, Zhao et al. 2012). Apart from that, when analysing 
the spectrum of functionalised-TiO2 particles new bands appeared, which could not be 
observed in the spectrum of bare-TiO2 particles. For example, only for amino, mercapto 
and carboxyl functionalised TiO2-particles (Figure 24), a new peak is observed at 
~950cm−1 which is characteristic of Si-O chemical bonds (Chen & Yakovlev 2010). This 
reconfirms condensation reaction between methoxy groups of APTS/MPTS and the TiO2 
surface hydroxyl groups (OH). Since the residual (non-reacted) and physisorbed APTS 
has been removed by centrifugation in ethanol (toluene) solution, the mentioned peaks 
show that grafting of APTS on the TiO2 particles has occurred successfully. Also, the 
broad band appearing at 3100–3600 cm-1 which is assigned to vibrations of hydroxyl 
groups (OH) on TiO2 surface is less visible for particles functionalised with APTS/MPTS, 
which coincides with a decrease of hydroxyl groups due to the attachment of the 
amino/thiol functional groups on surface of TiO2 particles (Sousa et al., 2012). As 
previously described in other studies (Cheng et al. 2006, Sabzi et al. 2009) the hydroxyl 
groups on the surface of the TiO2 particles (Ti-OH) are reactive sites for the reaction with 
functional groups of silane (i.e. APTES and MPTES) compounds. As shown by the peaks 
around 1100 cm-1 which are characteristic from O-Si vibration. Particularly after APTS-
functionalisation, new peaks can be observed at ~3000 cm-1, ~1800 cm-1 and ~1360 cm-
1, which can be assigned to N-H and C-N bonds as reported in previous studies related 
to surface functionalisation with amino silane agents (Díez-Pascual & Díez-Vicente 
2014, Lu et al. 2007, Wang et al. 2011, Zhao et al. 2012). For example, similar spectrum 
was observed by Sousa et al (2012) following functionalization of the silica nanotubes 
with APTES (Sousa et al. 2012).  Likewise, similar peaks were reported by Bloemen and 
co-workers when investigating amino-functionalisation of iron oxide particles (Bloemen 
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et al. 2012). On the other hand, peaks/bands corresponding to thiol (SH) group could not 
be clearly observed (Figure 32) for particles functionalised with mercapto-silane 
(MPTES). This could be explained based on relative low content of thiol and poor 
sensitivity of IR to this functional group, as previous observed by Zhang and co-workers 
(Zhang et al. 2013). However the presence of bands at ~3000 and 2857 cm−1 which can 
be respectively assigned to the methyl (C–H vibration) of methoxy (OCH3) and methylene 
(CH2) groups (Marjanovic et al. 2013, Ukaji et al. 2007, Wang et al. 2011) were obvious, 
suggesting the new functional groups were successfully attached to the surface of TiO2 
particles (Marjanovic et al. 2013, Rostamian et al. 2011, Ukaji et al. 2007, Wang et al. 
2011). 
Regarding the FT-IR spectrum of functionalised-TiO2 particles with succinic anhydride, 
new visible peaks which can be assigned to the carboxyl group where observed for 
amino route. For example, the presence of two new strong peaks between 1600-1800 
cm-1, which are characteristic of C=O stretching of carbonyl groups as reported in 
previous studies (Lee et al. 2006, Othman et al. 2012, Ramanathan et al. 2005, Siyamak 
et al. 2012). Likewise, when modifying TiO2 particles with polyacrylic acid (PAA), Othman 
and co-workers (2012) observed similar peaks around 1690 cm-1 (Othman, et al. 2012), 
which provided evidence to prove that carboxyl acid (-COOH) group was present on the 
surface of the TiO2 particles (Othman et al. 2012).Also, it worth to note that the peak at 
~1360 cm-1 (C-N bond,(Wang et al. 2011) which was observed in spectra of amino-
functionalised TiO2 particles was absent for carboxyl-functionalised TiO2 particles 
suggesting the successful surface modification of amine functionalised-TiO2 particles 
with carboxylic-acid (COOH). Furthermore, the two sharp peaks observed in the region 
of 1050-1160 cm-1 and 1185- 1277cm-1 for both carboxyl and DEX-loaded functionalised 
particles can be attributed to the symmetrical and asymmetrical stretching frequencies 
of the C-O ester groups. 
These peaks were not as clear in the spectrum of functionalised particles obtained by 
mercapto route. As for DEX functionalisation, the FT-IR equipment was not sensitive 
enough to detect the characteristic peaks/bands (as observed in pure DEX, Figure 103), 
it was clear that different spectrum was observed for DEX-loaded particles. Such as the 
presence of strong band around 3100–3600 cm-1 which coincides with the increased 
presence the hydroxyl groups (O–H) due to the attachment of COOH functional and OH 
groups on surface of functionalised-TiO2 particles. Also, for particles obtained by amino 
route, new band observed at ~1600-1800 cm-1, respectively suggests the presence of 
C=O stretching of ester groups and of hydroxyl groups (OH) on TiO2 surface. Similar 
peaks were observed by other studies, when analyzing the surface of DEX-loaded PLGA 
coatings (Zhang et al. 2015) and DEX-loaded onto layered double hydroxides (LDHs) 
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(Wang et al. 2015b). Furthermore, again for functionalised particles obtained by amino 
route, the two sharp peaks observed in the region of 1050-1160 cm-1 and 1185- 1277cm-
1 for both carboxyl and DEX-loaded functionalised particles can be attributed to the 
symmetrical and asymmetrical stretching frequencies of the C-O ester groups, 
respectively, as previously reported (Everaerts et al. 2008). Therefore, the peaks at 
~1075 and at ~1200 cm-1 that appear in the FT-IR spectrum of carboxyl and DEX-loaded 
TiO2 particles clearly suggest the presence of either the desired groups (i.e.  carboxyl, 
hydroxyl) or the DEX on the surface of functionalised TiO2 particles. 
As for DEX-loaded functionalised TiO2 particles obtained by LbL route, FTIR results 
(Figure 38) showed that most of the peaks found in the spectra CH/ALG multilayer DEX-
loaded functionalised TiO2 particles after the addition of CH, ALG and DEX layers were 
very similar. Except for the band at ~1350 cm-1 which can be assigned to the C-N bond 
and was observed for amino functionalised particle, that was absent on the spectra of 
DEX-loaded CH/ALG functionalised-TiO2 particles (Figure 38). Also, some new peaks 
were also observed when comparing the spectra of amino functionalised TiO2 particles 
with the one of CH/ALG multilayer DEX-loaded functionalised TiO2 particles; such as the 
strong peak observed at ~1650 cm-1 which belongs to the carbonyl group (C-O) 
stretching groups which are attributed to ALG and CH saccharide structure. Overall, 
these peaks match with the ones observed at spectrum of CH and ALG powders (Figure 
104, Figure 105), and were in agreement with the ones reported for previous studies 
involving deposition of CH/ALG (Fernandes et al. 2011, Kulig et al. 2016, Lawrie et al. 
2007, Li et al. 2008, MA Shafie, Attia Shafie 2013) onto drug-loaded particles.  
The low sensitivity of FTIR to detect the addition of new layers (particularly DEX layer) 
could be explained based on their thickness. As shown by TEM results (Figure 39), after 
the addition of each new layer there is a minimal increase on the size (<10nm). of 
functionalised-TiO2 particles, thus meaning that CH, ALG and DEX layers must be very 
thin (<10nm). This in agreement with previous studies (Morent et al. 2008) which have 
demonstrated the low sensitivity of FTIR to characterize surface modifications at 
nanometer level.  A possible solution could be the utilization of a more surface sensitive 
technique such as X-ray photoelectron spectroscopy (XPS).  
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4.1.5. Drug loading (%) and encapsulation efficiency (%) 
The drug loading (%) and encapsulation efficiency (%) were different when DEX was 
conjugated to functionalised-TiO2 particles by electrostatic interaction (LbL route) or by 
covalent bonding (amino and mercapto routes). When assessing encapsulation 
efficiency, the DEX-loaded functionalised TiO2-particles obtained by amino and 
mercapto (~68%) showed higher values than the ones observed for LbL route (~50%). 
Although the encapsulation efficiencies were higher for amino and mercapto routes, the 
total amount of DEX (mg) loaded per functionalised-particles (mg) was significantly 
higher for LbL route, as showed by drug loading calculations: ~40% (LbL route) and 
~13% (amino/mercapto routes).  
Moreover, for LbL route the number of CH/ALG layers surrounding DEX loaded-
functionalised-TiO2 particles has showed to significantly (p<0.05) affect the drug content 
and encapsulation efficiency. Consequently, results (Table 13) showed that for sample 
4 (DEX was surrounded by 4 CH/DEX/ALG layers), both encapsulation efficiency and 
drug loading were higher than for sample 0 (DEX was the outer layer). This difference 
was more evident for drug loading calculations (%), where an 0.37-fold increase of drug 
loading was observed for sample. This can be explained based on the number of DEX 
layers which are present in each sample: for sample 4 two layers of DEX were loaded 
into 250 mg of NH2-functionalised particles whilst only one layer was loaded for sample 
0. Therefore, a higher concentration of total DEX (~101mg) was loaded into the LbL 
particles sample 4, when compared to particles loaded with only one DEX layer (~67mg) 
(sample 0) onto 250mg of LbL-functionalised TiO2 particles. 
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4.2. DEX release profile  
The local delivery of glucocorticoids such as DEX, instead of systemic delivery, could be 
highly suitable for patients which undergo TJR surgery. Among others, the safe and 
effective deliver of the drug to the desired site of action by using drug-eluting implants 
would control the patient drug exposure over time, avoid the drug premature elimination, 
support the crossing of biological barriers, and minimize the side-effects caused by anti-
inflammatory drug exposure elsewhere in the body (Lyndon et al. 2014, Zilberman et al. 
2010). Also, and in terms of outcome for the patient, a post-operative dose of DEX would 
reduce the stress response and improve pain relief following surgery by modulating the 
acute phase response following hip and knee replacement (Allen et al. 2010, Backes et 
al. 2013, Salerno & Hermann 2006).  Even though they have shown exceptional 
capabilities in terms of applicability and versatility, regarding orthopaedic field, most of 
the anti-inflammatory drug-eluting implants are still in early developing stages. Being one 
of the biggest challenges related to the drug release profile, critical parameters such as 
release time and rate, as well as dosage for optimal therapeutic concentration (Santos 
et al. 2014) are still being optimized. Due to this need, in our study we have investigated 
a novel anti-inflammatory drug-eluting implant model system: functionalised-TiO2 
particles loaded with DEX, prepared by different synthetic routes. This way we could 
assess the effect of linker between DEX and functionalised-TiO2 particles on drug 
release kinetics e.g. release duration, rate, and concentration.  
Based on previous studies (Bhardwaj et al. 2007, Urbanska et al. 2014, Wang et al. 
2015b), we can assume that the DEX release profile will mainly depend on the structure 
and hydrolysis rate of the linker between DEX and functionalised-TiO2 particles, which 
are strongly affected by the type of route i.e. amino, mercapto or LbL utilized on this 
study, and by the pH conditions of surrounding environment. Aiming to assess the effect 
of different environments, different pH buffers were employed to study the release of 
DEX from the functionalised-TiO2 particles. PBS and acetate buffer were chosen to 
respectively mimic two distinct situations: physiological healthy conditions (pH~7.0), and 
inflammation represented by acid conditions (pH~6). 
Overall, the release profiles obtained in this work present a good reproducibility, as 
shown by the relatively small deviations (5% total drug released) in independent 
experiments.  Results from drug release studies have shown that release of DEX was in 
fact affected by type of synthetic route utilized to obtain functionalized-TiO2 particles, as 
well as pH of the release environment/media (Figure 40, Figure 41). For instance, for 
amino and mercapto routes where DEX was covalently bounded to carboxyl-
functionalised particles, drug was released within 24 hours. Furthermore, the highest 
concentrations of DEX were released under physiological conditions i.e. at pH=7 for both 
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amino (13.08 ±0.17 µg/mL) and mercapto (7.54±0.08 µg/mL) routes. This release profile 
can be explained based on the assumption that DEX is being released from 
functionalised-TiO2 particles in a manner consistent with ester bond hydrolysis, 
increased degradation is observed when the pH increases, thus leading to the higher 
release of DEX at physiological pH than that at more acidic conditions. A similar drug 
release profile was observed by Nuttelman and co-workers (Nuttelman et al. 2006), when 
DEX was covalently attached to polyethylene glycol (PEG)-based hydrogel scaffold. In 
addition, results showed that independently of the pH conditions, it was evident that 
higher concentration of DEX was released when amino route was applied. When 
comparing DEX concentration released from amino-functionalised particles with that of 
mercapto-functionalised-particles, a ~3.5-fold and a ~1.85-fold increase was observed 
respectively at pH=6 and pH=7. This drug release profile is in agreement with TGA 
analysis which reveals that a higher % of organic content is observed after DEX 
attachment to amino-functionalised TiO2 particles (6.37±0.83, Table 6) when compared 
to the ones obtained via mercapto route (4.79±0.37,Table 8). In this sense, since 
particles obtained via amino route have higher amount of DEX attached than the ones 
obtained via mercapto route, it makes sense that the concentration of drug released 
would be higher. 
As for LbL route (experiment 2), DEX was attached to (amino)-functionalised TiO2 
particles, with subsequent deposition of CH and ALG layers, interactions between layers 
are mainly electrostatic. The most attractive feature of LbL technique is the possibility of 
obtaining a tuneable drug release (Wood et al. 2005) and consequent controlled host 
response (Macdonald et al. 2011), which ameliorates both the medical and financial 
burden of complications from implantation  As for the polyelectrolytes pair, the 
advantages of CH and ALG have been previously highlighted in studies involving LbL 
coating of biomedical devices, including drug delivery (Hammond 2012, Tang et al. 
2006). Besides being non-toxic and biocompatible polymers CH/ALG multilayers have a 
superior advantage of protecting DEX layer and proving a more controlled release (De 
Villiers et al. 2012, Rivera et al. 2015). Moreover, it is a convenient alternative for the 
commonly described biodegradable pair of polymers PLGA and PLA, since it does not 
involve the utilization of organic solvents and associated toxicological effects (Caetano 
et al. 2016). Nonetheless, no study of LbL assembly CH/ALG on functionalised TiO2-
particles with DEX as drug model has been reported. The drug release studies showed 
that DEX was released from functionalised-TiO2 particles in a more controlled and 
prolonged manner (20 days release), when compared to that observed for mercapto and 
amino routes (24 hours). Consequently, allowing the possibility of obtaining a more 
prolonged and controlled release of DEX. These results are in line with previous studies 
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(Han et al. 2016, Jayant et al. 2009) that have demonstrated the efficacy of LbL coating 
in reducing the initial burst release, as well as prolonging the period of drug release 
(Buriuli & Verma 2017). Mainly because with LbL coating, the composition and number 
of layers surrounding the drug can be precisely tuned, hence allowing to modulate the 
release profile of drugs (Ariga et al. 2011, De Villiers et al. 2012, Wood et al. 2005). 
Moreover, the duration of DEX release from LbL-functionalised particles was higher than 
the one observed for other drug delivery systems reported in previous studies; such as 
14 days release observed for N-(2- hydroxypropyl) methacrylamide copolymer  (Wang 
et al. 2007), and the 15 days release observed for electro.spunned polycaprolactone 
nanofibers (Martins et al. 2010). 
The release of DEX from LbL particles involves two processes: a) bulk media solution 
diffuse into the LbL particles to dissolve the DEX drug and b) the dissolved DEX 
molecules diffuse out of the LbL particles, through the surrounding layers (Pargaonkar 
et al. 2005). Since, different pH release media conditions are known to dissolve DEX in 
a different manner, and the diffusion of DEX proceeds through the layers (Pargaonkar et 
al. 2005), from the surface toward the core (functionalised-TiO2-particles) different 
release profiles were observed. As can be seen in Figure 42 and Figure 43, in LbL route, 
overall DEX release profiles varied according to the (a) number of layers surrounding 
DEX layer, 0 layers (LbL 0) or 4 layers (LbL 4), and (b) the pH value of the release media 
(pH=6 vs pH=7). Accordingly, when comparing DEX released from LbL 0 and LbL 4, 
higher DEX concentrations were released from particles where DEX was the outer layer 
(LbL 0 and LbL 2). Whilst, when DEX layer was surrounded by CH/ALG layers (LbL 1, 
LbL3 and LbL 4) a more controlled release profile and smaller drug concentrations were 
released. In addition, a decrease of the initial burst release (24h) was observed for LbL 
particles surrounded by more CH/ALG layers. This trend was observed for both release 
media at pH=6 or pH=7. This could be attributed to the higher the number of CH/ALG 
layers surrounding DEX-loaded TiO2 particles which results in a higher the diffusional 
path length that DEX has to traverse (Jayant & Srivastava 2007, Santos et al. 2018), as 
well as in a decrease of DEX exposure due to being in particles surface (outer layer).In 
this sense, our results agree with literature, several examples of enhancing the number 
of coating layers in LBL particles have shown to decrease both drug release 
concentration and initial burst release  (Han et al. 2016, Jayant et al. 2009, Pargaonkar 
et al. 2005, Santos et al. 2018). Jayant and co-workers (2009) have reported a significant 
difference (p < 0.05) in the rate of DEX release when comparing uncoated and coated 
alginate microspheres. In this study the EDC/NHS-cross-linked (polyallylamine 
hydrochloride/ Poly (acrylic acid) coated-microspheres have shown to release only 29% 
(cumulative release) of DEX after 30 days, whereas for uncoated microspheres the 
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cumulative release of DEX was 100% after 22 days. Similar results were reported by 
Jayant and co-workers (2007), release studies showed that uncoated DEX-alginate 
microspheres demonstrate a cumulative release of 78% of initially encapsulated DEX as 
compared to one PSS/PAH bilayer coated microspheres, which demonstrate a 
cumulative release of 32%  (Jayant & Srivastava 2007).  
Apart from the effect of the number of layers, the pH value of the release media (pH=6 
vs pH=7) also showed to affect DEX release from LbL-functionalised TiO2 particles. The 
environmental conditions (i.e. pH of release media) on the quantity of DEX released can 
be extremely relevant for system application. In this context, the release profiles obtained 
in this study, could provide a good insight on the behaviour of this model system within 
the local where DEX will be released, the healthy (pH~7) and inflamed joints (pH~6) (De 
Nadai et al. 2013). Drug release studies performed in this study showed that 
independently of the number of layers (CH/ALG) surrounding DEX, a higher 
concentration of drug was released under more acidic conditions (pH<7) when compared 
to that released under physiological conditions (pH~7). This is agreement with previous 
studies (Feng et al. 2014, Han et al. 2016, Pargaonkar et al. 2005, Wang & Rempel 
2013), where pH conditions have shown to affect the drug release profile of LbL-coated 
particles. This pH-dependent release can be explained based on behaviour (i.e. degree 
of ionization) of CH and ALG under different pH conditions. It is well known that in 
CH/ALG LbL systems, the ionic interactions between the carboxylate groups of ALG and 
the protonated amines of CH are a requirement for a stable assembly (Caetano et al. 
2016, Lawrie et al. 2007). Previous studies have already reported this stability can be 
affected by pH, which cause variations degree of ionization of both CH and ALG (Santos 
et al. 2018, Shiratori & Rubner 2000). Mostly the pH variations affect the surface charge 
density, and hence alters the electrostatic interaction between CH/ALG layers. Since 
electrostatic interaction is the dominant driving force between CH/ALG layers and DEX, 
the differences observed in DEX release profile for different pH conditions can be 
explained based on the degree of ionization of CH and ALG polyelectrolytes (Feng et al. 
2014, Han et al. 2016, Lawrie et al. 2007). Taking CH layer as an example, usually CH 
(pKa≈6.0-6.5) becomes cationic at more acidic conditions (pH=5.0-6.0), and as the pH 
becomes more acidic the more cationic CH become (more protonated amine group) 
(Silva et al. 2015). Although as reported by Chang et al. (2015) at neutral pH=7, CH 
becomes deprotonated, thus CH positive surface charge decreases or even becomes 
negative, and due to the formation of intramolecular hydrogen bond the CH molecules 
start to aggregate (Chang et al. 2015). This decrease of surface charge and molecules 
aggregation of chitosan could explain the sustained release of neutral conditions 
(pH~7.0). An example of these findings and a similar drug release trend to one observed 
133 
 
in our study was reported by Feng and co-workers that showed that release rate of 
anticancer drug, doxorubicin, from CH/ALG multilayer mesoporous silica nanoparticles 
was much higher at lower pH (pH<7) than that at physiological conditions (pH=7.4) (Feng 
et al. 2014).  
Another probable explanation for higher DEX release under more acidic conditions can 
be based on ALG layer behaviour, more specifically on the degree of ionization of 
carboxyl groups. Typically, under more acidic conditions carboxyl groups are more prone 
to be deionized (Han et al. 2016)., thus diminishing the electrostatic interaction of ALG 
with the other layers (CH and DEX). Consequently, due to low electrostatic stability, 
layers surrounding DEX are more easily eroded than at under basic conditions. 
Furthermore, the DEX release profile can also be explained based on higher solubility of 
DEX at more acidic conditions which leads to release of higher concentrations. As 
previously reported by Wang and co-workers the highest release of DEX occurred under 
the most acidic release conditions (pH<7.4). This study was reported that after 14 days, 
the following percentage of loaded DEX was released from the N-(2- hydroxypropyl) 
methacrylamide copolymer: 14%, 2.5% and 1%, respectively at pH=5.0, pH=6.0 and 
pH=7.4 (Wang et al. 2007). Similarly, Chung and colleagues showed a higher release of 
DEX at pH=7.4 (1.4 µg/mL) when compared to that of pH=6.8 (6.4 µg/mL) (Chung et al. 
2015); when studying the ultrasensitive reactive oxygen species (ROS)-responsive 
hollow microsphere as anti-inflammatory drug delivery system. Also, Zolnik & Burgess 
(2007) reported that a faster release/kinetics of DEX from PLGA microspheres was 
observed at more acidic conditions (pH=2.4, 3.48/day)  when compared to that at 
physiological conditions (pH=7.4, 2.13/day ) (Zolnik & Burgess 2007).  
Another example of the pH influence on drug release profile was observed for LbL 3 
particles. More specifically the effect of pH conditions on the erosion of ALG layer, which 
was the outermost layer in LbL 3 particles (DEX+CH+DEX+ALG). As it was discussed 
above, the DEX release profile for all LbL-functionalised particles tested (LbL 0, LbL 1, 
LbL 2, LbL 3 and LbL 4) followed the same release trend, where the concentration of 
drug released from LbL particles has shown to decrease with the increasing number 
layers surrounding DEX. Accordingly, for LbL 0 and LbL 2 a higher concentration of DEX 
was released than for LbL 1, LbL 3 and LbL 4 particles. Furthermore, following the same 
logic the concentration of DEX released from LbL 3 was higher than the one released 
from LbL 4. Although at pH=7, a different behaviour was observed: DEX release profile 
obtained for LbL 3 particles was very similar to that of LbL 4 particles. Similar behaviour 
was reported by Han and co-workers, which have demonstrated that ALG layers were 
more easily eroded under acidic conditions (pH 6.0) than under weak basic conditions 
(pH 7.4) (Han et al. 2016). This resulted in weak interaction between ALG and DEX layer, 
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hence resulting in higher concentration of DEX released under more acidic conditions. 
On the other hand, at pH=7 DEX release was hindered by stronger interaction between 
DEX and ALG layer. 
Moreover, it was observed that DEX concentration/release rate released from LbL 
particles decreased over the time. Being the highest concentrations of DEX released 
during the initial days (24h and 48h), whilst smaller concentrations were released at 1 
and 2 weeks. Also, slightly higher concentrations of DEX were released at 72h, when 
comparing to the one release at 2W from both LbL 0 and LbL 4. This phenomenon can 
be related to the drug distribution across the LbL structure. The DEX encapsulated 
seems to have faced an extra physical barrier, resulting in a slowdown in the release 
rate; where the CH/ALG layers surrounding DEX act as a controllable barrier between 
the (amino)-functionalised TiO2 particles and the release conditions (Li, P., et al., 2008). 
Haidar and co-workers (2008) have previously demonstrated that CH/ALG layers, 
provide a protective effect for shell degradation, thus delaying release of biological 
compounds.  
The time-frame aspects of anti-inflammatory drug release that will modulate the foreign 
body response to implant are still not well understood. Although it is known that to obtain 
an efficiently modulation of inflammatory response, the release of drug should at least 
be controlled and continuous (Hickey, et al. 2002). Moreover, in terms of biological 
action, corticosteroids are known to bind to cytoplasmic glucocorticoid receptors, where 
at high-dose these drugs will increase the activation of anti-inflammatory genes, while at 
low concentrations a suppression of activated inflammatory genes will be observed 
(Dutra-Medeiros et al. 2014). 
Taking into account that the inflammatory tissue response starts during the first seconds 
after device implantation (Figure 4),  drug release profiles obtained for amino and 
mercapto route could be highly favourable to control initial acute inflammation (1-3 days) 
at the site of implantable devices (Hickey, Kreutzer, Burgess, & Moussy, 2002a). On the 
other hand, when LbL route was applied, a more prolonged (~20 days) and controlled 
release (CH/ALG layers-dependent) of DEX were observed, where overall a higher 
concentration of DEX was released from TiO2 particles under more acidic pH value 
(pH=~6). All these characteristics suggest the potential of model system obtained by LbL 
route to avoid a prolonged acute inflammation, known as chronic inflammation. 
Moreover, a low burst release of DEX (<10 mg/mL), which can be controlled by CH/ALG 
layers, is important to prevent local toxic side effects out coming from a high 
concentration of anti-inflammatory drugs (Oray et al. 2016, Petit et al. 2014). 
Overall, the release profiles obtained in this study for amino, mercapto and LbL routes 
show that that the model system developed here was able to protect DEX from the 
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surrounding environment, avoiding the immediate release. Particularly the one obtained 
by LbL route where DEX was released for prolonged period, and a controlled delivery of 
DEX at the implant site can be achieved by tailoring the number of CH/ALG layers around 
DEX. In addition, the highest concentrations of DEX were released under more acidic 
conditions, which is one of the pathological feature of inflamed joints (Wang et al. 2007). 
Due to these reasons, the release profile of DEX observed for TiO2 particles obtained by 
LbL route, could be very suitable to achieve an adequate anti-inflammatory action after 
joint replacement surgery. Mainly because the high-dose of DEX released in an initial 
phase (1st week) could increase the activation of anti-inflammatory genes, whereas low 
concentration released at second phase (2-3weeks) would promote the suppression of 
activated inflammatory genes (Dugel et al. 2015, Dutra-Medeiros et al. 2014), and thus 
promote implant osteointegration. Moreover, it has been reported that extended hospital 
course (>3days) for patients undergoing orthopaedic surgery, (Bhusal et al. 2016, Qu et 
al. 2015) is caused by the inappropriate pain control. In this case, the controlled and 
extended release of DEX observed from LbL-functionalised particles could potentially 
improve the quality of life and compliance of patients by providing a better pain 
management in a post-surgery phase, thus minimizing the time spend in the hospital 
(Bhusal et al. 2016).  
Another advantage of utilizing LbL route is that unlike amino and mercapto routes, no 
covalent binding is involved in the synthesis of DEX-loaded-functionalised TiO2 particles, 
which allows DEX to remain intact (De Villiers et al. 2012). Therefore, the DEX released, 
which was detected by HPLC is not seen as a new chemical entity, which in terms of 
biological effect could show even better results due to “purity” of drug released. 
Moreover, being a deposition technique LbL route can be utilized to uniformly coat TJR 
implant surface, both extremely small features or larger surfaces(Macdonald et al. 2011). 
Altogether these results suggest LbL route as the most appropriated synthetic route to 
obtain a release profile to modulate the inflammatory response in TJR. However, as 
described in the following section, more studies (e.g. assessment of the anti-
inflammatory effect and cellular viability) were needed to confirm these assumptions. 
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4.3. Raw 264.7 cell studies  
From a cellular point of view, macrophages are the first immune cells to act towards 
invading organisms or tissue injury, and they play a key role in inflammatory response 
(Goodman et al. 2014, Hallab 2016, Nich et al. 2013). Hence, making them the in vivo 
targets for the anti-inflammatory drug-eluting implant model system here in develop.  
Therefore, cytotoxic and anti-inflammatory properties of DEX-loaded functionalised-TiO2 
particles were tested in a rapid and reproducible in vitro mouse macrophage-like cellular 
model, by utilizing murine RAW 264.7 cells. Previous studies utilizing Raw 264.7 cells 
have confirmed their ability to produce and release markers of inflammation (Chan et al. 
2015, Hoareau et al. 2010, Joo et al. 2014). Therefore, these cells have proven a 
valuable tool for researchers conducting pharmacological research to identify novel anti-
inflammatory drug candidates. Lipopolysaccharide (LPS) was utilized to activate the Raw 
264.7 macrophages, resulting in the secretion of pro-inflammatory cytokines, including 
nitric oxide (NO) and tumour necrosis factor alpha (TNF-α) (Pinho et al. 2011, Sharma 
et al. 2007). The suppression of which was utilized to investigate anti-inflammatory effect 
of DEX released from functionalised-TiO2 particles. Overall, in vitro studies showed that 
both DEX released from amino, mercapto and LbL-functionalised particles exerted an 
anti-inflammatory activity by decreasing NO and TNF-α production in LPS-activated 
macrophages. Although LbL particles showed a prolonged release of DEX which 
resulted in a more continued anti-inflammatory activity (at least 2 weeks) than that 
observed for amino and mercapto particles (24 hours). The utilization of DEX as an anti-
inflammatory drug before and after joint replacement surgeries, mainly via oral 
administration, has been widely described (Backes et al. 2013, De Oliveira et al. 2011, 
Goodman et al. 2014). However, in this work, we elucidate for the first time the local anti-
inflammatory and respective cytotoxic effects of DEX released from functionalised TiO2 
particles on LPS-activated murine macrophages. 
 
4.3.1. Cellular viability  
Cytotoxicity testing of implantable devices, such as TJR, is recommended by regulatory 
bodies (American Society for Testing and Materials, ASTM F2033-12) and is considered 
as one of the most fundamental tests for biocompatibility (Koschwanez & Reichert 2007, 
Schuh 2008, Values et al. 2005). Moreover, being important inflammatory modulators, 
NO and TNF-α can also be cytotoxic mediators (Kröncke et al. 2001, Sedger & 
McDermott 2014). For instance, when assessing biological activity naphthoquinones, 
Pinho and co-workers have reported that macrophages death would decrease the 
number of NO producing cells (Pinho et al. 2011), and thus providing erroneous results 
about anti-inflammatory efficacy. For this reason, preliminary cell viability studies were 
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performed as a complement to the anti-inflammatory activity assessment. Aiming to 
guarantee that the anti-inflammatory effect of DEX released from functionalised TiO2-
particles obtained by different synthetic routes will not be due to cell death/toxicity.  
 
Importance of preliminary viability studies 
Although sometimes preliminary studies can be repetitive and time consuming, they are 
often conducted to investigate whether crucial components of an experiment will be 
feasible, thus obtaining a more efficient study. In our study, the preliminary experiments 
were important to guarantee that concentrations and type of treatments (i.e. filtered or 
non-filtered) will not cause cell toxicity or misleading/false anti-inflammatory effect.  
In a first stage preliminary studies were performed to investigate the toxicity of different 
concentrations of DEX alone and release buffers. Our results showed that the non-toxic 
effects of DEX occurred at lower doses (<20 µg/mg), at which increased cell growth and 
recovery from damage was observed even after 72h of exposure. However, at higher 
doses (60 and 100 µg/mL) and long-term exposure (72h), DEX has showed to be 
cytotoxic. Respectively a significant decrease on cellular viability of 50% was observed, 
when compared to control group. Similar results were reported by Wernecke at al. 
(2015), when assessing the dose and time dependence of DEX toxicity on chondrocytes 
(Wernecke et al. 2015). This study showed that low doses (2.5-50 μM) and short 
exposure times (<1 day) were correlated with maintenance of cell viability. On the other 
hand, for higher doses of DEX (>100 μM) and more prolonged culture times (72h), 
detrimental cellular effects were observed, such as decreased collagen levels, 
chondrotoxicity, and extracellular matrix breakdown.  
As for preliminary studies concerning release buffers, results showed that when 
incubated with LPS most of the release buffers concentrations induced significant 
(p<0.05) decrease on cellular viability, except for the one where release buffer was 
diluted to 1:10 (10% concentration). This information was crucial when assessing the 
toxicity of DEX released from functionalised-TiO2 particles, because treatments were 
diluted up to a concentration of 10% before being added to the Raw 264.7 cells. 
Moreover, when toxicity of DEX released from functionalised-TiO2 particles was 
investigated, results obtained by MTT assay showed that the LPS-activated Raw 264.7 
cells exposed to non-filtered samples presented significant (p<0.05) decrease on cellular 
viability. This decrease on cellular viability caused by non-filtered samples can be related 
to the presence of TiO2 particles in the sample, which were removed when sample was 
filtered. 
Together these results obtained from the preliminary studies were important to find out 
that samples should be filtered and diluted (1:10) before being added to Raw 264.7 cells, 
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otherwise the potential decrease of inflammatory markers (e.g. NO decrease) will be due 
to cell toxicity and not due to anti-inflammatory activity. Hence, the importance of 
performing preliminary studies before starting the main experiment was here in 
demonstrated. 
 
DEX released from functionalised-TiO2 particles  
Results obtained from viability studies (MTT assay) indicated that DEX released from 
functionalised-TiO2 particles obtained by amino/mercapto (Figure 51) and LbL (Figure 
52) routes, did not caused appreciable cytotoxicity in LPS-activated RAW 264.7 cells; 
except at 72 hours, where a higher decrease (10-15%) on viability was observed. The 
decrease of cellular viability observed for DEX released from functionalised-TiO2 
particles is in line with that of DEX alone. This decrease could be explained based on 
DEX ability of inhibiting nuclear factor-kappa B (NF-Кβ). This transcription factor which 
plays a central role in inflammation, is also involved in several cellular processes 
(Brantley et al. 2001) such as cell proliferation and apoptosis. Thus NF-Кβ inhibitory 
ability of DEX could be hampering the cellular proliferation, and thus decreasing cellular 
viability of Raw 264.7 macrophages over longer period of exposure. Moreover, most of 
the studies involving DEX exposure to Raw 264.7 macrophages are performed for 
shorter periods of time such as 6,18 or 24 hours, suggesting that over incubation period 
of 72h exposure might be causing media toxicity which results in a decrease on cellular 
viability without any external stimulus. Similar results were reported by Wernecke at al. 
(2015), when assessing DEX toxicity on chondrocytes (Wernecke et al. 2015). This study 
showed that short exposure times (<1 day) were correlated with maintenance of 
chondrocytes viability. On the other hand, for more prolonged culture times (72h), DEX 
may have detrimental effects on cells, such as decreased collagen levels, 
chondrotoxicity, and extracellular matrix breakdown. It is also worth emphasizing that 
although significant (p<0.05), when compared to control group, this decrease on cellular 
viability cause by DEX released from functionalised-TiO2 particles was not as significant 
(p<0.05) as the one induced on Raw macrophages treated with release buffer alone 
(~20%). In addition, results showed that cellular viability was never less than 80% relative 
to LPS control group. Because these are the same activated cells on which the anti-
inflammatory activity is tested, this noncytotoxic behaviour suggests that the efficacy 
reported will be primarily due to the anti-inflammatory activity.  
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4.3.2 Optimization of in vitro inflammation system model  
Exposure of macrophages to pathogens, such as bacterial LPS, initiates a signal 
transduction cascade that leads to secretion potent effector molecules, including 
increased production of pro-inflammatory cytokines such as TNF-α, and inflammatory 
mediators such as NO, the hallmarks of activated macrophages (Cho et al. 2008, Oh et 
al. 2012). In this context, the regulation of this signalling pathway is crucial for modulating 
the initial phases of the immune response to foreign pathogens. For that reason, in vitro 
models such as LPS-activated Raw 264.7 macrophages have been widely used for the 
screening of anti-inflammatory activity of different agents/compounds (Kim & Ha 2009, 
Pinho et al. 2011, Vairappan et al. 2013, Yang et al. 2014), and potential anti-
inflammatory delivery systems (Bosnjakovic et al., 2011; Joo et al., 2014; S.-Y. Lee, et 
al., 2013; Terra et al., 2007; Yuan, Chen, Sun, Guan, & Xu, 2013), as evidenced by the 
abundance of scientific articles published over the last 10 years 
In this study optimal experimental conditions, macrophages density and LPS 
concentration, were investigated to obtain a reliable and reproducible in vitro 
inflammation model. This is critical feature for any in vitro cell-based model when 
conducting biological research to identify novel drug delivery systems (Hughes et al. 
2011, McKim 2010), which may or may not possess inherent cellular toxicological 
properties. Due to rapidity and simplicity, the measurement of NO production by Griess 
reagent was utilized as screening tool for this optimisation study. Although NO production 
by Griess reagent assay has been commonly utilized by the scientists, the optimization 
of experimental conditions to obtain a reliable in vitro inflammation model were still 
investigated in this study. In addition,  the excessive production of NO has been 
considered to be toxic for macrophages (Mandrika et al. 2001). Hence the cellular 
viability of LPS-activated cells under different parameters (e.g. cell density and LPS 
concentration) was also investigated to complement the optimization of in vitro 
inflammation model. The importance of optimizing experimental conditions of 
inflammatory mediators production in LPS-activated macrophages have been described 
previous studies (Hosseini et al. 2014, Huang et al. 2012, Jacobs & Ignarro 2003). For 
instance, Huang and colleagues (2012) optimized the cell density, LPS concentration 
and duration of LPS stimulation to measure NO production in mouse peritoneal 
macrophages. A similar optimization study was performed by Tweedie et al. (2009) to 
measure TNF-α production in LPS-activated murine macrophages (Tweedie et al. 
2009a).    
In general, results showed that in fact NO production was affected by both cell density 
and LPS concentration. Similar results were reported by Hosseini and co-workers when 
optimising the conditions for evaluating NO production in microglia cell line (BV-2), NO 
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production followed a temporal pattern and showed to be cell-density and LPS-dose 
dependent (Hosseini et al. 2014). The optimal results, a quantifiable NO production at 
non-toxic levels, were obtained with combination of cell density of 2x104 cells/well and 
LPS concentration of 1 μg/mL.  
Moreover, with optimised cell density (2x104 cells/well), NO and TNF-α production by 
LPS-stimulated Raw 264.7 cells showed to be dose-dependent and to increase over time 
(Figure 60). At 24h, LPS-stimulated cells showed to produce significant level of 
inflammatory NO and TNF-α proteins, respectively with an approximate 20 and ~74-fold 
increase when compared to control group. This is line with previous studies which have 
shown that LPS-activation of macrophages results in concentration-dependent and 
increased NO (Pinho et al. 2011, Wu et al. 2003) and TNF-α production (Tweedie et al. 
2009b). Also, Chiou and co-workers (2000) showed a 16-fold increase in NO production 
of 24h-LPS-stimulated macrophages (1µg/mL) when compared to that of unstimulated 
ones. Similarly, an increased production TNF-α protein (112-fold increase) in LPS-
activated macrophages was observed by Miller & hunt (1998) when compared to that of 
unstimulated cells only after 6 hours-exposure. 
Furthermore, not only in LPS-stimulated cells the NO and TNF-α was increased (Figure 
60), but also the majority of RAW 264.7 cells acquired dendritic morphology upon LPS 
stimulation (Figure 58). As observed by fluorescent microscopy, results showed that 24h, 
LPS-activated Raw 264.7 macrophages developed elaborate filopodia-like protrusions, 
like dendritic-cells type. These changes in macrophages cells morphology and size upon 
LPS exposition were also described by other authors (Lee et al. 2008, Saxena et al. 
2003, van Helden et al. 2008); which have reported that when macrophages encounter 
stimuli like LPS, they undergo through morphological and phenotypic changes towards 
activated and polarized dendritic macrophages (M1 and M2 type) (Anderson et al. 2008, 
Mills & Ley 2014). 
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4.3.3 Anti-inflammatory activity  
In general, implants, such as TJR, undergo tissue response after implantation into living 
tissues (Wu et al. 2015). During inflammatory process, cytokines such as NO and TNF-
α are released, and thus they can be utilized for measuring the inflammatory reactions 
level after material implantation, including aseptic periprosthetic osteolysis (Bi et al. 
2017, Boyce et al. 2005, Holt et al. 2007). There is a considerable body of evidence 
showing that there is an increased presence of TNF-α and NO in the fluid and inflamed 
periprosthetic membrane tissue obtained from loosened implants (Banaszkiewicz 
2014a,b; Zhao et al. 2016). Because of its pivotal role in anti-inflammatory activity of 
macrophages, a significant effort has focused on developing therapeutic agents that 
regulate/decrease NO and TNF-α production.  
Preliminary studies 
Regarding NO production, preliminary studies showed that none of the tested 
compounds, DEX (Figure 61), release buffers (Figure 63, Figure 64), or DEX released 
from functionalised-TiO2 particles (filtered samples) (Figure 65) induced changes in NO 
basal levels, when incubated without LPS. Meaning that release buffers and DEX 
released itself did not exert any effect i.e. inflammation or death on unstimulated-cells.  
On the other hand, LPS-stimulated cells (control group) showed high and increasing 
levels of both NO and TNF-α during the study period of 72 hours. Although it should be 
noted that when LPS-activated Raw 264.7 cells were exposed to release buffers (Figure 
63.B,Figure 64.B), results showed that among all concentrations tested only 10% did not 
cause a significant decrease (p<0.05) on the NO production, when compared to LPS 
control group. Although less pronounced, the same effect was observed for cellular 
viability (Figure 45). It is known that release buffers do not exert anti-inflammatory 
activity, therefore the cell death which was caused by high concentration of PBS leaded 
to an incorrect interpretation of NO inhibition. From these results, we could then conclude 
that NO decrease observed for release buffers with concentrations higher than 10%, was 
mainly caused by significant cell toxicity and not due to anti-inflammatory activity. For 
this reason, only treatments (filtered samples with 10% concentration) which did not 
cause a decrease on cellular viability with statistical meaning were considered to exert 
an anti-inflammatory effect. Together these results obtained for cells exposed to different 
concentrations of release buffers, have shown the importance of simultaneous assessing 
NO production and cellular viability.  
Furthermore, when the effect of DEX alone (3.9–20 µg/mL) was assessed, a dose-
dependent decrease of NO and TNF-α was observed, accordingly this effect was at its 
greatest when cells were exposed to 20 µg/mL of DEX. These observations are 
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consistent with earlier reports from other investigators who have shown that DEX 
significantly decreased levels inflammatory mediators such as TNF-a (Bouwmeester et 
al. 2004, Hermoso et al. 2004, Miller and Hunt 1998) and NO (Korhonen et al. 2002, 
Pinho et al. 2011) in LPS-activated macrophages. Miller & Hunt (1998) have showed a 
significant decrease of TNF-a concentrations of LPS-activated RAW 264.7 macrophages 
when exposed to DEX (Miller & Hunt 1998). For instance Yoon and co-workers (2010) 
have shown that DEX (20µM or 8 µg/mL) decreased LPS-induced production of TNF-in 
Raw 264.6 macrophages by ~40% (% to LPS control) (Yoon et al. 2010) after 24h 
exposure. 
 
Model system: DEX-loaded-functionalised TiO2 particles 
As it was observed for DEX alone, DEX released from functionalised-TiO2 particles 
obtained by amino, mercapto and LbL routes, decreased both NO and TNF-α production 
in LPS-activated macrophages. Together with results obtained from cellular viability 
studies (viability>80%), the anti-inflammatory efficacy of model system here in reported 
was confirmed excluding the hypothesis of a non-specific decline in protein synthesis 
due to drug-induced toxicity. Similar effect was observed in previous studies where the 
anti-inflammatory compounds tested have shown to simultaneous reduce LPS-induced 
nitrite accumulation and TNF-α secretion in RAW 264.7 macrophages (Chan et al. 2015, 
Joo et al. 2014, Kiemer et al. 2002). Moreover, when evidenced the anti-inflammatory 
efficacy of model system was very similar to the one observed for cells treated with 
positive control (DEX 3.9 and 10 µg/mL). Similar studies have reported the anti-
inflammatory effect of DEX released from drug-eluting systems (Fratoddi et al. 2012, Luo 
et al. 2011, Ren et al. 2014, Vallejo-Heligon et al. 2016). Robinson and colleagues have 
shown that LPS activation of inflammatory cytokines expression was decreased through 
the presence of DEX (10µg/mL) released from amine-Functionalized Poly-p-xylene 
(Parylene A) surface, where a decrease of ~ 60% was observed on TNF-α expression 
when compared to LPS control group (Robinson et al. 2008). 
However, when the anti-inflammatory effect of the synthetic routes applied was 
compared different anti-inflammatory effect/trend was observed: DEX released from 
functionalised-TiO2 particles obtained by LbL route was more prolonged than that of 
amino and mercapto routes, 21 days instead of 24 hours. These results are in line with 
drug release studies which clearly showed that for particles obtained by LbL route DEX 
was released for longer periods (~21 days) than that of amino and mercapto routes (24h).  
Moreover, LbL showed to be a more controllable route, where the anti-inflammatory 
effect varied according to number of layers surrounding DEX. For example, under 
inflammatory conditions (pH<7), DEX released from LbL 0 was a more profound TNF-α 
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inhibitor than that of LbL 4, with highest inhibition observed at 72h of ~ 36% for the former 
(24h LbL 0) and 25% for the latter (24h LbL 4). Also, a stronger anti-inflammatory effect 
was observed for DEX released at 24h and 48h than that of 2 weeks. Once more, this 
anti-inflammatory effect is line with the drug release profile obtained for LbL 
functionalised-particles, where higher concentrations of DEX were released at earlier 
time points. Considering that acute inflammatory reaction occurs within 24–48 h (Jayant 
& Srivastava 2007), the demonstrated higher anti-inflammatory efficacy of DEX released 
at earlier time points will guarantee an effective modulation of acute phase. Moreover, 
although minor the anti-inflammatory effect observed for DEX released at 72h and 2W, 
is also important to guarantee that inflammation will be continuous modulated for at least 
2 weeks. Consequently, the continuous and effective anti-inflammatory effect observed 
in this study, suggest that local release of DEX at the implantation site via the TiO2 
implant surface will be an approach to suppress the local chronic inflammatory response, 
and consequently avoid aseptic loosening. 
Furthermore, it is important to highlight the biological relevance of this study, which 
simultaneous focuses on inhibition of different inflammatory mediators NO and TNF-α; 
and, also in contrast to most part of the studies reported in literature, the anti-
inflammatory effect was assessed for longer period (i.e. 72h study instead of 18h/24h). 
Hence from a biological point of view, the results obtained in this study provide a more 
comprehensive and consistent information about the anti-inflammatory mechanism of 
the model system developed here Particularly the 3 days lasting anti-inflammatory 
efficacy reported in this study, suggests that our model system will modulate acute phase 
(~2-3 days) thus avoiding the unfavourable chronic phase. In addition, DEX released 
from functionalised-particle was added to the cells, just before LPS addition. This 
observation might be of special importance to elucidate the mechanisms of action of an 
anti-inflammatory eluting implant, particularly as a protective compound to avoid chronic 
inflammation. In this context it is interesting to learn that pre-treatment of macrophages 
with DEX attenuated LPS-cytokine-induced NO and TNF-α production.  
 
Importance and potential application of model system  
The results of the present work showed that DEX released may modulate the intensity 
of inflammatory processes by inhibiting the secretion of TNF-α and NO pro-inflammatory 
mediators. In terms of clinical application, this model system could be very useful to 
improve TJR outcome. Particularly after TJR surgery, where a prolonged and 
exacerbated inflammatory response can prolong surgical recovery and compromise 
implant outcome. The local anti-inflammatory effect exerted by DEX, as demonstrated 
by NO and TNF-α decrease, could promote a controlled inflammatory response i.e. 
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appropriate balance between pro-inflammatory and anti-inflammatory mediators (Bhusal 
et al. 2016).  The need to modulate inflammation after TJR surgery is obvious, a 
prolonged (chronic) inflammatory response contributes to the pathogenesis of aseptic 
loosening, which is the most common indication for revision surgery. A body equilibrium 
around the implant, where appropriate conditions (i.e. bone formation over bone 
resorption) for bone growth are gathered, is a crucial factor to achieve osteointegration 
and long-term clinical function. There is strong evidence that TNF-α can promote bone 
resorption in vitro and in vivo in osteoblastic cell lines (Boyce et al. 2005, Holt et al. 2007, 
Lam et al. 2000, Lampiasi et al. 2016, Lin et al. 2014, Parameswaran & Patial 2010). 
Hence, being TNF-α a potent mediator of bone resorption (e.g. stimulates osteoclasts 
formation and differentiation), the TNF-α -inhibitory effect observed when LPS-activated 
cells were exposed to DEX, suggests that developed system would help to prevent 
periprosthetic osteolysis. Production of pro-inflammatory cytokines and mediators are 
crucial to resolve inflammation. Although, their overproduction often leads to less 
favourable outcomes such as chronic inflammation and tissue damage. Therefore, the 
NO and TNF-α inhibitory effect exerted DEX released from functionalised-TIO2 particles 
on inflamed cells may serve as a potential strategy for modulating inflammation after TJR 
surgery. 
Possible molecular mechanism to explain anti-inflammatory effect of DEX 
Glucocorticoids, such as DEX, are indicated for the treatment of many inflammatory 
conditions; previous studies (Barnes 2006, Hermoso et al. 2004) have shown that 
clinically glucocorticoids exert their anti-inflammatory effect by binding to a glucocorticoid 
receptor (GR), which switches off multiple inflammatory pathways and genes and thus 
decrease the expression of pro-inflammatory cytokines. By directly affecting steroid-
responsive gene transcription, DEX is known to suppress the production of pro-
inflammatory mediators and cytokines such as NO and TNF-α. The mechanism by which 
DEX suppresses the macrophage function, has been reported to involve the suppression 
NF-Кβ, which is in part mediated by induction of IkBα gene transcription and subsequent 
increase in IkBα protein synthesis. Then newly synthesized IkBα protein inhibits NF-Кβ 
translocation to the nucleus by binding to its free form in the cytoplasm (Author et al. 
1995, Beg & Baldwin As 1993), and hence resulting in a decrease in inflammatory 
proteins production; being all of this is triggered by DEX binding to GR expressed by 
macrophages (Crinelli et al. 2000). 
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Figure 70. Schematic figure of possible signalling mechanisms of DEX released 
from functionalised-TiO2 particles in inhibiting the LPS-induced inflammatory 
response.  
Inflammatory genes are activated by LPS, resulting in activation of IKK2, which activates the 
transcription factor NF-Кβ. A dimer of p50 and p65 NF-κB proteins translocate to the nucleus and 
binds to specific κB recognition sites, as well as to co-activators, such as CBP or pCAF, which 
have intrinsic histone acetyltransferase (HAT) activity. This results in acetylation of core histone 
H4, resulting in increased expression of genes encoding multiple inflammatory proteins. 
Simultaneously, after activation by corticosteroids the GR translocate to the nucleus (1.) and bind 
to coactivators to inhibit HAT activity directly and recruiting HDAC2 (2.), which reverses histone 
acetylation leading in suppression of the transcription (3.) of these activated inflammatory gene 
and consequent repression (4). (Abbreviations: CBP: cyclic binding protein; LPS: 
Lipopolysaccharide; IKK2: inhibitor of I-kB kinase-2, NF-Кβ: nuclear transcription factor Кβ; pCAF: 
p300-CBP associated factor; HAT: histone acetyltransferase; GR: glucorticoid receptor; HDAC2: 
histone deacetylase-2; DEX: dexamethasone). 
 
In more detail, (Figure 70) after activation by DEX, GR translocate to the nucleus and 
bind to coactivators to inhibit histone acetyltransferase (HAT) activity and recruiting 
histone deacetylase-2 (HDAC2), which reverses histone acetylation, leading in 
suppression of the LPS-activated inflammatory genes. Alternatively DEX can also 
interact with DNA recognition sites to active transcription of anti-inflammatory genes 
(Barnes 2006, Vandevyver et al. 2013). When anti-inflammatory mechanism of DEX on 
LPS-activated macrophages was investigated by Jeon and colleagues, results indicated 
a dose-related inhibition of NF-κB/Rel and AP-1 (Jeon et al. 2000). Specifically, as 
measured by electrophoretic mobility shift assay (EMSA), DEX inhibited DNA binding of 
NF-κB/Rel and AP-1 proteins to their cognate DNA sites. Similarly, Yanamoto and 
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Gaynor (2001) have showed that DEX inhibition of both NO and TNF-α was due to the 
suppression of NF-κB activation (Yamamoto & Gaynor 2001).This signalling pathway 
(Figure 70) might explain our observation of a DEX reduction in TNF-α and NO in LPS-
stimulated macrophages. Although further studies at transcription level are needed, the 
anti-inflammatory activity exerted by DEX released from functionalised-TiO2 particles on 
the investigated inflammatory mediators seems to be mediated via a direct interaction of 
DEX with NO and TNF-α due to trans repression of the NF-κB signaling pathway.  
 
 
. 
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5. Conclusion  
 
Despite being one the most common complication of TJR, there is no approved therapy 
to avoid or treat aseptic loosening following wear-induced periprosthetic 
inflammation/osteolysis.  Considerable research has been done to reduce wear debris 
release and their consequences, including modification on implants design and 
improvement of surgical techniques, although offering some promise none of these 
approaches have yet shown to inhibit or reverse particle-induced osteolysis in a human 
population with sufficiently powered, randomized, controlled trials. This leads to the 
conclusion that most part of the currently applied therapies, depend on the systemic 
administration of anti-inflammatory agents, meaning that their bioavailability at osteolytic 
lesions will mainly depend on the limited blood supply at bone-interface implant.  
Therefore, localised release of anti-inflammatory drugs from implanted TJR could 
modulate the environment of this host cell/implant interface and related inflammatory 
events. Thus, overcoming the aseptic loosening and improve performance of these life-
saving devices. 
As a proof-of-concept, in this study different routes i.e. amino, mercapto and LbL, were 
applied to develop a drug delivery model system, that allows localized and tuneable 
delivery of anti-inflammatory drugs.  
In general, results obtained from TGA analysis, SEM, TEM, FTIR and zeta potential 
measurements show that all routes applied to attach DEX to TiO2 particles were 
successful. Moreover, since the primary hydroxyl group used to attach DEX to carboxyl-
functionalized TiO2 particles is present in most of the glucocorticoids, this chemistry 
would be applicable to conjugate other anti-inflammatory drugs. As for LbL, the only 
requirement is to tailor the solution of the anti-inflammatory drug, so it behaves as anionic 
polyelectrolyte, this can be easily achieved by adjusting the pH of the solution.  
Overall results have also shown that depending on the synthetic route applied, the DEX-
loaded-functionalised TiO2 particles obtained present different features from 
size/morphology to drug release profiles. For example, when LBL route was utilized anti-
inflammatory drug was released in higher concentration, and during a longer period (i.e. 
3 weeks), when compared with DEX release profiles obtained for the mercapto and 
amino routes (24 hours). Hence, proving that different synthetic routes lead indeed to 
different release kinetics. Furthermore, in terms of clinical application, the results 
founded showed the possibility of tuning the pace and concentration of anti-inflammatory 
drug release through a different conjugation route.  
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Furthermore, in vitro studies using Raw 264.7 macrophages cell line indicated that DEX 
concentrations released from functionalised-TiO2 particles obtained via amino, mercapto 
and LbL routes, presented anti-inflammatory activity. In other words, results from this 
study have shown that DEX decreased the production of two important inflammatory 
mediators: NO and TNF-α, without considerably adverse cellular effects; such providing 
vital information for the future medical applications (i.e. TJR) of the drug eluting model 
system proposed in this study. Although, based on previous clinical studies/evidence, it 
is known that in theory the functionalised-TiO2 particles obtained by amino and mercapto 
routes, will not provide the release of DEX during the crucial time desirable to modulate 
inflammation i.e. period of 2 days to 2 weeks. On the other hand, when applied LbL 
technique, provided a prolonged anti-inflammatory effect (up to 2 weeks) when 
compared to amino and mercapto routes. In addition, by increasing the number of layers 
surrounding DEX it was possible to control the drug release rate and decrease the initial 
burst release; as well as to maintain the anti-inflammatory activity of DEX, as showed by 
Raw 264.7 macrophages studies. 
Gathering such experimental biological evidence was critical; firstly, because most of the 
Raw 264.7 macrophages studies reported on literature were performed for periods of 18-
24h. And, also because we could not find any study where Raw 264.7 macrophages had 
been exposed to PBS or acetate buffer media yet. Therefore, it is important to highpoint 
the importance of all preliminary experiments performed during this study to obtain 
reliable and reproducible data/results. Additionally, it is important to highlight the utility of 
the rapid and reproducible in vitro RAW 264.7 cell model, which allowed a good 
consistency in studying the anti-inflammatory role of DEX released from functionalised-
TiO2 particles. However, as most in vitro studies, RAW 264.7 cell model presents some 
limitations; parameters such as test sample concentrations, stability and/or potential 
transformation of test compounds, cell line specificity, duration of cell exposure to 
treatment samples, generation of artefacts by compounds in cell culture media, as well 
as other potential reactions should be considered when evaluating cell culture 
experimental results. Therefore, future animal studies should be designed to (i) 
investigate the potential of DEX loaded functionalised TiO2 particles for the modulation 
of acute inflammatory phase, and (ii) completely understand the molecular pathways 
involved in the DEX-mediated anti-inflammatory response, particularly at transcriptional 
level.  
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Nonetheless, the innovative results of this study are very promising both in terms of 1) 
model system of anti-inflammatory drug eluting implant, where DEX was successfully 
attached to TiO2-functionalised particles by all synthetic routes applied; and 2) biological 
studies, where as shown by our in vitro Raw 264.7 cell studies, the DEX released from 
TiO2-functionalised particles apart from not being toxic for the cells, it also showed to 
exhibit an anti-inflammatory activity by attenuating the production of two critical 
inflammatory mediators, TNF-α and NO in LPS-stimulated macrophages. Particularly 
when LbL route was applied, suggesting that continuous release (at least 2 weeks) of 
DEX using LbL CH/ALG functionalised-TiO2 surface would be able to control 
inflammation around the implant. 
In terms of clinical application, the local delivery of DEX, which is attached to implant 
surface, can also overcome the several limitations of anti-inflammatory/osteolytic 
therapies such as lack of efficacy, systemic side-effects, and poor patient compliance. 
Moreover, the post-surgery period and the treatment regimen can be simpler because it 
requires fewer anti-inflammatory dosages and doctor visits than the traditional TJR 
surgery. Particularly, the local delivery of DEX, could prevent the main drawbacks of the 
conventional systemic delivery of anti-inflammatory drug, such as associated renal and 
liver complications. Therefore, the model system here in could be a potential approach 
for patients which undergo TJR, to avoid progressive osteolysis and/or to patients who 
need repeated revision surgery after joint replacement. 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
6. References  
 
1. Aktan F. 2004. iNOS-mediated nitric oxide production and its regulation. Life 
Sciences. doi:10.1016/j.lfs.2003.10.042. 
2. Allen KD, Adams SB, Setton L a. 2010. Evaluating intra-articular drug delivery for 
the treatment of osteoarthritis in a rat model. Tissue Eng. Part B. Rev. 16(1):81–
92 
3. Almalki M, Lai E, Li C. 2017. Polyethylene Glycol - Functionalized Titanium 
Dioxide Nanoparticles for Extended Release of Diethylenetriaminepentaacetic 
Acid into Lung Fluid to Enhance the Decorporation of Radioactive Actinides. 
Nanosci. Nanomedicine Nanobiology J. 1(1):1–6 
4. Anderson J, Cramer S. 2015. Host Response to Biomaterials. Elsevier. Elsevier. 
doi:10.1016/B978-0-12-800196-7.00002-5. 
5. Anderson J, Rodriguez A, Chang DT. 2008. Foreign body reaction to 
biomaterials. Seminars in Immunology.doi:10.1016/j.smim.2007.11.004 
6. Anselmo AC, Mitragotri S. 2014. An overview of clinical and commercial impact 
of drug delivery systems. J. Control. Release. 190:15–28 
7. Ariga K, McShane M, Lvov YM, Ji Q, Hill JP. 2011. Layer-by-layer assembly for 
drug delivery and related applications. Expert Opin. Drug Deliv. 8(5):633–44 
8. Author G, Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. 1995. Role of 
Transcriptional Activation of IκBα in Mediation of Immunosuppression by. Source 
Sci. New Ser. J. Pet. Meteorit. D. E. Grady, J. Geophys. Res. 270(85):283–86 
9. Bach LG, Islam MR, Seo SY, Lim KT. 2013. A novel route for the synthesis of 
poly(2-hydroxyethyl methacrylate) grafted TiO 2 nanoparticles via surface thiol-
lactam initiated radical polymerization. J. Appl. Polym. Sci. 127:261–69 
10. Backes JR, Bentley JC, Politi JR, Chambers BT. 2013. Dexamethasone Reduces 
Length of Hospitalization and Improves Postoperative Pain and Nausea After 
Total Joint Arthroplasty: A Prospective, Randomized Controlled Trial. J. 
Arthroplasty. 28(8, Supplement):11–17 
11. Bagheri S, Shameli K, Abd Sharifah Bee. H. 2013. Synthesis and characterization 
of anatase titanium dioxide nanoparticles using egg white solution via sol-gel 
method. J. Chem. 848205, 5 pp. 
12. Bagherifard S. 2017. Mediating bone regeneration by means of drug eluting 
implants: From passive to smart strategies. Mater. Sci. Eng. C. 71:1241–52 
13. Banaszkiewicz PA. 2014a. Production of cytokines around loosened cemented 
acetabular components: Analysis with immunohistochemical techniques and in 
154 
 
situ hybridization. In Classic Papers in Orthopaedics, pp. 89–91 
14. Banaszkiewicz PA. 2014b. The synovial-like membrane at the bone-cement 
interface in loose total hip replacements and its proposed role in bone lysis. In 
Classic Papers in Orthopaedics, pp. 117–19 
15. Banerjee I, Pangule RC, Kane RS. 2011. Antifouling coatings: Recent 
developments in the design of surfaces that prevent fouling by proteins, bacteria, 
and marine organisms 
16. Barnes PJ. 2006. How corticosteroids control inflammation: Quintiles Prize 
Lecture 2005 
17. Bartczak D, Kanaras AG. 2011. Preparation of peptide-functionalized gold 
nanoparticles using one pot EDC/Sulfo-NHS coupling. Langmuir. 27(16):10119–
23 
18. Baschant U, Culemann S, Tuckermann J. 2013. Molecular determinants of 
glucocorticoid actions in inflammatory joint diseases 
19. Bastian O, Pillay J, Alblas J, Leenen L, Koenderman L, Blokhuis T. 2011. 
Systemic inflammation and fracture healing. J. Leukoc. Biol. 89(5):669–73 
20. Bauer S, Schmuki P, von der Mark K, Park J. 2012. Engineering biocompatible 
implant surfaces. Part I: Materials and surfaces. Prog. Mater. Sci. 
21. Bayliss LE, Culliford D, Monk AP, Glyn-Jones S, Prieto-Alhambra D, et al. 2017. 
The effect of patient age at intervention on risk of implant revision after total 
replacement of the hip or knee: a population-based cohort study. Lancet. 
389(10077):1424–30 
22. Beck RT, Illingworth KD, Saleh KJ. 2012. Review of periprosthetic osteolysis in 
total joint arthroplasty: An emphasis on host factors and future directions. J. 
Orthop. Res. 30(4):541–46 
23. Bedke J, Stenzl A. 2010. Immunologic mechanisms in RCC and allogeneic renal 
transplant rejection 
24. Beg AA, Baldwin As J r. 1993. The I kB proteins: multifunctional regulators of 
Rel/NF-kB transcription factors. Genes Dev. 7:2064–70 
25. Bhandari M, Smith J, Miller LE, Block JE. 2012. Clinical and economic burden of 
revision knee arthroplasty. Clin. Med. Insights Arthritis Musculoskelet. Disord. 
5:89–94 
26. Bhardwaj U, Sura R, Papadimitrakopoulos F, Burgess DJ. 2007. Controlling 
acute inflammation with fast releasing dexamethasone-PLGA microsphere/pva 
hydrogel composites for implantable devices. J. diabetes Sci. Technol. 1(1):8–17 
27. Bhusal P, Harrison J, Sharma M, Jones DS, Hill AG, Svirskis D. 2016. Controlled 
release drug delivery systems to improve post-operative pharmacotherapy 
155 
 
28. Bi X, Han L, Qu T, Mu Y, Guan P, et al. 2017. Anti-inflammatory effects, SAR, 
and action mechanism of monoterpenoids from radix paeoniae alba on LPS-
stimulated RAW264.7 cells. Molecules. 22(5): 
29. Bixler GD, Bhushan B. 2012. Biofouling: lessons from nature. Philos. Trans. R. 
Soc. A Math. Phys. Eng. Sci. 370(1967):2381–2417 
30. Bloemen M, Brullot W, Luong TT, Geukens N, Gils A, Verbiest T. 2012. Improved 
functionalization of oleic acid-coated iron oxide nanoparticles for biomedical 
applications. J. Nanoparticle Res. 14(9): 
31. Bogdan C. 2001. Nitric oxide and the immune response. Nat. Immunol. 
2(10):907–16 
32. Bosco R, Van Den Beucken J, Leeuwenburgh S, Jansen J. 2012. Surface 
Engineering for Bone Implants: A Trend from Passive to Active Surfaces. 
Coatings. 2(4):95–119 
33. Bosnjakovic A, Mishra MK, Ren W, Kurtoglu YE, Shi T, et al. 2011. 
Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to 
macrophages involved in periprosthetic inflammation. Nanomedicine 
Nanotechnology, Biol. Med. 7(3):284–94 
34. Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, et al. 2004. A 
physical and functional map of the human TNF-alpha/NF-kappa B signal 
transduction pathway. Nat. Cell Biol. 6(2):97–105 
35. Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, et al. 2005. TNF-alpha and pathologic 
bone resorption. Keio J. Med. 54(3):127–31 
36. Brantley DM, Chen CL, Muraoka RS, Bushdid PB, Bradberry JL, et al. 2001. 
Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in 
mouse  mammary epithelium. Mol. Biol. Cell. 12(5):1445–55 
37. Bridges AW, García AJ. 2008. Anti-inflammatory polymeric coatings for 
implantable biomaterials and devices. J. Diabetes Sci. Technol. 2(6):984–94 
38. Bryan NS, Grisham MB. 2007. Methods to detect nitric oxide and its metabolites 
in biological samples. Free Radic. Biol. Med. 43(5):645–57 
39. Buckley CD. 2011. Why does chronic inflammation persist: An unexpected role 
for fibroblasts 
40. Buriuli M, Verma D. 2017. Polyelectrolyte complexes (PECs) for biomedical 
applications. In Advanced Structured Materials, Vol. 66, pp. 45–93 
41. Caetano LA, Almeida AJ, Gonçalves LMD. 2016. Effect of experimental 
parameters on alginate/chitosan microparticles for BCG encapsulation. Mar. 
Drugs. 14(5): 
42. Caminade A-M, Turrin C-O. 2014. Dendrimers for drug delivery. J. Mater. Chem. 
156 
 
B. 2(26):4055 
43. Cao H, Xu SY. 2008. EDC/NHS-crosslinked type II collagen-chondroitin sulfate 
scaffold: Characterization and in vitro evaluation. J. Mater. Sci. Mater. Med. 
19(2):567–75 
44. Chan PM, Tan YS, Chua KH, Sabaratnam V, Kuppusamy UR. 2015. Attenuation 
of Inflammatory Mediators (TNF-α and Nitric Oxide) and Up-Regulation of IL-10 
by Wild and Domesticated Basidiocarps of Amauroderma rugosum (Blume & T. 
Nees) Torrend in LPS-Stimulated RAW264.7 Cells. PLoS One. 10(10): 
45. Chang SH, Lin HTV, Wu GJ, Tsai GJ. 2015. pH Effects on solubility, zeta 
potential, and correlation between antibacterial activity and molecular weight of 
chitosan. Carbohydr. Polym. 134:74–81 
46. Chen Q, Yakovlev NL. 2010. Adsorption and interaction of organosilanes on TiO2 
nanoparticles. Appl. Surf. Sci. 257(5):1395–1400 
47. Chen Y, Song S, Yan Z, Fenniri H, Webster TJ. 2011. Self-assembled rosette 
nanotubes encapsulate and slowly release dexamethasone. Int. J. 
Nanomedicine. 6:1035–44 
48. Cheng Q, Li C, Pavlinek V, Saha P, Wang H. 2006. Surface-modified antibacterial 
TiO2/Ag+ nanoparticles: Preparation and properties. Appl. Surf. Sci. 
252(12):4154–60 
49. Cherian JJ, Jauregui JJ, Banerjee S, Pierce T, Mont MA. 2015. What Host 
Factors Affect Aseptic Loosening After THA and TKA? 
50. Chiang ZC, Yu SH, Chao AC, Dong GC. 2012. Preparation and characterization 
of dexamethasone-immobilized chitosan scaffold. J. Biosci. Bioeng. 113(5):654–
60 
51. Cho H, Seon M, Lee Y, Kim J, Kim S, Park J. 2008. 3,3’-Diindolylmethane 
suppresses the inflammatory response to lipopolysaccharide in murine 
macrophages. J Nutr. 138(1):17–23 
52. Chung MF, Chia WT, Wan WL, Lin YJ, Sung HW. 2015. Controlled Release of 
an Anti-inflammatory Drug Using an Ultrasensitive ROS-Responsive Gas-
Generating Carrier for Localized Inflammation Inhibition. J. Am. Chem. Soc. 
137(39):12462–65 
53. Cobelli N, Scharf B, Hardin J, Santambrogio L, Crisi GM, et al. 2011. Mediators 
of the inflammatory response to joint replacement devices. Nat. Rev. Rheumatol. 
20(10):S234–35 
54. Cohly H, Stephens J, Markhov  a, Angel M, Campbell W, et al. 2001. Cell culture 
conditions affect LPS inducibility of the inflammatory mediators in J774A.1 murine 
macrophages. Immunol. Invest. 30(1):1–15 
157 
 
55. Conde J, Dias JT, Grazu V, Moros M, Baptista P V., de la Fuente JM. 2014. 
Revisiting 30 years of biofunctionalization and surface chemistry of inorganic 
nanoparticles for nanomedicine. Front. Chem. 2: 
56. Coutinho AE, Chapman KE. 2011. The anti-inflammatory and 
immunosuppressive effects of glucocorticoids, recent developments and 
mechanistic insights 
57. Crinelli R, Antonelli  a, Bianchi M, Gentilini L, Scaramucci S, Magnani M. 2000. 
Selective inhibition of NF-kB activation and TNF-alpha production in 
macrophages by red blood cell-mediated delivery of dexamethasone. Blood 
Cells. Mol. Dis. 26(3):211–22 
58. Cummings NA, Nordby GL. 1966. Measurement of synovial fluid pH in normal 
and arthritic knees. Arthritis Rheum. 9(1):47–56 
59. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. 2010. 
In-stent restenosis in the drug-eluting stent era 
60. Das K, Bose S, Bandyopadhyay A. 2009. TiO2 nanotubes on Ti: Influence of 
nanoscale morphology on bone cell-materials interaction. J. Biomed. Mater. Res. 
- Part A. 90(1):225–37 
61. Dattani R. 2007. Femoral osteolysis following total hip replacement 
62. Dawes GJS, Fratila-Apachitei LE, Necula BS, Apachitei I, van Leeuwen JPTM, 
et al. 2011. Effects of Dexamethasone Loaded Plga Microspheres on Human 
Fetal Osteoblasts. J. Biomater. Appl. 
63. De Jonge LT, Leeuwenburgh SCG, Wolke JGC, Jansen JA. 2008. Organic-
inorganic surface modifications for titanium implant surfaces 
64. De Nadai TR, De Nadai MN, Albuquerque AAS, De Carvalho MTM, Celotto AC, 
Evora PRB. 2013. Metabolic acidosis treatment as part of a strategy to curb 
inflammation 
65. De Oliveira GS, Almeida MD, Benzon HT, McCarthy RJ. 2011. Perioperative 
single dose systemic dexamethasone for postoperative pain: a meta-analysis of 
randomized controlled trials. Anesthesiology. 115(3):575–88 
66. De Oliveira GS Jr.; Almeida MD; Benzon HT;McCarthy RJ. 2011. Perioperative 
Single Dose Systemic Dexamethasone for. Anesthesiology. 115(3):575–88 
67. De Villiers MM, Otto DP, Lvov YM. 2012. Application of Electrostatic Layer-by-
Layer Nanocoating in Drug Delivery 
68. Díez-Pascual AM, Díez-Vicente AL. 2014. Effect of TiO2 nanoparticles on the 
performance of polyphenylsulfone biomaterial for orthopaedic implants. J. Mater. 
Chem. B. 2(43):7502–14 
69. Doadrio AL, Conde A, Arenas MA, Hernández-López JM, de Damborenea JJ, et 
158 
 
al. 2015. Use of anodized titanium alloy as drug carrier: Ibuprofen as model of 
drug releasing. Int. J. Pharm. 492(1–2):207–12 
70. Dohan Ehrenfest DM, Coelho PG, Kang BS, Sul YT, Albrektsson T. 2010. 
Classification of osseointegrated implant surfaces: Materials, chemistry and 
topography 
71. Dugel PU, Bandello F, Loewenstein A. 2015. Dexamethasone intravitreal implant 
in the treatment of diabetic macular edema. Clin. Ophthalmol. 9:1321–35 
72. Dutra-Medeiros M, Alkabes M, Nucci P. 2014. Effectiveness of the 
Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic 
Macular Oedema. Eur. Ophthalmic Rev. 67–73 
73. Elron-Gross I, Glucksam Y, Biton IE, Margalit R. 2009. A novel Diclofenac-carrier 
for local treatment of osteoarthritis applying live-animal MRI. J. Control. Release. 
135(1):65–70 
74. Erdemli Ö, Özen S, Keskin D, Usanmaz A, Batu ED, et al. 2014. In vitro 
evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and 
PCL microspheres on human rheumatoid arthritis synoviocytes. J. Biomater. 
Appl. 29(4):524–42 
75. Evans CH, Kraus VB, Setton LA. 2014. Progress in intra-articular therapy. Nat. 
Rev. Rheumatol. 10(1):11–22 
76. Everaerts F, Torrianni M, Hendriks M, Feijen J. 2008. Biomechanical properties 
of carbodiimide crosslinked collagen: Influence of the formation of ester 
crosslinks. J. Biomed. Mater. Res. - Part A. 85(2):547–55 
77. Fan J, Myant C, Underwood R, Cann P. 2012. Synovial fluid lubrication of artificial 
joints: protein film formation and composition. Faraday Discuss. 156(0):69–85 
78. Feng W, Nie W, He C, Zhou X, Chen L, et al. 2014. Effect of pH-responsive 
alginate/chitosan multilayers coating on delivery efficiency, cellular uptake and 
biodistribution of mesoporous silica nanoparticles based nanocarriers. ACS Appl. 
Mater. Interfaces. 6(11):8447–60 
79. Fernandes LL, Resende CX, Tavares DS, Soares GA, Castro LO, Granjeiro JM. 
2011. Cytocompatibility of chitosan and collagen-chitosan scaffolds for tissue 
engineering  
80. Fratoddi I, Venditti I, Cametti C, Palocci C, Chronopoulou L, et al. 2012. 
Functional polymeric nanoparticles for dexamethasone loading and release. 
Colloids Surfaces B Biointerfaces. 93:59–66 
81. Gallo J, Goodman SB, Konttinen YT, Wimmer MA, Holinka M. 2013. Osteolysis 
around total knee arthroplasty: A review of pathogenetic mechanisms 
82. Ganesh M, Lee SG. 2013. Synthesis, characterization and drug release capability 
159 
 
of new cost effective mesoporous silica nano particle for ibuprofen drug delivery. 
Int. J. Control Autom. 6(5):207–16 
83. Gao Y, Masuda Y, Seo W-S, Ohta H, Koumoto K. 2004. TiO2 nanoparticles 
prepared using an aqueous peroxotitanate solution. Ceram. Int. 30(7):1365–68 
84. Getts DR, Terry RL, Getts MT, Deffrasnes C, Müller M, et al. 2014. Therapeutic 
inflammatory monocyte modulation using immune-modifying microparticles. Sci. 
Transl. Med. 6(219): 
85. Gillies ER, Fréchet JMJ. 2005. Dendrimers and dendritic polymers in drug 
delivery 
86. Ginebra MP, Canal C, Espanol M, Pastorino D, Montufar EB. 2012. Calcium 
phosphate cements as drug delivery materials 
87. Gong D, Shi W, Yi S, Chen H, Groffen J, Heisterkamp N. 2012. TGFβ signaling 
plays a critical role in promoting alternative macrophage activation. BMC 
Immunol. 13:31 
88. Goodman S. 2014. Bearing Surfaces for Joint Replacement: New Materials or 
New Problems. In Metal-on-Metal Bearings: A Clinical Practicum, Vol. 
9781461489, eds. LC Jones, WO Haggard, AS Greenwald, pp. 13–20. New York, 
NY: Springer New York 
89. Goodman SB, Gibon E, Pajarinen J, Lin T-HT-H, Keeney M, et al. 2014. Novel 
biological strategies for treatment of wear particle-induced periprosthetic 
osteolysis of orthopaedic implants for joint replacement. J. R. Soc. Interface. 
11(93):20130962 
90. Goodman SB, Ma T. 2010. Cellular chemotaxis induced by wear particles from 
joint replacements. Biomaterials. 31(19):5045–50 
91. Goodman SB, Yao Z, Keeney M, Yang F. 2013. The future of biologic coatings 
for orthopaedic implants. Biomaterials. 34(13):3174–83 
92. Goriainov V, Cook R, Latham JM, Dunlop DG, Oreffo ROC. 2014. Bone and 
metal: An orthopaedic perspective on osseointegration of metals 
93. Gouda M. 2012. Augmentation of Multifunctional Properties of Cellulosic Cotton 
Fabric Using Titanium Dioxide Nanoparticles. Adv. Nanoparticles. 01(03):29–36 
94. Gutowski CJ, Zmistowski BM, Clyde CT, Parvizi J. 2014. The economics of using 
prophylactic antibiotic-loaded bone cement in total knee replacement. Bone Jt. J. 
96 B(1):65–69 
95. Haak-Frendscho M, Wynn TA, Czuprynski CJ, Paulnock D. 1990. Transforming 
growth factor-beta 1 inhibits activation of macrophage cell line RAW 264.7 for cell 
killing. Clin. Exp. Immunol. 82(2):404–10 
96. Hallab NJ. 2016. Biologic Responses to Orthopedic Implants: Innate and 
160 
 
Adaptive Immune Responses to Implant Debris. Spine (Phila. Pa. 1976). 41 
Suppl 7:S30-1 
97. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, et al. 2011. 
Dexamethasone intravitreal implant in patients with macular edema related to 
branch or central retinal vein occlusion: Twelve-month study results. 
Ophthalmology. 118(12):2453–60 
98. Hammond PT. 2012. Building biomedical materials layer-by-layer. Mater. Today. 
15(5):196–206 
99. Han U, Seo Y, Hong J. 2016. Effect of pH on the structure and drug release 
profiles of layer-by- layer assembled films containing polyelectrolyte , micelles , 
and graphene oxide. Sci. Rep. 6(April):1–10 
100. Hausmann EHS, Hao SY, Pace JL, Parmely MJ. 1994. Transforming 
growth factor-beta 1 and gamma interferon provide opposing signals to 
lipopolysaccharide-activated mouse macrophages. Infect. Immun. 62(9):3625–
32 
101. Hermanson GT. 2013. Functional Targets for Bioconjugation. In 
Bioconjugate Techniques, pp. 127–228 
102. Hermanson GT, Hermanson GT. 2013. Chapter 4 – Zero-Length 
Crosslinkers. In Bioconjugate Techniques, pp. 259–73 
103. Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA. 2004. 
Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like 
receptor 2 gene expression. Mol. Cell. Biol. 24(11):4743–56 
104. Hickey T, Kreutzer D, Burgess DJ, Moussy F. 2002a. In vivo evaluation 
of a dexamethasone/PLGA microsphere system designed to suppress the 
inflammatory tissue response to implantable medical devices. J. Biomed. Mater. 
Res. 61(2):180–87 
105. Hickey T, Kreutzer D, Burgess DJ, Moussy F. 2002b. 
Dexamethasone/PLGA microspheres for continuous delivery of an anti-
inflammatory drug for implantable medical devices. Biomaterials. 23(7):1649–56 
106. Hickok NJ, Shapiro IM. 2012. Immobilized antibiotics to prevent 
orthopaedic implant infections 
107. Hoareau L, Bencharif K, Rondeau P, Murumalla R, Ravanan P, et al. 
2010. Signaling pathways involved in LPS induced TNFalpha production in 
human adipocytes. J. Inflamm. (Lond). 7:1 
108. Holt G, Murnaghan C, Reilly J, Meek RMD, Features S. 2007. The biology 
of aseptic osteolysis. Clin. Orthop. Relat. Res. 460(460):240–52 
109. Holte K, Kehlet H. 2002. Perioperative single-dose glucocorticoid 
161 
 
administration: Pathophysiologic effects and clinical implications 
110. Hosseini NK, Jose S, Vidyadaran S, Nordin SA. 2014. Optimization of cell 
density and LPS concentration for the evaluation of nitric oxide production on BV-
2 cells in a Griess assay. Malaysian J. Med. Heal. Sci. 10(2):1–8 
111. Huang L, Xia H, Lun Y, Yu C, Zhang Q, et al. 2012. Optimization of a 
lipopolysaccharide-stimulated nitric oxide production model in mouse peritoneal 
macrophages. J. Neurosci. Methods. 32(11):1646–50 
112. Huebner KD, Shrive NG, Frank CB. 2014. Dexamethasone inhibits 
inflammation and cartilage damage in a new model of post-traumatic 
osteoarthritis. J. Orthop. Res. 32(4):566–72 
113. Hughes JP, Rees S, Kalindjian SB, Philpott KL. 2011. Principles of early 
drug discovery. Br. J. Pharmacol. 162(6):1239–49 
114. Hughes SF, Hendricks BD, Edwards DR, Maclean KM, Bastawrous SS, 
Middleton JF. 2010. Total hip and knee replacement surgery results in changes 
in leukocyte and endothelial markers. J. Inflamm. 7:2 
115. Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, et al. 2014. 45-
day mortality after 467779 knee replacements for osteoarthritis from the National 
Joint Registry for England and Wales: An observational study. Lancet. 
384(9952):1429–36 
116. Iloki Assanga SB, Gil-Salido AA, Lewis Lujan LM, Rosas-Durazo A, 
Acosta-silva AL, et al. 2013. Cell growth curves for different cell lines and their 
relationship with biological activities. Int. J. Biotechnol. Mol. Biol. Res. 4(4):60–
70 
117. Ingham E, Fisher J. 2005. The role of macrophages in osteolysis of total 
joint replacement 
118. Ion R, Vizireanu S, Stancu CE, Luculescu C, Cimpean A, Dinescu G. 
2015. Surface plasma functionalization influences macrophage behavior on 
carbon nanowalls. Mater. Sci. Eng. C. 48:118–25 
119. Isowa N, Xavier  a M, Dziak E, Opas M, McRitchie DI, et al. 1999. LPS-
induced depolymerization of cytoskeleton and its role in TNF-alpha production by 
rat pneumocytes. Am. J. Physiol. 277(3 Pt 1):L606–15 
120. Issa K, Mont MA. 2013. Total hip replacement: Mortality and risks 
121. Italiani P, Boraschi D. 2014. From monocytes to M1/M2 macrophages: 
Phenotypical vs. functional differentiation 
122. Jacobs AT, Ignarro LJ. 2003. Cell density-enhanced expression of 
inducible nitric oxide synthase in murine macrophages mediated by interferon-β. 
Nitric Oxide. 8(4):222–30 
162 
 
123. Jäger M, Zilkens C, Zanger K, Krauspe R. 2007. Significance of nano- 
and microtopography for cell-surface interactions in orthopaedic implants 
124. Jayant RD, McShane MJ, Srivastava R. 2009. Polyelectrolyte-coated 
alginate microspheres as drug delivery carriers for dexamethasone release. Drug 
Deliv. 16(6):331–40 
125. Jayant RD, Srivastava R. 2007. Dexamethasone release from uniform 
sized nanoengineered alginate microspheres. J. Biomed. Nanotechnol. 
3(3):245–53 
126. Jebens EH, Monk-Jones ME. 1959. On the viscosity and pH of synovial 
fluid and the pH of blood. J. Bone Joint Surg. Br. 41–B(2):388–400 
127. Jeon YJ, Han SH, Lee YW, Lee M, Yang KH, Kim HM. 2000. 
Dexamethasone inhibits IL-1β gene expression in LPS-stimulated RAW 264.7 
cells by blocking NF-κB/Rel and AP-1 activation. Immunopharmacology. 
48(2):173–83 
128. Joo T, Sowndhararajan K, Hong S, Lee J, Park SY, et al. 2014. Inhibition 
of nitric oxide production in LPS-stimulated RAW 264.7 cells by stem bark of 
Ulmus pumila L. Saudi J. Biol. Sci. 21(5):427–35 
129. Kallala RF, Vanhegan IS, Ibrahim MS, Sarmah S, Haddad FS. 2015. 
Financial analysis of revision knee surgery based on NHS tariffs and hospital 
costs: does it pay to provide a revision service? Bone Joint J. 97–B(2):197–201 
130. Kawai M, Mödder UI, Khosla S, Rosen CJ. 2011. Emerging therapeutic 
opportunities for skeletal restoration 
131. Kawakami T, Kawamura K, Fujimori K, Koike A, Amano F. 2016. Influence 
of the culture medium on the production of nitric oxide and expression of inducible 
nitric oxide synthase by activated macrophages in vitro. Biochem. Biophys. 
Reports. 5:328–34 
132. Kiemer AK, Müller C, Vollmar AM. 2002. Inhibition of LPS-induced nitric 
oxide and TNF-α production by α-lipoic acid in rat Kupffer cells and in RAW 264.7 
murine macrophages. Immunol. Cell Biol. 80(6):550–57 
133. Kim I-T, Ryu S, Shin J-S, Choi J-H, Park H-J, Lee K-T. 2012. Euscaphic 
acid isolated from roots of Rosa rugosa inhibits LPS-induced inflammatory 
responses via TLR4-mediated NF-kappaB inactivation in RAW 264.7 
macrophages. J. Cell. Biochem. 113(6):1936–46 
134. Kim ID, Ha BJ. 2009. Paeoniflorin protects RAW 264.7 macrophages from 
LPS-induced cytotoxicity and genotoxicity. Toxicol. Vitr. 23(6):1014–19 
135. Koju N, Sikder P, Ren Y, Zhou H, Bhaduri SB. 2017. Biomimetic coating 
technology for orthopedic implants 
163 
 
136. Konttinen YT, Takagi M, Mandelin J, Lassus J, Salo J, et al. 2001. Acid 
attack and cathepsin K in bone resorption around total hip replacement 
prosthesis. J. Bone Miner. Res. 16(10):1780–86 
137. Korhonen R, Lahti A, Hämäläinen M, Kankaanranta H, Moilanen E. 2002. 
Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric 
oxide production by destabilizing mRNA in lipopolysaccharide-treated 
macrophages. Mol. Pharmacol. 62(3):698–704 
138. Koschwanez HE, Reichert WM. 2007. In vitro, in vivo and post 
explantation testing of glucose-detecting biosensors: Current methods and 
recommendations 
139. Kröncke KD, Fehsel K, Kolb-Bachofen V. 1997. Nitric oxide: cytotoxicity 
versus cytoprotection- how, why, when, and where? Nitric Oxide. 1(2):107–20 
140. Kröncke KD, Fehsel K, Suschek C, Kolb-Bachofen V. 2001. Inducible 
nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell 
survival. Int. Immunopharmacol. 1:1407–20 
141. Kulig D, Zimoch-Korzycka A, Jarmoluk A, Marycz K. 2016. Study on 
alginate-chitosan complex formed with different polymers ratio. Polymers (Basel). 
8(5): 
142. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. 2007. Projections of primary 
and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. 
Bone Joint Surg. Am. 89(4):780–85 
143. Kurtz SM, Lau E, Ong K, Zhao K, Kelly M, Bozic KJ. 2009. Future young 
patient demand for primary and revision joint replacement: National projections 
from 2010 to 2030. Clin. Orthop. Relat. Res. 467(10):2606–12 
144. Labek G, Thaler M, Janda W, Agreiter M, Stockl B. 2011. Revision rates 
after total joint replacement: CUMULATIVE RESULTS FROM WORLDWIDE 
JOINT REGISTER DATASETS. Bone Joint J. 93–B(3):293–97 
145. Lai W-Y, Kao C-T, Hung C-J, Huang T-H, Shie M-Y. 2014. An evaluation 
of the inflammatory response of lipopolysaccharide-treated primary dental pulp 
cells with regard to calcium silicate-based cements. Int. J. Oral Sci. 6(2):94–98 
146. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. 
2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages 
exposed to permissive levels of RANK ligand. J. Clin. Invest. 106(12):1481–88 
147. Lampiasi N, Russo R, Zito F. 2016. The Alternative Faces of Macrophage 
Generate Osteoclasts 
148. Landgraeber S, J??ger M, Jacobs JJ, Hallab NJ. 2014. The pathology of 
orthopedic implant failure is mediated by innate immune system cytokines 
164 
 
149. Langlois J, Hamadouche M. 2011. New animal models of wear-particle 
osteolysis 
150. Lawrie G, Keen I, Drew B, Chandler-Temple A, Rintoul L, et al. 2007. 
Interactions between Alginate and Chitosan Biopolymers Characterized Using 
FTIR and XPS. Biomacromolecules. 8(8):2533–41 
151. Lee DK, Jang S, Kim MJ, Kim JH, Chung MJ, et al. 2008. Anti-proliferative 
effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer 
cell lines. BMC Cancer. 8:310 
152. Lee JW, Serna F, Nickels J, Schmidt CE. 2006. Carboxylic acid-
functionalized conductive polypyrrole as a bioactive platform for cell adhesion. 
Biomacromolecules. 7(6):1692–95 
153. Lee K, Goodman SB. 2008. Current state and future of joint replacements 
in the hip and knee 
154. Lee SY, Kim HJ, Han JS. 2013. Anti-inflammatory effect of oyster shell 
extract in LPS-stimulated raw 264.7 cells. Prev. Nutr. Food Sci. 18(1):23–29 
155. Li G, Xie B, Pan C, Yang P, Ding H, Huang N. 2014. Facile conjugation 
of heparin onto titanium surfaces via dopamine inspired coatings for improving 
blood compatibility. J. Wuhan Univ. Technol. Mater. Sci. Ed. 29(4):832–40 
156. Li MD, Yang X. 2011. A retrospective on nuclear receptor regulation of 
inflammation: Lessons from GR and PPARs 
157. Li P, Dai Y-N, Zhang J-P, Wang A-Q, Wei Q, Ping L. 2008. Chitosan-
Alginate Nanoparticles as a Novel Drug Delivery System for Nifedipine. 
www.ijbs.org Int J Biomed Sci. 4(3): 
158. Li Y-F, Rubert M, Yu Y, Besenbacher F, Chen M. 2015. Delivery of 
dexamethasone from electrospun PCL–PEO binary fibers and their effects on 
inflammation regulation. RSC Adv. 5(43):34166–72 
159. Lieder R, Darai M, Thor MB, Ng CH, Einarsson JM, et al. 2012. In vitro 
bioactivity of different degree of deacetylation chitosan, a potential coating 
material for titanium implants. J. Biomed. Mater. Res. - Part A. 100 A(12):3392–
99 
160. Lin TH, Tamaki Y, Pajarinen J, Waters HA, Woo DK, et al. 2014. Chronic 
inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a 
therapeutic target 
161. Linden J. 2012. Translational medicine: Longer life for artificial joints 
162. Longhofer LK, Chong A, Strong NM, Wooley PH, Yang S-Y. 2017. 
Specific material effects of wear-particle-induced inflammation and osteolysis at 
the bone–implant interface: A rat model. J. Orthop. Transl. 8:5–11 
165 
 
163. Lopes PP, Silva MS, Fernandes MHV. 2013. Influence of ibuprofen 
addition on the properties of a bioactive bone cement. J. Mater. Sci. Mater. Med. 
24(8):2067–76 
164. Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. 2012. The dramatic 
increase in total knee replacement utilization rates in the United States cannot be 
fully explained by growth in population size and the obesity epidemic. J. Bone 
Joint Surg. Am. 94(3):201–7 
165. Lu Y, Pelton R, Brook MA. 2007. Biotinylation of TiO2 nanoparticles and 
their conjugation with streptavidin. Langmuir. 23(10):5630–37 
166. Lucke S, Hoene A, Walschus U, Kob A, Pissarek JW, Schlosser M. 2015. 
Acute and chronic local inflammatory reaction after implantation of different 
extracellular porcine dermis collagen matrices in rats. Biomed Res. Int. 2015: 
167. Lundberg JO, Weitzberg E, Gladwin MT. 2008. The nitrate-nitrite-nitric 
oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 7(2):156–
67 
168. Luo X, Matranga C, Tan S, Alba N, Cui XT. 2011. Carbon nanotube 
nanoreservior for controlled release of anti-inflammatory dexamethasone. 
Biomaterials. 32(26):6316–23 
169. Lyndon JA, Boyd BJ, Birbilis N. 2014. Metallic implant drug/device 
combinations for controlled drug release in orthopaedic applications 
170. MA Shafie, Attia Shafie FHM. 2013. Formulation and Evaluation of 
Betamethasone Sodium Phosphate Loaded Nanoparticles for Ophthalmic 
Delivery. J. Clin. Exp. Ophthalmol. 4(2):1–11 
171. Ma W, Cheetham AG, Cui H. 2016. Building nanostructures with drugs 
172. Macdonald ML, Samuel RE, Shah NJ, Padera RF, Beben YM, Hammond 
PT. 2011. Tissue integration of growth factor-eluting layer-by-layer 
polyelectrolyte multilayer coated implants. Biomaterials. 32(5):1446–53 
173. MacInnes SJ, Gordon A, Wilkinson JM. 2012. Risk factors for aseptic 
loosening following total hip arthroplasty. Recent Adv. Arthroplast. 275–94 
174. MacMahon PJ, Eustace SJ, Kavanagh EC. 2009. Injectable 
Corticosteroid and Local Anesthetic Preparations: A Review for Radiologists. 
Radiology. 252(3):647–61 
175. Mandrika I, Muceniece R, Wikberg JE. 2001. Effects of melanocortin 
peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA 
binding and nitric oxide production in macrophage-like RAW 264.7 cells:: 
Evidence for dual mechanisms of action. Biochem. Pharmacol. 61(5):613–21 
176. Marjanovic V, Lazarevic S, Jankovic-Castvan I, Jokic B, Bjelajac A, et al. 
166 
 
2013. Functionalization of thermo-acid activated sepiolite by amine-silane and 
mercapto-silane for chromium(VI) adsorption from aqueous solutions. Hem. Ind. 
67(5):715–28 
177. Martins A, Duarte ARC, Faria S, Marques AP, Reis RL, Neves NM. 2010. 
Osteogenic induction of hBMSCs by electrospun scaffolds with dexamethasone 
release functionality. Biomaterials. 31(22):5875–85 
178. Masuzaki T, Ayukawa Y, Moriyama Y, Jinno Y, Atsuta I, et al. 2010. The 
effect of a single remote injection of statin-impregnated poly (lactic-co-glycolic 
acid) microspheres on osteogenesis around titanium implants in rat tibia. 
Biomaterials. 31(12):3327–34 
179. McKim JM. 2010. Building a Tiered Approach to In Vitro Predictive 
Toxicity Screening: A Focus on Assays with In Vivo Relevance. Comb. Chem. 
High Throughput Screen. 13(2):188–206 
180. Middleton CA, Pendegrass CJ, Gordon D, Jacob J, Blunn GW. 2007. 
Fibronectin silanized titanium alloy: A bioinductive and durable coating to 
enhance fibroblast attachment in vitro. J. Biomed. Mater. Res. - Part A. 
83(4):1032–38 
181. Mihalko WM, Djenderedjian L, Cheema PS, Smith R. 2014. Effects of 
gelsolin on macrophage inflammatory responses to orthopaedic implant wear 
debris. J. Long. Term. Eff. Med. Implants. 24(1):57–63 
182. Miller L, Hunt JS. 1998. Regulation of TNF-alpha production in activated 
mouse macrophages by progesterone. J. Immunol. 160(10):5098–5104 
183. Mills CD, Ley K. 2014. M1 and M2 macrophages: The chicken and the 
egg of immunity 
184. Minagar S, Berndt CC, Wang J, Ivanova E, Wen C. 2012. A review of the 
application of anodization for the fabrication of nanotubes on metal implant 
surfaces. Acta Biomater. 8(8):2875–88 
185. Morent R, De Geyter N, Leys C, Gengembre L, Payen E. 2008. 
Comparison between XPS- And FTIR-analysis of plasma-treated polypropylene 
film surfaces. Surf. Interface Anal. 40(3–4):597–600 
186. Moskowitz JS, Blaisse MR, Samuel RE, Hsu HP, Harris MB, et al. 2010. 
The effectiveness of the controlled release of gentamicin from polyelectrolyte 
multilayers in the treatment of Staphylococcus aureus infection in a rabbit bone 
model. Biomaterials. 31(23):6019–30 
187. National Joint Registry. 2016. National Joint Registry. 12th Annual 
progress report National Joint Registry Reports. 
http://www.njrreports.org.uk/hips-all-procedures-activity/H03v2NJR 
167 
 
188. National Joint Registry. 2017. 14th Annual Report-National Joint Registry 
for England, Wales, Northern Ireland and the Isle of Man 
189. Nich C, Takakubo Y, Pajarinen J, Ainola M, Salem A, et al. 2013. 
Macrophages-Key cells in the response to wear debris from joint replacements. 
J. Biomed. Mater. Res. A. 101(10):3033–45 
190. Nine M, Choudhury D, Hee A, Mootanah R, Osman N. 2014. Wear Debris 
Characterization and Corresponding Biological Response: Artificial Hip and Knee 
Joints. Materials (Basel). 7(2):980–1016 
191. Nuttelman CR, Tripodi MC, Anseth KS. 2006. Dexamethasone-
functionalized gels induce osteogenic differentiation of encapsulated hMSCs. J. 
Biomed. Mater. Res. - Part A. 76(1):183–95 
192. Oh Y-CC, Cho W-KK, Oh JH, Im GY, Jeong YH, et al. 2012. Fermentation 
by Lactobacillus enhances anti-inflammatory effect of Oyaksungisan on LPS-
stimulated RAW 264.7 mouse macrophage cells. BMC Complement. Altern. 
Med. 12(1):17 
193. Oida T, Weiner HL. 2010. Depletion of TGF-Beta from fetal bovine serum. 
J. Immunol. Methods. 362(1–2):195–98 
194. Oray M, Abusamra K, Ebrahimiadib N, Meese H, Foster CS. 2016. Long-
term side effects of glucocorticoids. Expert Opin. Drug Saf. 
338(1):14740338.2016.1140743 
195. Othman SH, Abdul Rashid S, Mohd Ghazi TI, Abdullah N. 2012. 
Dispersion and stabilization of photocatalytic TiO 2 nanoparticles in aqueous 
suspension for coatings applications. J. Nanomater. 2012: 
196. Papadimitriou S, Bikiaris D. 2009. Novel self-assembled core-shell 
nanoparticles based on crystalline amorphous moieties of aliphatic copolyesters 
for efficient controlled drug release. J. Control. Release. 138(2):177–84 
197. Parameswaran N, Patial S. 2010. Tumor necrosis factor-α signaling in 
macrophages. Crit. Rev. Eukaryot. Gene Expr. 20(2):87–103 
198. Pargaonkar N, Lvov YM, Li N, Steenekamp JH, De Villiers MM. 2005. 
Controlled release of dexamethasone from microcapsules produced by 
polyelectrolyte layer-by-layer nanoassembly. Pharm. Res. 22(5):826–35 
199. Pedersen BK, Febbraio MA. 2008. Muscle as an Endocrine Organ: Focus 
on Muscle-Derived Interleukin-6. Physiol. Rev. 88(4):1379–1406 
200. Pereira-da-silva MDA, Ferri FA. 2017. 1 - Scanning Electron Microscopy 
201. Perni S, Martini-Gilching K, Prokopovich P. 2018. Controlling release 
kinetics of gentamicin from silica nano-carriers. Colloids Surfaces A 
Physicochem. Eng. Asp. 541:212–21 
168 
 
202. Petit A, Sandker M, Müller B, Meyboom R, van Midwoud P, et al. 2014. 
Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-
capped PCLA-PEG-PCLA thermogels. Biomaterials. 35(27):7919–28 
203. Petruson K, Stalfors J, Jacobsson KE, Ny L, Petruson B. 2005. Nitric 
oxide production in the sphenoidal sinus by the inducible and constitutive 
isozymes of nitric oxide synthase. Rhinology. 43(1):18–23 
204. Pierson JL, Harris WH. 1994. Cemented revision for femoral osteolysis in 
cemented arthroplasties. Results in 29 hips after a mean 8.5-year follow-up. J. 
Bone Joint Surg. Br. 76(1):40–44 
205. Pinho BR, Sousa C, Valentão P, Andrade PB. 2011. Is nitric oxide 
decrease observed with naphthoquinones in LPS stimulated RAW 264.7 
macrophages a beneficial property? PLoS One. 6(8): 
206. Pioletti DP. 2008. Using drug delivery systems to enhance joint 
replacement. In Joint Replacement Technology, pp. 397–406 
207. Popat KC, Eltgroth M, Desai TA. 2007. Drug eluting nanostructured 
coatings. NSTI Nanotech 2007 Conf. St. Clara, Calif. 
208. Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, et al. 2005. 
Macrophage activation switching: An asset for the resolution of inflammation. 
Clin. Exp. Immunol. 142(3):481–89 
209. Pu H-L, Chiang W-L, Maiti B, Liao Z-X, Ho Y-C, et al. 2014. Nanoparticles 
with dual responses to oxidative stress and reduced pH for drug release and anti-
inflammatory applications. ACS Nano. 8(2):1213–21 
210. Qu H, Bhattacharyya S, Ducheyne P. 2015. Silicon oxide based materials 
for controlled release in orthopedic procedures 
211. Rajamaki K, Nordstrom T, Nurmi K, Akerman KEO, Kovanen PT, et al. 
2013. Extracellular acidosis is a novel danger signal alerting innate immunity via 
the  NLRP3 inflammasome. J. Biol. Chem. 288(19):13410–19 
212. Rajpura A, Board T. 2013. Complications following total hip arthroplasty. 
In Arthroplasty-Update. InTech 
213. Ramanathan T, Liu H, Brinson LC. 2005. Functionalized SWNT/polymer 
nanocomposites for dramatic property improvement. J. Polym. Sci. Part B Polym. 
Phys. 43(17):2269–79 
214. Rao AJ, Gibon E, Ma T, Yao Z, Smith RL, Goodman SB. 2012. Revision 
joint replacement, wear particles, and macrophage polarization. Acta Biomater. 
8(7):2815–23 
215. Ren K, Dusad A, Yuan F, Yuan H, Purdue PE, et al. 2014. 
Macromolecular prodrug of dexamethasone prevents particle-induced peri-
169 
 
implant osteolysis with reduced systemic side effects. J. Control. Release. 
175(1):1–9 
216. Ren K, Dusad A, Zhang Y, Wang D. 2013. Therapeutic intervention for 
wear debris-induced aseptic implant loosening. Acta Pharm. Sin. B. 3(2):76–85 
217. Ren K, Purdue PE, Burton L, Quan LD, Fehringer E V., et al. 2011a. Early 
detection and treatment of wear particle-induced inflammation and bone loss in 
a mouse calvarial osteolysis model using HPMA copolymer conjugates. Mol. 
Pharm. 8(4):1043–51 
218. Ren PG, Irani A, Huang Z, Ma T, Biswal S, Goodman SB. 2011b. 
Continuous infusion of UHMWPE particles induces increased bone macrophages 
and osteolysis. Clin. Orthop. Relat. Res. 469(1):113–22 
219. Revell PA. 2014. Joint Replacement Technology, Vol. 2. Elsevier 
220. Ricciotti E, Fitzgerald GA. 2011. Prostaglandins and inflammation. 
Arterioscler. Thromb. Vasc. Biol. 31(5):986–1000 
221. Rick Sumner D. 2013. Biological control of peri-implant bone remodeling 
and implant loosening (Sun Valley 2012). IBMS Bonekey. 10: 
222. Rivera MC, Pinheiro AC, Bourbon AI, Cerqueira MA, Vicente AA. 2015. 
Hollow chitosan/alginate nanocapsules for bioactive compound delivery. Int. J. 
Biol. Macromol. 79:95–102 
223. Robinson EM, Lam R, Pierstorff ED, Ho D. 2008. Localized therapeutic 
release via an amine-functionalized poly-p-xylene microfilm device. J. Phys. 
Chem. B. 112(37):11451–55 
224. Rostamian R, Najafi M, Rafati AA. 2011. Synthesis and characterization 
of thiol-functionalized silica nano hollow sphere as a novel adsorbent for removal 
of poisonous heavy metal ions from water: Kinetics, isotherms and error analysis. 
Chem. Eng. J. 171(3):1004–11 
225. Rozkydal Z, Janik P, Janicek P, Kunovsky R. 2007. Revision knee 
arthroplasty due to aseptic loosening. Acta Chir. Orthop. Traumatol. Cech. 
74(1):5–13 
226. Ryu JJ, Shrotriya P. 2013. Synergistic mechanisms of bio-tribocorrosion 
in medical implants. In Bio-Tribocorrosion in Biomaterials and Medical Implants, 
pp. 25–44 
227. Saag KG, Furst DE, Greene JM. 2008. Major side effects of systemic 
glucocorticoids 
228. Sabio G, Davis R. 2014. TNF-a and MAP kinase signalling pathways. 
Semin. Immunol. 26(3):237–45 
229. Sabzi M, Mirabedini SM, Zohuriaan-Mehr J, Atai M. 2009. Surface 
170 
 
modification of TiO2 nano-particles with silane coupling agent and investigation 
of its effect on the properties of polyurethane composite coating. Prog. Org. 
Coatings. 65(2):222–28 
230. Salerno A, Hermann R. 2006. Efficacy and safety of steroid use for 
postoperative pain relief. Update and review of the medical literature. J. Bone 
Joint Surg. Am. 88(6):1361–72 
231. Santos A, Aw MS, Bariana M, Kumeria T, Wang Y, Losic D. 2014. Drug-
releasing implants: current progress, challenges and perspectives. J. Mater. 
Chem. B. 2(37):6157–82 
232. Santos AC, Caldas M, Pattekari P, Fontes Ribeiro C, Ribeiro AJ, et al. 
2018. Chapter 16 – Layer-by-Layer coated drug-core nanoparticles as versatile 
delivery platforms. Des. Dev. New Nanocarriers. 595–635 
233. Saxena RK, Vallyathan V, Lewis DM. 2003. Evidence for 
lipopolysaccharideinduced differentiation of RAW264.7 murine macrophage cell 
line into dendritic like cells. J. Biosci. 28(1):129–34 
234. Schäcke H, Döcke WD, Asadullah K. 2002. Mechanisms involved in the 
side effects of glucocorticoids. Pharmacol. Ther. 96(1):23–43 
235. Schroer WC, Berend KR, Lombardi A V., Barnes CL, Bolognesi MP, et al. 
2013. Why are total knees failing today? Etiology of total knee revision in 2010 
and 2011. J. Arthroplasty. 28(8 SUPPL):116–19 
236. Schuh JCL. 2008. Medical Device Regulations and Testing for 
Toxicologic Pathologists. Toxicol. Pathol. 36(1):63–69 
237. Sedger LM, McDermott MF. 2014. TNF and TNF-receptors: From 
mediators of cell death and inflammation to therapeutic giants - past, present and 
future 
238. Sharma JN, Al-Omran A, Parvathy SS. 2007. Role of nitric oxide in 
inflammatory diseases. Inflammopharmacology. 15(6):252–59 
239. Shiratori SS, Rubner MF. 2000. pH-dependent thickness behavior of 
sequentially adsorbed layers of weak polyelectrolytes. Macromolecules. 
33(11):4213–19 
240. Sidney LE, Heathman TRJ, Britchford ER, Abed A, Rahman C V., Buttery 
LDK. 2015. Investigation of Localized Delivery of Diclofenac Sodium from 
Poly(D,L-Lactic Acid- co -Glycolic Acid)/Poly(Ethylene Glycol) Scaffolds Using an 
In Vitro Osteoblast Inflammation Model. Tissue Eng. Part A. 21(1–2):362–73 
241. Silva JM, Caridade SG, Costa RR, Alves NM, Groth T, et al. 2015. PH 
Responsiveness of Multilayered Films and Membranes Made of 
Polysaccharides. Langmuir. 31(41):11318–28 
171 
 
242. Singh AK. 2016. Experimental Methodologies for the Characterization of 
Nanoparticles. In Engineered Nanoparticles, pp. 125–70 
243. Singhatanadgit W. 2009. Biological Responses to New Advanced Surface 
Modifications of Endosseous Medical Implants. Bone Tissue Regen. Insights. 
2:1–11 
244. Siyamak S, Ibrahim NA, Abdolmohammadi S, Wan Yunus WMZ, Rahman 
MZAB. 2012. Effect of fiber esterification on fundamental properties of oil palm 
empty fruit bunch fiber/poly(butylene adipate-co-terephthalate) biocomposites. 
Int. J. Mol. Sci. 13(2):1327–46 
245. Slack SM, Horbett TA. 1995. The Vroman Effect. In Proteins at Interfaces 
II: Fundamentals and Applications, Vol. 602, pp. 112–28 
246. Smith C, Erasmus PJ, Myburgh KH. 2006. Endocrine and immune effects 
of dexamethasone in unilateral total knee replacement. J. Int. Med. Res. 
34(6):603–11 
247. Sobieszczyk S, Klotzke R. 2011. Nanotubular titanium oxide layers for 
enhancement of bone-implant bonding and bioactivity. Adv. Mater. Sci. 11(1):17–
26 
248. Solary E. 2012. When monocyte life hangs by a thread. Blood. 
119(12):2699–2700 
249. Soromou LW, Zhang Z, Li R, Chen N, Guo W, et al. 2012. Regulation of 
inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine 
macrophage by 7-O-methyl-naringenin. Molecules. 17(3):3574–85 
250. Sousa CT, Nunes C, Proença MP, Leitão DC, Lima JLFC, et al. 2012. PH 
sensitive silica nanotubes as rationally designed vehicles for NSAIDs delivery. 
Colloids Surfaces B Biointerfaces. 94:288–95 
251. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, et al. 2010. A novel 
nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is 
enhanced when encapsulated in exosomes. Mol. Ther. 18(9):1606–14 
252. Sun J, Zhang X, Broderick M, Fein H. 2003. Measurement of Nitric Oxide 
Production in Biological Systems by Using Griess Reaction Assay. Sensors. 
3(8):276–84 
253. Taha M, Chai F, Blanchemain N, Goube M, Martel B, Hildebrand HF. 
2013. Validating the poly-cyclodextrins based local drug delivery system on 
plasma-sprayed hydroxyapatite coated orthopedic implant with toluidine blue O. 
Mater. Sci. Eng. C. 33(5):2639–47 
254. Takakubo Y, Berce A, Trebše R, Tamaki Y, Milošev I, et al. 2013. Wear 
and corrosion in the loosening of total joint replacements (TJRs). In Bio-
172 
 
Tribocorrosion in Biomaterials and Medical Implants, pp. 74–110 
255. Takashiba S, Van Dyke TE, Amar S, Murayama Y, Soskolne AW, Shapira 
L. 1999. Differentiation of monocytes to macrophages primes cells for 
lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor κB. 
Infect. Immun. 67(11):5573–78 
256. Talmo CT, Shanbhag AS, Rubash HE. 2006. Nonsurgical management 
of osteolysis: Challenges and opportunities. Clin. Orthop. Relat. Res., pp. 254–
64 
257. Talorete TPN, Bouaziz M, Sayadi S, Isoda H. 2006. Influence of medium 
type and serum on MTT reduction by flavonoids in the absence of cells. 
Cytotechnology. 52(3):189–98 
258. Tamaki Y, Sasaki K, Sasaki A, Takakubo Y, Hasegawa H, et al. 2008. 
Enhanced osteolytic potential of monocytes/macrophages derived from bone 
marrow after particle stimulation. J. Biomed. Mater. Res. - Part B Appl. Biomater. 
84(1):191–204 
259. Tang Z, Wang Y, Podsiadlo P, Kotov NA. 2006. Biomedical applications 
of layer-by-layer assembly: From biomimetics to tissue engineering 
260. Tavakoli-Darestani R, Manafi-Rasi A, Kamrani-Rad A. 2014. 
Dexamethasone-loaded hydroxyapatite enhances bone regeneration in rat 
calvarial defects. Mol. Biol. Rep. 41(1):423–28 
261. Tejero R, Anitua E, Orive G. 2014. Toward the biomimetic implant 
surface: Biopolymers on titanium-based implants for bone regeneration 
262. Terra X, Valls J, Vitrac X, Mérrillon JM, Arola L, et al. 2007. Grape-seed 
procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 
macrophages by inhibiting NFkB signaling pathway. J. Agric. Food Chem. 
55(11):4357–65 
263. The NJR Editorial Board. 2016. 13th Annual Report-National Joint 
Registry for England, Wales, Northern Ireland and the Isle of Man 
264. Torrecillas R, Moya JS, Draz LA, Bartolomé JF, Fernández A, Lopez-
esteban S. 2009. Nanotechnology in joint replacement 
265. Tweedie D, Luo W, Short RG, Brossi A, Holloway HW, et al. 2009a. A 
cellular model of inflammation for identifying TNF-α synthesis inhibitors. J. 
Neurosci. Methods. 183(2):182–87 
266. Tweedie D, Luo W, Short RG, Brossi A, Holloway HW, et al. 2009b. A 
cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. J. 
Neurosci. Methods. 183(2):182–87 
267. Ukaji E, Furusawa T, Sato M, Suzuki N. 2007. The effect of surface 
173 
 
modification with silane coupling agent on suppressing the photo-catalytic activity 
of fine TiO2 particles as inorganic UV filter. Appl. Surf. Sci. 254(2):563–69 
268. Ulrich SD, Seyler TM, Bennett D, Delanois RE, Saleh KJ, et al. 2008. 
Total hip arthroplasties: What are the reasons for revision? Int. Orthop. 
32(5):597–604 
269. Urbanska J, Karewicz A, Nowakowska M. 2014. Polymeric delivery 
systems for dexamethasone 
270. Vairappan C, Kamada T, Lee W-W, Jeon Y-J. 2013. Anti-inflammatory 
activity of halogenated secondary metabolites of Laurencia snackeyi (Weber-van 
Bosse) Masuda in LPS-stimulated RAW 264.7 macrophages. J. Appl. Phycol. 
25(6):1805–13 
271. Vallejo-Heligon SG, Brown NL, Reichert WM, Klitzman B. 2016. Porous, 
Dexamethasone-loaded polyurethane coatings extend performance window of 
implantable glucose sensors in vivo. Acta Biomater. 30:106–15 
272. Vallés G, Pérez C, Boré A, Martín-Saavedra F, Saldaña L, Vilaboa N. 
2013. Simvastatin prevents the induction of interleukin-6 gene expression by 
titanium particles in human osteoblastic cells. Acta Biomater. 9(1):4916–25 
273. Values T, Hip T, Materials P. 2005. Standard Specification for Total Hip 
Joint Prosthesis and Hip Endoprosthesis Bearing Surfaces Made of Metallic , 
Ceramic , and Polymeric. Components. (June):1–5 
274. van der Bruggen T, Nijenhuis S, van Raaij E, Verhoef J, Sweder van 
Asbeck B. 1999. Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha 
Production by Human Monocytes Involves the Raf-1/MEK1-MEK2/ERK1-ERK2 
Pathway. Infect. Immun. 67(8):3824–29 
275. van Helden SFG, van Leeuwen FN, Figdor CG. 2008. Human and murine 
model cell lines for dendritic cell biology evaluated. Immunol. Lett. 117(2):191–
97 
276. Van Manen MD, Nace J, Mont M a. 2012. Management of primary knee 
osteoarthritis and indications for total knee arthroplasty for general practitioners. 
J. Am. Osteopath. Assoc. 112(11):709–15 
277. Vandevyver S, Dejager L, Tuckermann J, Libert C. 2013. New insights 
into the anti-inflammatory mechanisms of glucocorticoids: An emerging role for 
glucocorticoid-receptor-mediated transactivation 
278. von Knoch F, Marchie A, Malchau H. 2010. Total joint registries: a 
foundation for evidence-based arthroplasty. Virtual Mentor. 12(2):124–29 
279. von Wilmowsky C, Moest T, Nkenke E, Stelzle F, Schlegel KA ndreas. 
2014. Implants in bone: part I. A current overview about tissue response, surface 
174 
 
modifications and future perspectives 
280. Vuk AŠ, Ješe R, Orel B, Dražič G. 2005. The effect of surface hydroxyl 
groups on the adsorption properties of nanocrystalline TiO2 films. Int. J. 
Photoenergy. 7(4):163–68 
281. Waldron NH, Jones CA, Gan TJ, Allen TK, Habib AS. 2013. Impact of 
perioperative dexamethasone on postoperative analgesia and side-effects: 
Systematic review and meta-analysis. Br. J. Anaesth. 110(2):191–200 
282. Wang D, Miller SC, Liu X-M, Anderson B, Wang XS, Goldring SR. 2007. 
Novel dexamethasone-HPMA copolymer conjugate and its potential application 
in treatment of rheumatoid arthritis. Arthritis Res. Ther. 9(1):R2 
283. Wang H, Rempel GL. 2013. PH-responsive polymer core-shell 
nanospheres for drug delivery. J. Polym. Sci. Part A Polym. Chem. 51(20):4440–
50 
284. Wang S, Wen S, Shen M, Guo R, Cao X, et al. 2011. 
Aminopropyltriethoxysilane-mediated surface functionalization of hydroxyapatite 
nanoparticles: synthesis, characterization, and in vitro toxicity assay. Int. J. 
Nanomedicine. 6:3449–59 
285. Wang T, Jiang H, Wan L, Zhao Q, Jiang T, et al. 2015a. Potential 
application of functional porous TiO2 nanoparticles in light-controlled drug 
release and targeted drug delivery. Acta Biomater. 13:354–63 
286. Wang W-R, Li A, Mei W, Zhu R-R, Li K, et al. 2015b. Dexamethasone 
sodium phosphate intercalated layered double hydroxides and their therapeutic 
efficacy in a murine asthma model. RSC Adv. 5(30):23826–34 
287. Wang X, Chen D, Cao L, Li Y, Boyd BJ, Caruso RA. 2013. Mesoporous 
titanium zirconium oxide nanospheres with potential for drug delivery 
applications. ACS Appl. Mater. Interfaces. 5(21):10926–32 
288. Wernecke C, Braun HJ, Dragoo JL. 2015. The effect of intra-articular 
corticosteroids on articular cartilage: A systematic review. Orthop. J. Sport. Med. 
3(5):1–7 
289. Wissink MJB, Beernink R, Pieper JS, Poot AA, Engbers GHM, et al. 2001. 
Immobilization of heparin to EDC/NHS-crosslinked collagen. Characterization 
and in vitro evaluation. Biomaterials. 22(2):151–63 
290. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. 2014. The role of 
inflammatory and anti-inflammatory cytokines in the pathogenesis of 
osteoarthritis 
291. Wood KC, Boedicker JQ, Lynn DM, Hammond PT. 2005. Tunable drug 
release from hydrolytically degradable layer-by-layer thin films. Langmuir. 
175 
 
21(4):1603–9 
292. Wu C-H, Chen T-L, Chen T-G, Ho W-P, Chiu W-T, Chen R-M. 2003. Nitric 
oxide modulates pro- and anti-inflammatory cytokines in lipopolysaccharide-
activated macrophages. J. Trauma. 55:540–45 
293. Wu D, Chen X, Chen T, Ding C, Wu W, Li J. 2015. Substrate-anchored 
and degradation-sensitive anti-inflammatory coatings for implant materials. Sci. 
Rep. 5:11105 
294. Wu EC, Andrew JS, Buyanin A, Kinsella JM, Sailor MJ. 2011. Suitability 
of porous silicon microparticles for the long-term delivery of redox-active 
therapeutics. Chem. Commun. 47(20):5699 
295. Wu P, Grainger DW. 2006. Drug/device combinations for local drug 
therapies and infection prophylaxis 
296. Wu S, Weng Z, Liu X, Yeung KWK, Chu PK. 2014. Functionalized TiO2 
based nanomaterials for biomedical applications. Adv. Funct. Mater. 
24(35):5464–81 
297. Yamamoto Y, Gaynor RB. 2001. Therapeutic potential of inhibition of the 
NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 
107(2):135–42 
298. Yang X, Kang M-C, Li Y, Kim E-A, Kang S-M, Jeon Y-J. 2014. Anti-
inflammatory activity of questinol isolated from marine-derived fungus Eurotium 
amstelodami in lipopolysaccharide-stimulated RAW 264.7 macrophages. J. 
Microbiol. Biotechnol. 24(10):1346–53 
299. Yodyingyong S, Sae-Kung C, Panijpan B, Triampo W, Triampo D. 2011. 
Physicochemical properties of nanoparticles titania from alcohol burner 
calcination. Bull. Chem. Soc. Ethiop. 25(2):263–72 
300. Yoon W-J, Lee NH, Hyun C-G. 2010. Limonene Suppresses 
Lipopolysaccharide-Induced Production of Nitric Oxide, Prostaglandin E2, and 
Pro-inflammatory Cytokines in RAW 264.7 Macrophages. J. Oleo Sci. 59(8):415–
21 
301. Yoshioka Y, Yamamuro  a, Maeda S. 2003. Nitric oxide at a low 
concentration protects murine macrophage RAW264 cells against nitric oxide-
induced death via cGMP signaling pathway. Br. J. Pharmacol. 139(1):28–34 
302. Yuan F, Chen J, Sun PP, Guan S, Xu J. 2013. Wedelolactone inhibits 
LPS-induced pro-inflammation via NF-kappaB Pathway in RAW 264.7 cells. J. 
Biomed. Sci. 20(1):84 
303. Zamora R, Vodovotz Y, Billiar TR. 2000. Inducible nitric oxide synthase 
and inflammatory diseases. Mol. Med. 6:347–73 
176 
 
304. Zaveri TD, Lewis JS, Dolgova N V., Clare-Salzler MJ, Keselowsky BG. 
2014. Integrin-directed modulation of macrophage responses to biomaterials. 
Biomaterials. 35(11):3504–15 
305. Zhang BGX, Myers DE, Wallace GG, Brandt M, Choong PFM. 2014a. 
Bioactive coatings for orthopaedic implants-recent trends in development of 
implant coatings 
306. Zhang J-M, An J. 2007. Cytokines, Inflammation and Pain. Int Anesth. 
Clin. 45(2):27–37 
307. Zhang J, Liu Y, Luo R, Chen S, Li X, et al. 2015. In vitro hemocompatibility 
and cytocompatibility of dexamethasone-eluting PLGA stent coatings. Appl. Surf. 
Sci. 328:154–62 
308. Zhang Z, Nix CA, Ercan UK, Gerstenhaber JA, Joshi SG, Zhong Y. 2014b. 
Calcium binding-mediated sustained release of minocycline from hydrophilic 
multilayer coatings targeting infection and inflammation. PLoS One. 9(1): 
309. Zhao AS, Zhou S, Wang Y, Chen J, Ye CR, Huang N. 2014. Molecular 
interaction of fibrinogen with thermally modified titanium dioxide nanoparticles. 
RSC Adv. 4(76):40428–34 
310. Zhao J, Milanova M, Warmoeskerken MMCG, Dutschk V. 2012. Surface 
modification of TiO2 nanoparticles with silane coupling agents. Colloids Surfaces 
A Physicochem. Eng. Asp. 413(September):273–79 
311. Zhao YP, Wei JL, Tian QY, Liu AT, Yi YS, et al. 2016. Progranulin 
suppresses titanium particle induced inflammatory osteolysis by targeting 
TNFalpha signaling. Sci Rep. 6(February):20909 
312. Zilberman M, Kraitzer A, Grinberg O, Elsner JJ. 2010. Drug-eluting 
medical implants 
313. Zolnik BS, Burgess DJ. 2007. Effect of acidic pH on PLGA microsphere 
degradation and release. J. Control. Release. 122(3):338–44 
 
 
 
 
 
 
177 
 
I. Appendix  
 
A. Preliminary in vitro studies 
 
Cell density optimization   
Initially the aim of this study was to assess the behaviour of Raw macrophages 264.7 
cell line upon exposure to dexamethasone-loaded functionalised TiO2 particles for 7 
days. To start these experiments, we decided to use the cell density reported in similar 
reports (Pinho et al. 2011), where a density of 1.5 x 104 cells/well was initially utilized for 
LPS-activated macrophages studies. The first preliminary cytotoxicity studies were 
performed for 7 days, although we noticed that after 5 days of culture the macrophages 
started overgrowing the well (Figure 71).  
 
Figure 71. Raw 264.6 cells growth, with cell seeding density of 1.5 x 104 cells/well, 
was observed with inverted microscope for 7 days. All pictures have x4 
magnification. 
The MTT assay performed for 5 days, showed that this cell overgrowing was indeed 
causing a remarkable decrease of viability, when cells were exposed to dexamethasone 
and LPS combination or LPS alone (data not shown). Leading to the conclusion that the 
low cellular viability (<50%) observed was not caused by the treatments but due to the 
excess of cells inside the well (Figure 71). After performing preliminary cytotoxicity 
studies and observed the reduced cellular viability after 5 days of culture, we decided to 
study the cellular viability and nitric oxide production for only 3 days. This was a crucial 
parameter for our study, mainly because cytotoxicity has been related to NO production 
(Kröncke et al. 1997, Yoshioka et al. 2003). Therefore, the low cellular viability due to 
cell death observed could result in NO production, and lead to false results for the studies 
performed in LPS-activated cells.  
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Preliminary toxicity studies (RPMI media) 
After optimizing the cell density (1.5 x 104 cells/well) and number of culture days (3 days), 
the cellular viability was then assessed when cells were exposed to DEX, and to the 
broths, collected from amino and mercapto routes (Figure 72).these results showed that 
only higher concentration of DEX (>100µg/mL) significantly reduced cellular viability.  
 
 
Figure 72. Effect of dexamethasone in cell viability. RAW 264.7 macrophages were 
exposed to range of concentrations between 3.9 and 100 μg/mL during 18h, 24h, 
and 72 hours. Cell viability was assessed by MTT (a) and LDH assay (b).  
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Figure 73. Effect of broths, collected different time points (24h-144h) from drug 
release studies (Amino Route) performed at pH 4, in cell viability. RAW 264.7 
macrophages were exposed to broths during 18h, 1day, and 3 days. Cell viability 
was assessed by MTT (a) and LDH assay (b). 
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Figure 74. Effect of broths, collected at 24h time point, from drug release studies 
(Mercapto Route) performed at pH 4, in cell viability. RAW 264.7 macrophages 
were exposed to broths during 18h, 1day, and 3 days. Cell viability was assessed 
by MTT (a) and LDH assay (b). 
 
When cells were exposed to broths collected from drug release studies performed at 
pH=4, results obtained (Amino Figure 73, and Mercapto Figure 74) show that for all 
broths tested the cellular viability was very low (<50% when compared to control), 
especially after 72h exposure.  Moreover, broths obtained from the drug release studies 
of particles obtained via mercapto and amino route present very similar results, in other 
words all treatments collect from drug release studies performed at pH=4 cause a 
significant decrease (p<0.05) on cellular viability which was clearly time-dependent.  
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Figure 75. Effect of broths, collected at 24h time point) from drug release studies 
(Amino Route) performed at pH 7, in cell viability. RAW 264.7 macrophages were 
exposed to broths during 18h, 1 day, and 3 days. Cell viability was assessed by 
MTT (a) and LDH assay (b). 
 
The cells exposed to broths collected from drug release studies performed at pH=7 
(Amino Figure 75, and Mercapto Figure 76) still showed low cellular viability low (>60-
70%) when compared to control, and was also time-dependent. Nonetheless the cellular 
viability when cells were exposed to broth collected at pH=7 was significantly higher 
(p<0.01) than the one observed for pH=4 ( 
Figure 77). For this reason, only broth collected at pH=6 and 7 were tested on the cells. 
 
 
182 
 
 
Figure 76. Effect of broths, collected at 24h time point, from drug release studies 
(Mercapto Route) performed at pH 7, in cell viability. RAW 264.7 macrophages 
were exposed to broths during 18h, 1day, and 3 days. Cell viability was assessed 
by MTT (a) and LDH assay (b). 
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Figure 77. Comparison of broths effect on cell viability, when collected from drug 
release studies performed at pH 4 and 7 for (A) amino and (B) mercapto routes. 
RAW 264.7 macrophages were exposed to 24h time point broths during 18, 24, and 
72 hours. Cell viability was assessed by MTT assay. 
 
Culture media change: From RPMI to DMEM Media  
As a next step in this study, the NO production in LPS-activated cells was measured. 
Although initially we didn’t get reproducible data, because RPMI 1640 medium (RPMI) 
has calcium nitrate in its composition (0.1g/L), which altered the levels of NO measured. 
This originated erratic results, where control cells (cells only exposed to media) showed 
higher NO production than LPS activated cells. Therefore, we decided to grow cells in 
DMEM media, which is known to have undetectable levels of nitrate. The nutrient content 
and concentrations, which vary in different culture media, are known to regulate 
physicochemical and physiological parameters of cells, such as growth (Iloki Assanga et 
al. 2013). Previous studies (Cohly et al. 2001, Kawakami et al. 2016) have shown that 
activation of various macrophages was influenced by culture medium. Particularly, 
Kawakami and co-workers (2016) showed that the NO production and iNOS expression 
in LPS-activated macrophages were remarkably different when different culture media, 
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F-12 and DMEM, were utilized. As previously reported (Talorete et al. 2006) the culture 
medium type has a significant effect on MTT reduction, particularly when it is used to 
measure cytotoxicity. For this reason, we decided to repeat all the cellular viability 
experiments, previously done with RPMI media for dexamethasone, with and without 
LPS. 
 
DEXAMETHASONE 
Therefore, the cellular viability of DMEM-cultured Raw macrophages when exposed to 
DEX was assessed (Figure 78). Methylthiazolyl Tetrazolium (MTT) assay (Figure 78.a), 
and Lactase dehydrogenase assay (LDH release) (Figure 78.b) were used as indicators 
of cellular viability.  
18 24 48 72
 
Figure 78. Effect of dexamethasone in cell viability. RAW 264.7 macrophages were 
exposed to range of concentrations between 3.9 and 100 μg/mL during 18h, 1day, 
2 days and 3 days. Cell viability was assessed by MTT (a) and LDH assay (b).  
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Based on MTT assay, results show that exposure to dexamethasone concentrations up 
to 20 µg/mL during 72h exposure, did not show to considerable/significant (p>0.05) 
decrease the cellular viability of Raw 264.7 cells. The cellular viability observed for these 
concentrations was very close to values observed for the control. 
On the other hand, higher concentrations of DEX, such as 40, 60 and 100 µg/mL, show 
to affect cellular viability in a significant way (p<0.05). Where the higher decrease on 
cellular viability, 20% when compared to the control, was observed after 72h, when cells 
were exposed to a dexamethasone concentration of 100 µg/mL. Moreover, after 24h 
exposure, macrophages show an increase on cell viability when compared to control 
(Figure 78.a). These differences in cell viability were not verified in the LDH assay (Figure 
78.b). Results obtained with LDH assay, show that when exposed to all dexamethasone 
concentrations (3.9-100 µg/mL), macrophages release only release significant (p<0.05) 
amounts of LDH after 48h exposure. Therefore, as MTT assay allowed detecting more 
alterations on cellular viability than the measure of LDH release, the results presented 
herein for cell viability after treatments with broths and LPS were obtained by MTT assay. 
Regarding these differences observed for cell viability measured by MTT and LDH, the 
same results were reported by other authors (Pinho et al., 2011) where Raw 264.4 cells 
were exposed to DEX. Thus, showing that MTT assay is more sensitive in detecting 
alterations on cells survival than the measure of LDH release.   
 
Figure 79. Effect of dexamethasone in cell viability of LPS-activated cells. RAW 
264.7 macrophages were exposed to range of concentrations between 3.9 and 100 
μg/mL and also to LPS (1µg/mL) during 18h, 1day, 2 days and 3 days. Cell viability 
was assessed by MTT assay. 
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NO production inhibition  
By the second year of the PhD (August-October 2016), we had to discard the Raw 264.7 
cells, because they stopped producing nitric oxide. Before discarding the cells, we tried 
to understand what was beyond the lack of NO production. Initially, the LPS activation 
experiment was repeated by starting to stimulate the cells with different concentrations 
of LPS to see how the cells reacted. Results obtained from this experiment (Figure 80). 
show that the amount of NO measured (µM/mL) was the same for LPS-activated cells (1 
or 0.5µg/mL) or untreated cells (control) for all time points. 
 
 
Figure 80. Nitric oxide (NO) production upon exposure to LPS during 18h, 24h, 48h 
and 72h.  
Our next step was to measure the amount of NO on nitrite standard solutions (10 and 20 
µM/mL), to assess if the Griess Reagent kit was still working (data not shown). We also 
tested the cells for mycoplasma (data not shown). The results obtained showed that both 
hypothesis was wrong, cells were not contaminated by neither mycoplasma or the Griess 
reagent was not working. As reported previously (Lai et al. 2014, Tweedie et al. 2009a) 
, we know that when exposed to LPS, macrophages (M0) undergo classical activation, 
where they differentiate into M1 macrophages. The classical activated M1 macrophages 
produce pro-inflammatory cytokines and also activate iNOS pathway, which is essential 
for generating NO molecule (Bogdan 2001, Kawakami et al. 2016). In contrast, when 
macrophages are exposed to anti-inflammatory stimulus, such as IL-4 or transforming 
growth factor β (TGF-β) (Gong et al. 2012, Oida & Weiner 2010), they undergo an 
alternative activation and become polarized into M2 macrophages. Being anti-
inflammatory, these macrophages produce anti-inflammatory cytokines, which cause an 
increased expression of Arginase-1, an enzyme which competes with iNOS for a 
common limiting substrate L-arginine. So macrophage polarization states will depend on 
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the induction of iNOS (M1) or Arginase-1 (M2), which compete for the same L-arginine 
substrate (Mills & Ley 2014). Therefore, our hypothesis was that the batch of fetal bovine 
serum (FBS) had significant amounts of TGF-β (anti-inflammatory cytokine), which 
hindered the M1 polarization, and thus inhibited the macrophages ability to produce NO 
in response to LPS. This hypothesis is consistent with other studies (Haak-Frendscho et 
al. 1990, Hausmann et al. 1994), which also reported the inhibitory effect of TGF- β on 
iNOS mRNA expression/NO production by LPS-activated Raw 264.7 cells. 
B. Complementary Images 
HPLC calibration curve for DEX 
To evaluate the concentration of DEX in the samples collected, a calibration curve of the 
HPLC detection of DEX was obtained (Figure 81). Briefly, a standard calibration curve 
was obtained by plotting the concentration (µg/mL) of standard DEX versus peak area 
(mAu). To prepare the standards, a stock solution of DEX (1mg/mL) was diluted to a 
range of concentration between 0.4 and 25 µg/mL. Results are presented as the average 
and standard deviation of three samples. 
 
 Figure 81. DEX standard calibration curve for different DEX concentrations (0-500 
µg/mL) 
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Calibration curve for Nitric oxide (NO) 
A standard calibration curve to quantify nitrite concentration on biological samples was 
generated using sodium nitrite (NaNO2) as an external standard. 
 
 
Figure 82 Standard curve for nitrite (NO2-) (colorimetric): mean of triplicates (+/-SD) with 
background readings subtracted. 
 
Calibration curve for tumour necrosis factor alpha (TNF-α). 
 
 
Figure 83. Standard curve for murine tumour necrosis factor alpha (TNF-α). 
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Raw 264.7 Cell Studies 
 
 
Figure 84. Effect of filtered and non-filtered broths, collected from drug release 
studies (LbL Route) performed at pH 6, in cell viability. RAW 264.7 macrophages 
were exposed to broths during (A) 18h, (B) 24h, (C) 48h and (D) 72 hours. Cell 
viability was assessed by MTT assay. 
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Figure 85. Effect of filtered and non-filtered broths, collected from drug release 
studies (LbL route) performed at pH 7, in cell viability. LPS-activated-RAW 264.7 
macrophages were exposed to (A) 18h, (B) 24h, (C) 48h and (D) 72 hours. Cell 
viability was assessed by MTT assay. 
 
 
Figure 86. Nitric oxide (NO) production upon exposure to different LPS 
concentrations (0.1-1µg/mL range) prepared from fresh and frozen LPS stock 
solution during 18, 24, 48 and 72 hours. 
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Figure 87. Cellular viability of Raw 264.7 macrophages without (A.) and with (B.) 
LPS (1µg/mL) during 18, 24, 48 and 72 hours-exposure was assessed by MTT 
assay, when different cell densities were utilized.  
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Figure 88. Effect of LPS in Raw 264.7 cell viability was observed under inverted 
microscopy. 
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Figure 89. Effect of different concentrations of acetate, buffer utilized for drug 
release studies, with LPS in cell viability. RAW 264.7 macrophages were exposed 
to range of acetate buffer (pH=6) concentrations (10-100%) diluted in DMEM media, 
during 18, 24, 48 and 72 hours.  Study done with 2 x10^4 cells /well + DMEM. Final 
graphs n=2 
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Figure 90. The effect of LPS (1 μg/mL) on the cellular viability of Raw 264.7 
macrophages during 24, 48 and 72 hours-exposure was assessed by inverted 
microscopy, when different cell densities A (2x10^4 cells/well) and B (2.5x10^4 
cells/well) were utilized. 
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Figure 91. Effect of DEX released from functionalised-TiO2 particles (amino and 
mercapto route) in NO production (µM/mL) in RAW 264.7 macrophages. Cells were 
exposed to broths collected at 24hours from drug release studies performed at 
pH=6 (A) and pH=7 (B) during 18, 24, 48 and 72 hours. 
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Figure 92. Effect of DEX released from functionalised-TiO2 particles (amino and 
mercapto route) in TNF-α production (pg/mL) in RAW 264.7 macrophages. Cells 
were exposed to broths collected at 24hours from drug release studies performed 
at pH=6 during 18, 24, 48 and 72 hours.  
 
 
Figure 93. Effect of DEX released from functionalised-TiO2 particles (LbL route) in 
nitric oxide (NO) production (µM/mL) in RAW 264.7 macrophages. Cells were 
exposed to broths collected from drug release studies performed at pH=6 (A,B) 
and pH=7 (C,D), from particles surrounded by 0 layers and 4 layers during 18, 24, 
48 and 72 hours. Broths used to treat the cells were collected at different time 
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points to assess the effect of DEX released after (A, C) 24h and 48h (24h 0 and 4 
layers, 48h 0 and 4 layers), and 72h and 2W (72h 0 and 4 layers, 2 W 0 and 4 layers). 
 
 
Figure 94. Effect of DEX released from functionalised-TiO2 particles with 0 and 4 
layers in TNF-α production (pg/mL) in RAW 264.7 macrophages. Cells were 
exposed to broths collected at 24h, 48h (A) or to 72h and 2 weeks (B) from drug 
release studies performed at pH=6 during 18, 24, 48 and 72 hours. 
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Figure 95. FT-IR spectra for different steps of TiO2 nanoparticles functionalisation 
using amino route: bare-TiO2 particles (---), amino-functionalised TiO2 particles (--
-), carboxyl-functionalised TiO2 particles (---), and DEX-loaded TiO2 particles (---).  
 
 
Figure 96. FT-IR spectra for different steps of TiO2 nanoparticles functionalisation 
using mercapto route: bare-TiO2 particles (---), mercapto-functionalised TiO2 
particles (---), carboxyl-functionalised TiO2 particles (---), and DEX-loaded TiO2 
particles (---). 
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Figure 97. FT-IR spectra for pure Dexamethasone powder. 
 
C.  Particles Characterisation 
 
Energy dispersive spectrometer (EDS) 
Backscattered electron images in the scanning electron microscopy (SEM) display 
different compositional contrast that results from different atomic number elements and 
their distribution. On the other hand, the X-rays, which result from the electron beam 
interaction with the sample are simultaneous detected by an energy Dispersive detector 
which displays the signal as a spectrum of intensity versus X-ray energy, proving 
information on the chemical composition of the sample. Therefore, imaging by combined 
SEM/EDS allowed the analysis of the surface of functionalised-TiO2 particles and in-
depth information regarding chemical composition. Although EDS is not considered a 
surface analysis technique, it can be used in semi-quantitative mode to determine 
chemical composition of functionalised participles by peak-height ratio relative to a bare 
TiO2 particles (Figure 98.). The EDS analyses for different functionalised particles 
obtained via amino and mercapto routes are respectively shown in Figure 99 and Figure 
100 
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Figure 98. Energy Dispersive X-ray spectroscopy (EDS) performed on the bare-
TiO2 particles. 
 
For amino route (Figure 99) after amino-functionalisation, the particles seem to be mainly 
composed of Si (Silicon), in contrast to the bare TiO2 particles which mainly consist of Ti 
and O, i.e. titania. Silicon peak might suggest the presence of amino-silane (APTS) on 
the particles surface. As for carboxyl-functionalised particles, unexpectedly the Ti peak 
is higher, when compared to amino-functionalised particles, Regarding, DEX-loaded 
functionalised TiO2 particles, the Si, Ti and O peaks are smaller when compared to 
carboxyl-functionalised particles, although the drug coating must be too thin for 
unambiguous detection by EDS. For mercapto route (Figure 100), after mercapto-
functionalisation, new Si (Silicon) and S (Sulphur) peaks are observed, in contrast to the 
bare TiO2 particles which mainly consist of Ti and O, i.e. titania. The sulphur and silicon 
peaks may indicate the presence of mercapto-silane on particles surface. Although, for 
carboxyl-particles no visible differences were observed when comparing them with 
mercapto-functionalised particles. On the other hand, dexamethasone-loaded TiO2 
particles, the S peak disappeared suggesting mercapto group (SH) was replaced by 
other groups. As all characterisation techniques, EDS has limitations in terms of analysis. 
It does not accurately detect the presence of light elements (Z<11), such as Nitrogen (for 
amino group), and fluorine (for DEX) are not identified even though they are present in 
the sample. The use of a more sensitive technique, such as XPS, could solve this 
problem. 
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Figure 99. Energy Dispersive X-ray spectroscopy (EDS) (A) and Scanning Electron 
Microscopy (SEM) (B) performed on the functionalised-TiO2 particles obtained by 
Amino route. From left to right, amino-TiO2 and succinilated-TiO2 particles, and 
Dex-loaded-TiO2 conjugated particles.  
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Figure 100. Energy Dispersive X-ray spectroscopy (EDS) (A) and Scanning 
Electron Microscopy (SEM) (B) performed on the functionalised-TiO2 particles 
obtained by Mercapto route. From left to right, mercapto-TiO2 and succinilated-
TiO2 particles, and Dex-loaded-TiO2 conjugated particles. 
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Fourier Transformed infra-red spectroscopy  
 
 
Figure 101. FT-IR spectra for different steps of TiO2 nanoparticles functionalisation 
using amino route: bare-TiO2 particles (---), amino-functionalised TiO2 particles (--
-), carboxyl-functionalised TiO2 particles (---), and DEX-loaded TiO2 particles (---).  
 
 
Figure 102. FT-IR spectra for different steps of TiO2 nanoparticles functionalisation 
using mercapto route: bare-TiO2 particles (---), mercapto-functionalised TiO2 
particles (---), carboxyl-functionalised TiO2 particles (---), and DEX-loaded TiO2 
particles (---). 
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Figure 103. FT-IR spectra for pure Dexamethasone powder. 
 
 
 
 
Figure 104. FTIR spectra for pure (powder form) alginate (---).  
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Figure 105. FTIR spectra for pure (powder form) chitosan (---).  
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D. Additional information 
Honor/Awards 
 April 2017: “Dexamethasone-loaded TiO2 nanoparticles to locally target wear-
debris induced inflammation” was awarded with the best lecture at Postgraduate 
Research day, organized by the School of Pharmacy & Pharmaceutical Science, 
Cardiff University. (28th April) 
 December 2016: Travel grant from British Council Researcher Links and Newton 
Fund was awarded to attend to Researcher Links Workshop: Healthcare 
Technologies for Aging Populations in Chengdu, China. 
 May 2016: Sponsorship from Research & Engagement Committee of the School 
of Pharmacy & Pharmaceutical Science (Cardiff University) for attending to the 
10th World Biomaterials Congress, Montréal, Canada 17th- 22th May. 
 April 2016: “Dexamethasone-loaded TiO2 nanoparticles to locally target wear-
debris induced inflammation” was awarded with the best poster prize at 
Postgraduate Research day, organized by the School of Pharmacy & 
Pharmaceutical Science, Cardiff University. (6th April). 
 May 2015: Sponsorship from Research & Engagement Committee of the School 
of Pharmacy & Pharmaceutical Science (Cardiff University) to purchase a Fourier 
transformed Infrared spectroscopy(FITR) for the PhD students of Pharmacy & 
Pharmaceutical Sciences School 
Published work 
To date I have published 1 paper, and co-authored one book chapter and two reviews: 
 "Hollow chitosan/alginate nanocapsules for bioactive compound delivery" 
in International journal of biological macromolecules (2015), Volume 76, pp 95-
102. 
  “Edible Bio-Based Nanostructures: Delivery, Absorption and Potential Toxicity” 
in Food Engineering Reviews (2015), Volume 7, Issue 4, pp 491-513.  
 “Design of bio-nanosystems for functional compounds delivery” in Food 
Engineering Reviews (2014), Volume 6, Issue 1, pp 1–19 
 "Flavouring and coating technologies for preservation and processing of foods" 
in Conventional and advanced food processing technologies (2013).  
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Poster and Oral Presentations 
 “Anti-inflammatory drug-eluting joint replacement: model system “. Oral 
presentation at Researcher Links Workshop: Healthcare Technologies for Aging 
Populations in Chengdu, China (December 2016) 
 “Dexamethasone-loaded TiO2 nanoparticles to locally target wear-debris induced 
inflammation”. Frontiers. Bioeng. Biotechnol. Conference Abstract: 10th World 
Biomaterials Congress (May 2016).  
Teaching and Supervision 
 March 2015 - November 2016: Teaching and Demonstrating by working as an 
assistant of lecturers of Pharmacy School and Cardiff Medical School (Health 
simulating center) in three different areas:  Training (Blood pressure 
measurement, Inhalers utilization and technique, Basic Life support and 
Cardiopulmonary resuscitation (CPR), help with different courses such as 
Standard operation procedures and monograph preparation lecturers. 
 October 2014 – January 2014: Co-supervisor of Pharmacy graduate student 
on final project “Preparation and characterization of Titanium-based 
nanoparticles loaded with anti-inflammatory drugs” 
Networking and Collaboration evidence 
 March 2016 –Ongoing: Committee member of Cardiff Institute of Tissue 
Engineering and Repair (CITER). CITER is an internationally recognized center 
of excellence in the field of tissue repair, regeneration and rehabilitation focusing 
on interdisciplinary research, education and clinical practice. 
 May 2016: Volunteer organization member of 10th World Biomaterials Congress, 
Montreal, Canada 17-22th May. The skills and dedication of volunteers greatly 
contribute to the overall quality of the conference. This role was a great 
opportunity to meet, interact and network with a multicultural team of students 
from all over the world that share a common interest in Biomaterials.  
 December 2014- May 2015: Organization member of Annual Speaking of 
Science Conference, 9th May 2015. This conference provides a valuable 
opportunity for postgraduates to give talks and posters across a wide range of 
subjects and disciplines. This forces them to simplify complex research ideas for 
a general audience and as a result the participating delegates discover the 
essence of research being undertaken across the scientific schools.  
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 March 2014 – Ongoing: Post Graduate Staff Student Panel (SPSS) of Pharmacy 
and Pharmaceutical Sciences School. The SSP responsibilities include helping 
with the induction event, welcome party and research day. We also discuss any 
issues that arise in the postgraduate community and make suggestions to 
enhance the post-graduated research experience. 
 
 
 
 
 
 
 
 
 
